

**YEDİTEPE UNIVERSITY**  
**FACULTY OF MEDICINE**  
**PHASE III**  
**ACADEMIC PROGRAM BOOK**  
**2016 - 2017**

**Student's**

**Name** : .....

**Number** : .....



**YEDİTEPE UNIVERSITY**  
**FACULTY OF MEDICINE**  
**PHASE III**

**Contents**

<b>AIM AND OUTCOMES OF MEDICAL EDUCATION PROGRAM .....</b>	<b>1</b>
<b>COORDINATION COMMITTEES .....</b>	<b>4</b>
<b>DESCRIPTION and CONTENT .....</b>	<b>5</b>
<b>AIMS and LEARNING OBJECTIVES of PHASE III.....</b>	<b>6</b>
<b>INTRODUCTION to CLINICAL PRACTICE- III (MED 303) .....</b>	<b>9</b>
<b>SPECIFIC SESSIONS / PANELS .....</b>	<b>11</b>
<b>INDEPENDENT LEARNING .....</b>	<b>15</b>
<b>ASSESSMENT PROCEDURE.....</b>	<b>17</b>
<b>EXAM RULES .....</b>	<b>20</b>
<b>COURSE LOCATIONS .....</b>	<b>21</b>
<b>ACADEMIC CALENDAR of PHASE III 2016 - 2017 .....</b>	<b>22</b>
<b>RECOMMENDED TEXTBOOKS .....</b>	<b>24</b>
<b>COMMITTEES.....</b>	<b>25</b>
<b>COMMITTEE I - INFECTIOUS DISEASES.....</b>	<b>26</b>
<b>COMMITTEE II - CARDIOVASCULAR &amp; RESPIRATORY SYSTEMS .....</b>	<b>37</b>
<b>COMMITTEE III - HEMATOPOIETIC SYSTEM.....</b>	<b>49</b>
<b>COMMITTEE IV - GASTROINTESTINAL SYSTEM.....</b>	<b>57</b>
<b>COMMITTEE V - ENDOCRINOLOGY and REPRODUCTIVE SYSTEMS .....</b>	<b>66</b>
<b>COMMITTEE VI - URINARY SYSTEM .....</b>	<b>76</b>
<b>COMMITTEE VII - NERVOUS SYSTEM AND PYSCHIATRY .....</b>	<b>85</b>
<b>COMMITTEE VIII - MUSCULOSKELETAL SYSTEM .....</b>	<b>96</b>
<b>STUDENT COUNSELING.....</b>	<b>105</b>
<b>CONTACT .....</b>	<b>108</b>



## YEDİTEPE UNIVERSITY FACULTY OF MEDICINE

### AIM AND OUTCOMES OF MEDICAL EDUCATION PROGRAM \*,\*\*

\*“Consensus Commission Report” based on draft compiled at “*Workshop for Revision of Aim and Outcomes of Medical Education Program at Yeditepe University Faculty of Medicine*”

\*\*© 2011, Yeditepe University Faculty of Medicine

#### AIM

The aim of medical education program **is to graduate physicians** who

- **are aware of** the local and global health issues
- **have acquired competence** in knowledge, skills and attitudes to manage and provide primary health care service
- **know, apply and care** for ethical principles of the medical profession
- **keep up with** current knowledge at national and international level
- **are capable of** systematical thinking
- **are** investigative and questioning
- continually **renovate** and **improve** themselves
- **are capable of** teamwork
- **use** technology competently in medicine and related areas
- **have** effective communication skills
- **have** community leadership qualifications

#### OUTCOMES

Graduate should be able to:

##### 1) **practice** as a physician,

- **oriented towards**
  - **individual and non-individual factors affecting health**
  - **sustainment and improvement of healthy condition**
  - **clinical conditions which**
    - **are frequent in community**
    - and/or**
    - **pose high risk for individual or community health**
    - and/or**
    - **life-threatening or constitute an emergency**
- **at a competency level appropriate to deliver primary health care services compatible with surrounding context of health determinants.**

1.1 **explain** normal structural components of human body, their functions and operational mechanisms at organismal, multisystem, system, organ, tissue, cellular and molecular levels.

1.2 **explain** healthy condition and factors affecting health.

1.3 **explain** and **relates** causes of clinical conditions, courses of effect and outcomes.

1.4 **explain** changes (*i.e. physiological and pathological*) in structural components of body, their functions and operational mechanisms under healthy and clinical conditions.

1.5 **explain** most frequently occurring or most important clinical complaints (*i.e. chief complaint*), symptoms, signs, laboratory and imaging findings and their emergence mechanisms in clinical conditions.

1.6 **explain** current medical and surgical methods used in interventions directed towards health conditions.

1.7 **use** contextually appropriate medical history taking method, out of different types (*e.g. comprehensive, focused or hypothetico-deductive*) and systematically, to gather medical information from healthy individual, patient or patient's companions (*i.e. heteroanamnesis*), in case of an encounter with a healthy person or a patient who seeks health care service for a health condition.

1.8 **employ** physical examination methods for systems in case of an encounter with a healthy person or a patient who seeks health care service for a health condition.

1.9 accurately **interpret** findings in medical history and physical examination, in case of an encounter with a healthy person or a patient who seeks health care service for a health condition.

- 1.10 **implement** diagnostic procedures (e.g. *point of care testing, physician office testing*) required for primary health care, in case of an encounter with a healthy person or a patient who seeks health care service for a health condition.
- 1.11 **select (utilize)** tests shown to be highly effective in clinical decision making by evidence-based medicine from the aspects of reliability, practicality and outcome measures, in case of an encounter with a healthy person or a patient who seeks health care service for a health condition, and **interpret** results.
- 1.12 **make** clinical decisions (e.g. *benefit estimation, risk estimation, prevention, screening, test requisition, diagnosis, triage, staging, consultation, prognosis, watchful-waiting, intervention, monitoring, end of intervention, discharge, control, end of follow-up*) shown to be highly effective from the aspects of outcome measures by evidence-based medicine, in case of an encounter with a healthy person or a patient who seeks health care service for a health condition.
- 1.13 accurately **perform** interventional procedures (i.e. *interventional clinical skills, competencies and proficiencies*) required for primary health care, in case of an encounter with a healthy person or a patient who seeks health care service for a clinical condition.
- 1.14 **coordinate** referral or transport of patient, when necessary and with patient-centered approach, to secondary health care institution, without posing any risk to patient's health, security and confidentiality, in case of an encounter with a patient who seeks health care service for a clinical condition.
- 1.15 **manage** request or symptom, healthy or clinical condition, and healthy individual or patient, with beneficiary-centered approach, and with clinical decisions made by analytical and critical thinking, clinical reasoning and problem solving methods, in case of an encounter with a patient who seeks health care service for a health condition.
- 1.16 **execute** protective and therapeutic medical practices that are individual, family and community-oriented, easily accessible, integrated and coordinated, continuous, comprehensive, and based on the principles of confidentiality, in primary health care services.
- 1.17 **identify** factors that pose a high risk to individual and community health, and **determine** individuals or populations at risk in advance or at an early stage and implement the necessary measures.
- 1.18 **value** preventive health services, **offer** primary prevention (i.e. *prevention of diseases for the protection of health*), secondary prevention (i.e. *early diagnosis and treatment*) and tertiary prevention (i.e. *rehabilitation*) services, and **provide** consultancy on these issues.
- 1.19 **provide** life-style consultancy and design services to sustain and improve individual and community health.

## 2) **manage** primary health care services.

- 2.1 **manage** health care team in primary health care organization.
- 2.2. **lead** community with sense of responsibility, good behavior and manners in consideration of individual behaviors and social dynamics of community, and if there is a necessity, **develop** projects directed towards health care services.
- 2.3 **define** health management and economics principles, models for organization and finance of health care services.
- 2.4 **use** health care resources with cost-effective manners.

## 3) **advocate individual and community health under all circumstances.**

- 3.1. **provide** consultancy services to sustain and promote the health of individual and community.
- 3.2. **explain** epidemiology of clinical conditions, and **define** measures to reduce frequencies.
- 3.3. **describe** completely all high risk factors for the community health (e.g. *natural disasters, nuclear accidents, fire, war, bio-terrorism, etc.*), and **implement** necessary measures in order to prevent effects on health.
- 3.4. **explain** health determinants completely (e.g. *physical environment, social environment, genetic background, individual response -behavior, biology-, health care services, welfare, etc.*), including conditions that prevent access to health care.

## 4) **perform medical practices according to regulatory and ethical principles and in consideration of behavioral sciences, social sciences, and humanities.**

- 4.1 **recognize** determinants affecting individual behaviors and attitudes, and social dynamics. 3

- 4.2 **recognize** basic ethical principles completely, and **distinguish** ethical and legal problems.
- 4.3 **recognize** regulations concerning national and international health systems.
- 4.4 **employ** safety, security and confidentiality principles completely for beneficiaries of health care services, companions and visitors, and health care workers.
- 4.5 **use** medical record and information systems according to regulations and ethical principles.
- 4.6 **value** informed consent taking in the framework of patients' rights, and **employ** fully.
- 4.7 **interpret** historical, anthropological and philosophical evolution of medicine, health and disease concepts, and **relate** to current medical practice
- 5) establish** correct and effective communication with all stakeholders of health care services and collaborate.
- 5.1. **communicate** by using problem solving abilities during all of professional life with health care beneficiaries, co-workers, accompanying persons, visitors, patient's relatives, care givers, colleagues, other individuals and organizations.
- 5.2. **collaborate** with related organizations and institutions, with other professionals and health care workers as a team member through using problem solving abilities.
- 5.3. **communicate** with all stakeholders with consideration of socio-cultural differences.
- 6) promote self medical knowledge and skills in view of the current scientific developments throughout own career.**
- 6.1. **adopt** and **implement** the importance of lifelong self-learning.
- 6.2. **recognize** importance of updating knowledge and skills; **search** current advancements and improve own knowledge and skills.
- 6.3. **speak** at least one foreign language at advanced level to follow the international literature and communicate with colleagues.
- 6.4. **recognize** methods to reach current scientific knowledge, and **use** available technology.
- 6.5. **recognize** principles of evidence-based medicine, and **implement** in health care services.
- 6.6. **develop** and **present** research projects.
- 7) manage own postgraduate career.**
- 7.1. **recognize** and **investigate** postgraduate work domains and job opportunities.
- 7.2. **determine** postgraduate work domains, job opportunities and requirements for application, **distinguish** and **plan** requirements for further training and work experience.
- 7.3. **prepare** a resume, and **recognize** job interview methods.
- 7.4. recognize health technologies expected to be implemented in near future and emerging work areas.

**COORDINATION COMMITTEES**  
**(TEACHING YEAR 2016–2017)**

**PHASE-III COORDINATION COMMITTEE**

Ferda KALEAĞASIOĞLU, MD, Prof. (Coordinator)  
Naz Berfu AKBAŞ, MD, Assist. Prof. (Co-coordinator)  
Ayşegül Ç. KUŞKUCU, MD, Assist. Prof. (Co-coordinator)  
Hale ARIK TAŞYIKAN, MD, Assist. Prof. (Co-coordinator)  
Serdar ÖZDEMİR, MD, Assist. Prof. (Co-coordinator)  
Erdem SÖZTUTAR, MD (Co-coordinator)

**ICP-III COORDINATION COMMITTEE**

Özlem TANRIÖVER, MD, Assoc. Prof. (Coordinator)  
Ayşe Arzu AKALIN, MD, Assist. Prof. (Co-coordinator)



## **DESCRIPTION and CONTENT**

Physiopathological process and pathological process.

Infectious Diseases, Cardiovascular System, Respiratory System, Hematopoietic System, Gastrointestinal System, Endocrine System, Urogenital System, Nervous System, Psychiatry, Musculoskeletal System, Basic Clinical Skills, Biomedical Ethics and Deontology, Biostatistics.

Emergency Medicine, Family Medicine, Anesthesiology and Reanimation, Neurosurgery, Biostatistics, Biomedical Ethics and Deontology, Pediatrics, Pediatric Surgery, Pediatric Psychiatry, Endocrinology, Infectious Diseases, Immunology, Phytotherapy, Physical Therapy and Rehabilitation, Physiopathology, Gastroenterohepatology, General Surgery, Pulmonary Diseases, Thoracic Surgery, Ophthalmology, Public Health, Hematology/Oncology, Obstetrics and Gynecology, Cardiology, Otorhinolaryngology, Nephrology, Neurology, Orthopedics and Traumatology, Pathology, Psychiatry, Radiology, Rheumatology, Medical Pharmacology, Medical Genetics, Medical Microbiology, Urology, Medical Education.

## AIMS and LEARNING OBJECTIVES of PHASE III

### AIMS

#### *In evidence based manner:*

1. **to remind** anatomy, histology and physiology of body systems,
2. **to convey** necessary knowledge, related to body systems, on prevention of clinical conditions' emergence, protection and improvement of health in healthy conditions.
3. at multi-system level or related to a body system, for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency;
  - 3.1. **to convey** necessary knowledge on risk factors, etiopathogenesis, physiopathology, and pathology,
  - 3.2. **to convey** knowledge on epidemiology,
  - 3.3. **to convey** knowledge on frequently encountered clinical complaints, symptoms, signs and findings,
  - 3.4. **to convey** necessary knowledge on health care processes, clinical decision making process, clinical decisions and clinical practices, with performance measures, for managing at the level of 7primary health care service,
4. **to convey** knowledge on pharmacology of drugs that are effective at multi-system level, specifically on a body system or on clinical conditions involving a specific body system,
5. **to convey** knowledge on phytotherapeutic agents that are effective at multi-system level, specifically on a body system or on clinical conditions involving a specific body system,
6. **to convey** knowledge on biostatistical analysis,
7. **to convey** basic legal and ethical principles that should be followed in practice of medical profession,
8. **to equip with** basic and advanced professional and clinical (interventional or non-interventional) skills necessary for practice of medical profession.

### LEARNING OBJECTIVES

#### *At the end of this phase, student should be able to:*

- 1.0. **recall** anatomy, histology and physiology of body systems.
- 2.0. **list** necessities for prevention of clinical conditions' emergence, protection and improvement of health in healthy conditions in relation to body systems.
- 3.0. **explain** risk factors and etiopathogenesis, at multi-system level or related to a body system, of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency.
- 4.0. at cellular or tissue level,
  - 4.1. **recognize** morphological characteristics,
  - 4.2. **show** basic pathological changes that occur in clinical conditions.
- 5.0. at multi-system level or related to a body system, of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency;
  - 5.1. **explain** mechanisms of destruction at molecule, cell, tissue, organ, system, multi-system and organismal level,
  - 5.2. **describe** structural and functional changes caused,
  - 5.3. **list** clinical courses in time.
- 6.0. **explain** mechanisms of emergence for frequently encountered;

- 6.1. clinical complaints,
  - 6.2. symptoms,
  - 6.3. signs,
  - 6.4. laboratory and imaging findings
- of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency.
- 7.0. at multi-system level or related to a body system,
    - for healthy conditions in an individual or community with a request, or
    - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
    - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
- explain** in an evidence-based manner and with performance measures from the aspects of reliability, practicality and outcomes,
- health care processes,
  - acquisition of subjective or objective data, information and knowledge required for clinical decision making,
  - clinical decision making process,
  - clinical decisions and
  - clinical practices
- which are required for management at primary health care service level.
- 7.1. practice of history taking and physical examination (*cardiovascular-C2, pulmonary-C2, gastrointestinal-C4, gynecological-C5, breast-C5, neonatal, prepubertal/pubertal-C6, neurological/neuropsychiatric-C7, musculoskeletal-C8*)
  - 7.2. evaluation of emergency case (*sepsis and septic shock-C1, dyspnea-C2, acute abdominal pain-C4, urological emergencies-C6, neurological emergencies-C7, trauma-C8*)
  - 7.3. approach to healthy individual or patient (*fever-C1, cardiovascular disease-C2, chest pain-C2, cough and hemoptysis-C2, dyspnea-C2, anemia-C3, lymphadenopathy-C3, diarrhea-C4, pregnancy-C5, urinary tract infection-C6, neurological symptoms-C7, headache-C7, depression-C7, dementia-C7, musculoskeletal dysfunction-C8*)
  - 7.4. laboratory and imaging tests/examinations
    - 7.4.1. based on laboratory disciplines/subdisciplines:
      - 1. medical biochemistry tests:
        - i. (*venous blood collection-C5*)
        - ii. (*thyroid function tests-C5, diabetes tests-C5*)
      - 2. medical microbiology tests:
        - i. (*urine sample collection-C1, throat swab specimen-C5, sputum sample collection-C5, urethral-vaginal-cervical discharge/swab specimen-C6, fecal specimen collection-C6, wound sample collection-, blood collection for culture-*)
        - ii. (*urine strip/dipstick test-C1, urine culture-C1, rapid screening (antigen/antibody) tests-C5, throat culture-C5, sputum culture-C5, urethral-vaginal-cervical discharge culture-C6, fecal culture-C6, wound culture-, blood culture-*)
      - 3. medical pathology tests:
        - i. (*C2, C4, C6, C7, C8, Pap smear collection*)
        - ii. (*C2, C4, C6, C7, C8, Pap smear*)
      - 4. other laboratory tests:
        - i. (*peripheral/venous blood collection for hematology tests-C3, blood sample collection for therapeutic drug monitoring-C8*)
        - ii. (*pulmonary function tests-C2, hematology tests for anemia-C3, monetarization of drug therapy-C8*)
    - 7.4.2. imaging tests/examinations based on disciplines/subdisciplines: 8

5. radiological examinations: (*radiological examinations in gynecology-C5, breast imaging-C5, urology-C6, conventional neuroradiological examinations-C7, spinal neuroradiology-C7, cranial CT-C7, cranial MRI-C7, radiological imaging of musculoskeletal system-C8, radiological examinations in benign ve malign tumors of bones-C8*)

6. nuclear medicine examinations: (*nuclear medicine tests in infectious diseases-C1, radionuclide ventriculography-C2, myocardial scintigraphy-C2, cardiac PET-C2, ventilation/perfusion scintigraphy-C2, PET in lung cancer-C2, nuclear medicine tests in hematology-C3, scintigraphy of liver/spleen-C4, PET in gastrointestinal system tumors-C4, radioisotope imaging of thyroid and parathyroid-C5, renal scintigraphy (GFR, ERPF, Renogram)-C6, brain perfusion scintigraphy-C7, brain PET-C7, bone scintigraphy-C8*)

7.4.3. point of care testing

a. based on laboratory disciplines/subdisciplines;

1. medical biochemistry tests: (*diabetes tests-C5, cardiac markers-, coagulation tests-, blood gases-*).

2. medical microbiology tests: (*urine strip/dipstick test-C1, rapid screening (antigen/antibody tests-C5)*)

3. other laboratory tests: (*hematology-peripheral blood smear examination-C3, hematology-complete blood count-*)

7.5. making preliminary diagnosis or definitive diagnosis decision

7.6. making non-intervention or intervention decision

7.7. practicing non-intervention or intervention

7.8. referral/transport of healthy individual or patient

## **INTRODUCTION to CLINICAL PRACTICE- III (MED 303)**

### **Aim**

This course aims to equip the students with basic medical skills such as history taking regarding to systems and in general, physical and mental examination in simulated environments in pre-clinical period and to give the students opportunity to develop skills by applying non –invasive or invasive procedures on the mannequins before encountering with real patients. The students improve the gained skills by observing real encounters in the clinical settings during 2nd and 3rd year.

### **Learning Objectives**

#### **Description**

ICP is a three year longitudinal course that aims to introduce students to the concepts and main elements of medical practice. It will also be an introduction to the medical profession as a whole and will provide a foundation for clinical practice. The course provides knowledge, cognitive and motor skills and experience in fundamental processes and aspects of medical practice. It involves the application of scientific theory, quality assurance and evidence-based best practice protocols.

#### **Credit Facility:**

This course has 5 ECTS credits for the first and third year students while it is 4 ECTS for the second year students and all of the students are required to pass this course in order to pass the year.

#### **Content of the ICP I-II-III**

First year medical students gain knowledge on First Aid approaches, develop skills in Basic Life Support, Patient/Casualty Transportation and Bandaging Techniques regarding to First Aid. They also acquire basic knowledge on communication and experience patient-doctor encounter with simulated patients (SP's).

The second years ICP Program consist of modules like handwashing, wearing sterile gloves, assessing vital signs, nasogastric intubation, bladder catheterization, intramuscular, subcutaneous, intradermal and intravenous injections as well as iv. catheterization.

In the third year medical students practice with SP's clinical skills like history taking and physical examination focused on body systems and in general and also . mental examination They also gain clinical skills such as suturing techniques and Advanced Cardiac Life Support.

#### **Clinical Skills Laboratory**

The Clinical Skills Laboratory is designed for teaching and assessing students at undergraduate level (during the preclinical period from first-year to third year). The lab provides learners with the ideal setting to practice the clinical skills of history taking, physical examination, communication, and gives opportunities to practice invasive and non invasive procedural skills on mannequins.

Each exam room is equipped with video cameras and microphones to record the encounter. An observation area at the center of the lab allows faculty and students to observe the encounters live or view digital recordings for subsequent analysis.

#### **Simulated Patients (SPs)**

The simulated patient encounters provide transition of students from the classroom to standardized patient contact in safe environments.

Encounters with specially trained individuals, known as simulated patients (SPs), simulate specific cases in outpatient and emergency settings. The pool of SPs consist of adults, from various backgrounds.

Clinical cases are created through research and extensive training of the patients portraying these roles.

**Assessment:** The Assessment procedure of ICP is given in Assessment Table in this booklet.

**Rules for Attendance of the Students:** Students are grouped into 4 and group lists are announced in the announcement board at the beginning of the year. Any changes to practical groups on a week by week basis, will only be considered in exceptional situations such as a medical one. Any changes must be requested by a petition along with relevant documentation to the course coordinator. Any change in sessions will only be accepted interchangeably with another student in another group based on availability of work spaces and course coordinator's discretion (based on evidence provided).

Students are required to follow the rules of professional ethics in the laboratory at any time.

When an OSCE is conducted both students and faculty members complete a written evaluation of the event for the improvement of the course and OSCE.

## **SPECIFIC SESSIONS / PANELS**

### **Introductory Session**

#### **Aim of the session:**

The session provides basic information about Yeditepe University Faculty of Medicine Undergraduate Medical Education Program (YUFM/UG-ME) and the educational phase relevant to the students. This session orients the students to the program and the phase.

#### **Objectives of the Session:**

1. To provide basic information about the YUFM/UG-ME.
2. To provide basic information about the phase.
3. To provide essential information on social programs and facilities.

#### **Rules of the Session:**

1. The session will be held in two types, conducted by Phase Coordinator and Committee Coordinator, respectively.
2. The first type will be held once in the first week of the educational phase. The second type will be held at the beginning of each committee.
3. Students should attend the session.

#### **Implementation of the Session:**

In the first type, Phase Coordinator will present brief information on the following topics:

- Organizational Chart of Yeditepe University Faculty of Medicine Undergraduate Program (YUFM/UG-ME), Work Descriptions and Introduction of Committees Members,
- Directives on YUFM/UG-ME,
- YUFM/UG-ME Program Outcomes
- Learning Objectives of the Phase
- Academic Program of the Phase
- Teaching and Learning Methods
- Learning Environments and Sources/Resources
- Attendance
- Elective Courses (only in Phase I and Phase II)
- Assessment Procedure
- Grade Point Average, Cumulative Grade Point Average (GPA, cGPA) Calculation
- Pass/Fail Conditions
- Feedback of the Previous Year and Program Improvements
- Social Programs and Facilities

In the second type, Committee Coordinator will present brief information on the following topics:

- Learning Objectives of the Committee
- Academic Program of the Committee
- Teaching and Learning Methods
- Learning Environments and Sources/Resources, References
- Attendance
- Assessment Methods and Question Distribution Table
- Committee Score Calculation Method
- Pass/Fail Conditions
- Feedback of the Previous Year and Program Improvements
- Social Programs and Facilities

## **Committee Evaluation Session**

### **Aim of the Session:**

The aim of the session is to evaluate the committee educational program, with all its components, by the students and the committee coordinators. This session will contribute to the improvement of the educational program in general by giving the opportunity to identify the strengths of the committee educational program and revealing the areas which need improvement.

### **Objectives of the Program Evaluation Session** are to;

- establish a platform for oral feedbacks in addition to the systematically written feedback forms
- give the opportunity to the students and the coordinators to discuss the committee period face to face
- allow the students to review the committee exam questions together with faculty members.

### **Process:**

The total duration of the session is 90 minutes and the session consists of two parts. The first part (30 minutes) is dedicated to oral feedback by the students. All of the oral feedback will be recorded and reported by the committee coordination team. In the second part (60 minutes) committee exam questions will be reviewed and discussed by students and faculty.

### **Rules of the Committee Evaluation Session :**

1. The **Committee Evaluation Session** will be held on the last day of each committee after the committee exam.
2. Students are required to attend the session.
3. The Committee coordinator will lead the session.
4. The faculty members who had contributed questions in the committee exam should attend the session.
5. Students must comply with the feedback rules while giving verbal feedback and all participants shall abide by rules of professional ethics.



## **Committee Improvement Session**

### **Aim:**

The aim of this session is sharing the program improvements based on the evaluation of the educational program data, with the students and the faculty members.

### **Objectives:**

1. To share the improvements within educational program with the students and the faculty members.
2. To inform the students and the faculty members about the processes of the program improvement
3. To encourage student participation in the program improvement processes.

### **Rules:**

1. Program improvements session will be implemented once a year. The implementation will be performed at the beginning of the spring semester.
2. Students are required to attend the session.
3. The phase coordinator will monitor the session. If necessary the dean, vice deans and heads of the educational boards will attend to the session.
4. All faculty members will be invited to the session.

### **Implementation:**

#### **Before the Session**

1. Phase coordinator will report the results of the improvements of the educational program.
2. The program improvements report has three parts. The first part of the report includes improvements that have been completed, and those that are currently in progress. The second part of the report includes, improvements that are planned in medium term, and the third part of the report includes, improvements that are planned in the long term.
3. The program improvements report also includes the program evaluation data (student feedbacks, faculty feedbacks, results of the educational boards meetings etc.) in use of improvements.

#### **During the Session**

4. The phase coordinator will present the program improvements report to the students and the faculty members.
5. Students can ask questions about, and discuss, the results of the program improvement.

**Process:** The total period of session is 30 minutes and has two parts. The first part (15 minutes) covers, presenting of the program improvement report. The second part (15 minutes) covers, students' questions and discussion.

#### **After the Session**

6. The program improvement brief will be published on the website of Yeditepe University Faculty of Medicine (<http://med.yeditepe.edu.tr>).

## **Multidisciplinary Case Discussion Panel**

### **Aim:**

The aim of this instructional method is, to integrate what students learnt during committee, to fit in the clinical context and to promote deep learning.

### **Objectives:**

1. To relate learning objectives of the committee,
2. To relate clinical cases and learning subjects,
3. To explain learning objectives in the resolution of clinical cases,
4. To value the importance of multidisciplinary study in the resolution of clinical cases.

### **Implementation:**

#### **Before the Panel**

1. Case/cases that will be discussed in the panel will be chosen by a multidisciplinary team, in compliance with committee learning objectives.
2. The resources to analyse the cases will be specified by multidisciplinary team.
3. Students can get hard copies of the cases and the list of sources from student affairs at the beginning of the committee.
4. Students shall study cases in the context of learning objectives before the panel.
5. Before the panel, students may consult the faculty members for information about cases.

#### **During the Panel**

6. Cases will be shared visually with students by the multidisciplinary team.
7. Possible resolution of cases will be shared and discussed with students by the multidisciplinary team.
8. After the resolution of cases, students can ask questions to faculty members about the committee learning objectives in the context of cases.

**Process:** The total duration of the Panel is 60 minutes and has 2 parts. The first part (40 minutes), covers the presentation of cases, resolution of cases, asking questions to students and discussion as suitable to learning objectives during the resolution by multidisciplinary team. The second part (20 minutes), covers students' questions and discussion.

#### **After the Panel**

9. Students may continue reviewing the cases in the context of committee learning objectives.
10. The multidisciplinary team will review the usefulness of cases as a learning tool in the context of committee learning objectives. "The Panel Report" will be written by the multidisciplinary team.

## INDEPENDENT LEARNING

### Description:

"Independent learning" is a process, a method and a philosophy of education in which a student acquires knowledge by his or her own efforts and develops the ability for inquiry and critical evaluation. It includes freedom of choice in determining one's learning objectives, within the limits of a given project or program and with the aid of a faculty adviser. It requires freedom of process to carry out the objectives, and it places increased educational responsibility on the student for the achieving of objectives and for the value of the goals (1).

### Aim:

The aim of this instructional strategy is to develop the students' ability, to learn individually, so they are prepared for the classroom lessons, lectures, laboratory experiences and clinical practices, exams, professional life and have the abilities needed for lifelong learning.

### Objectives:

*With this instructional strategy, students will develop;*

- the skills that will help them to learn independently.
- self-discipline in their work habits.
- their evidence based research skills by using reliable resources.
- their teamwork skills by studying together.
- their clinical skills as self-directed working in the clinical skills laboratory.

### Rules:

1. All of the students will define independent learning process according to below algorithm.
2. All of the students will be required to fill out a form, which is a self-assessment form for the independent learning (methodology: timing, sources, strategy, etc.).
3. The students' academic performance and independent learning methodology will be analyzed comparatively, and feed-back on further improvements will be provided.

### What a student should do for learning independently?

1. **Analyzing:** First you will need to analyze carefully, what your problems and weaknesses are. For example, if you are studying anatomy, is your weak area broadly upper limb, lower limb, or what?
2. **Addressing:** Once you've decided your specific problems, you can list them. Which one needs to be addressed urgently? Work out your priorities. Whatever your subject area is, don't be afraid to return to the basics if necessary. It may give you more confidence in the long run to ensure you have a proper understanding of basic concepts and techniques.
3. **Accessing:** If you need reliable information, or if you need to read about a subject and put it into context, a textbook may be the best place to start. However, the Internet may be helpful if you need very up-to-date information, specific facts, or an image or video etc. If you need an academic research article, reports or case studies for your topic, then a database (Pubmed etc.) would be the best option.
4. **Timing:** In the weekly syllabus you will see, a specific time called "independent learning hour" for your independent work. In addition to these hours, the students should also have their own time schedule for their study time at home.
5. **Planning:** Your next step will be to work out a realistic study-plan for your work. What goals could you literally set for yourself? Don't make them too ambitious but set minor goals or targets that you know you will be able to achieve without having to spend a very long time working on them. How many hours will you need to achieve them? How will you know when you've achieved them?
6. **Recording:** When you work independently, it's a good idea to keep a written record of the work you've done. This can help with further planning and also give a sense of achievement as well as provide something to include in a progress file. As time goes by you may surprise yourself with what you've been able to achieve. This could motivate you to keep going, as could increase your confidence, and even improve your results
7. **Reflecting:** Reflecting on what you've done can help you decide whether the activity was really effective, whether an alternative approach might be better on another occasion, whether you spent the right amount of time and whether you have achieved the target you'd set yourself.

8. **Improving:** Once you've achieved the target, the process of planning can start again. Your needs and priorities may have changed, so think about them and then set yourself to another target.

**Reminder:** For further information about the independent learning, please contact the Department of Medical Education.

**Reference:**

1. Candy, P. (1991) Self-direction for lifelong learning: a comprehensive guide to theory and practice. San Francisco: Jossey Bass.

**For further reading useful resources to recommend to students:**

- Burnapp, D. (2009). Getting Ahead as an International Student. London: Open University Press.
- Marshall, L. & Rowland, F. (1998) A Guide to learning independently. London: Open University Press.
- University of Southampton / UKCISA online resource 'Prepare for Success'

## ASSESSMENT PROCEDURE

The Assessment Procedure of the Phase III covers exams and scores and their abbreviations that shown below.

- Exams:
  - Committee Exam (CE)
  - Mid-term Exam (MTE)
  - Final Exam (FE)
  - Incomplete Exam (ICE)
  - Make-up Exams (MUE)
- Scores\*:
  - Committee Score (CS)
  - Committees Mean Score (CMS)
  - Introduction to Clinical Practice Score (ICPS)
  - Scientific Project Score (SPS)
  - Final Exam Score (FES)
  - Incomplete Exam Score (ICES)
  - Term Score (TS)

\* All scores have a range of 0-100 points.

Assessment approaches, assessment methods and assessment tools, that related with the exam and score types, are shown in below table.

Assessment Approaches	Assessment Methods	Question Types / Assessment Tools	Exams	Derived Scores
Knowledge-based Assessment	WE: Written Examination	MCQ: Multiple Choice Questions	CE, MTE, FE, ICE	CS, ICPS, FES, ICES
		EMQ: Extended Matching Questions	CE	CS
		FSAQ: Fill-in-the-Blank Short Answer Questions	MuE	CS
Competency-based Assessment	OSCE: Objective Structured Clinical Examination	OSCE Checklist		ICPS
Performance-based Assessment	PWPE: Project Writing and Presenting Evaluation	PWPE Checklist		SPS

Exams Information (MED 302, MED 303)	
<b>CE</b>	For the proportional correspondence of individual learning objectives, please see the committee's assessment matrix table/page.
<b>FE</b>	FE consists of 200 MCQs. For the proportional contribution of each committee, please see the committee's assessment matrix table/page.
<b>ICE</b>	ICE consists of 200 MCQs. For the proportional contribution of each committee, please see the committee's assessment matrix table/page.
<b>MUE</b>	MUE will be held only twice in a term. MUE consists of FSAQs. MUE content will be developed by the coordination committees.

Scores Information (MED 302, MED 303)	
<b>CS</b>	The committee score is based on various question types/numbers and/or assessment tools (MCQ, EMQ, MEQ or Checklists). Please see the committee's assessment matrix table/page for the specifications.
<b>CMS</b>	= Average of CSs
<b>ICPS</b>	= (50% OSCE1) + (50% OSCE2)
<b>SPS</b>	= Score information is shown in below Scientific Projects Assessment Table.
<b>FES</b>	= Final Exam Score
<b>ICES</b>	= Incomplete Exam Score
<b>TS</b> <i>for students, <u>who are exempted</u> from FE</i>	= 96% of CMS + 4% of SPS
<b>TS</b> <i>for students, <u>who are not exempted</u> from FE</i>	= 96% of (60% of CMS + 40% of FES or ICES) + 4% of SPS

Pass or Fail Calculations of the Courses
<b>Basic Medical Sciences III (MED 302)</b>
<b>Pass; TS <math>\geq 50</math></b>
<b>Fail; FES <math>&lt; 50</math> (barrier point), ICES <math>&lt; 50</math> (barrier point), or/and TS <math>&lt; 50</math></b>
<i>The student is <u>exempted</u> from FE, if the CMS is <math>\geq 75</math> and all CSs are <math>\geq 50</math></i>
<i>The FE and ICE <u>barrier point</u> is <u>not applied</u> to the students whose all CSs are <math>\geq 50</math></i>
<b>Introduction to Clinical Practise III (MED 303)</b>
<b>Pass; ICPS <math>\geq 50</math></b>
<b>Fail; ICPS <math>&lt; 50</math></b>

*The Assessment Procedure of the Phase III will be announced and explained in the introductory session at the beginning of the academic year.*

### **Definitions of the Assessment Methods and Question Types**

**MCQ** consist of a question, followed by five plausible alternative responses from which the student has to select the correct one.

**EMQ** are similar to multiple choice questions but with one key difference, that they test knowledge in a far more applied, in depth, sense. EMQ is based on a single theme, two or more questions and has a long option list.

**MEQ** is made up of one or more short answer questions. The student is provided with basic science or clinical information and then asked to write brief responses to one or more questions. When a series of questions is presented, additional information about the original problem can be provided at each subsequent step, guiding the students through an analytical process.

**FSAQ**, Fill-in-the-Blank Short Answer Questions are typically composed of a brief prompt that demands a written answer that varies in length from one or two words to a sentence.

**OSCE** describes a form of competency-based testing used to measure a student's clinical competence. During an OSCE, students are observed and evaluated as they go through a series of stations in which they interview, examine and treat simulated patients who present with some type of medical problem.

### **SCIENTIFIC PROJECTS – III**

The aim of Scientific Projects program is to develop awareness in medical students for the importance of scientific projects in profession and provide them opportunity to gain knowledge, skills and attitudes in writing and conducting a scientific project. Throughout the year, each Phase Three student is expected to prepare a scientific project proposal. Students are free to choose their research area and advisor for their prospective research project. Students who wish to apply for a “TUBITAK 2209-A National Grant Program for University Students” has to send in their proposals before February 2016, the rest should hand in their proposals before the end of March. Scientific Projects course has 4% contribution to Term Score (TS).

**SCIENTIFIC PROJECTS ASSESSMENT TABLE**

<b>CRITERIA</b>	<b>Unsatisfactory</b>	<b>Below Expectations</b>	<b>Meets Expectations</b>	<b>Above Expectations</b>	<b>Clearly Outstanding</b>	<b>Not Addressed / Observed</b>
Is the question/ problem presented clearly?	1	2	3	4	5	0
Creativity/originality of the Project	1	2	3	4	5	0
Is set up of the Project suitable to obtain aims?	1	2	3	4	5	0
Presentation of aims in an easy to understand format	1	2	3	4	5	0
Review of project proposal in light of literature	1	2	3	4	5	0
Proposal presentation in correct format	1	2	3	4	5	0
Does proposal explain the project's significance and contributions well?	1	2	3	4	5	0
Project calendar presentation	1	2	3	4	5	0
<b>TOTAL POINTS</b>	<b>40 x 2.5=100 pts (if all criteria has 5 points)</b>					

## EXAM RULES

- **Seating-** Students will be seated by the exam observers or proctors. Students are not allowed to change their seats without permission.
- **Electronics** – During examinations or tests, students are prohibited from using electronic devices or any other means of communication and recording that have not been approved beforehand. All electronic devices are prohibited. Anyone who fails to comply with these regulations may be charged with academic fraud.
- **Absence** – No additional time will be given to students who are absent for part of the exam, regardless of the reason for their absence.
- **Scratch Paper** – Students are not allowed to bring scratch paper into the exam room.
- **Meaning of Questions** – Students may not consult the supervisor as to the meaning of any question.
- **Signature** – Students must sign their multiple-choice answer sheets and/or written-answer sheets.
- **Other activities requiring disciplinary action-**
  - Students must not give or receive Assistance of any kind during the exam.
  - Gaining access to exam questions before the exam.
  - Using an unauthorized calculator or other mechanical aid that is not permitted.
  - Looking in the exam book before the signal to begin is given.
  - Marking or otherwise writing on the exam book or answer sheet before the signal to begin is given.
  - Making any changes, additions, deletions or other marking, erasing or writing on the exam book or answer sheet after the time for the exam has expired.
  - Having access to or consulting notes or books during the exam.
  - Looking at or copying from another student's paper.
  - Enabling another student to copy from one's paper.
  - Talking or otherwise communicating with another student during the exam or during the read through period.
  - Disturbing other students during the exam.
  - Consulting other persons or resources outside the exam room during the exam.
  - Copying questions or answers either on paper or with an electronic device to take from the exam room.
  - Taking an exam book or other exam materials from the exam room.
  - Taking an exam in place of another student.
  - Arranging to have another person take an exam for the student.
  - Disobeying to the conduct of supervisor during the exam.
  - Disclosing the contents of an exam to any other person.
  - Failing to remain in the exam room for a given period of time by the supervisors.
  - Failing to follow other exam instructions.

Those students found to have committed academic misconduct will face administrative sanctions imposed by the administration of Yeditepe University Faculty of Medicine according to the disciplinary rules and regulations of the Turkish Higher Education Council (YÖK) for students (published in the Official Journal on August 18th, 2012). The standard administrative sanctions include, the creation of a disciplinary record which will be checked by graduate and professional life, result in grade "F" on the assignment, exams or tests or in the class. Students may face suspension and dismissal from the Yeditepe University **for up to one school year**. In addition, student may lose any academic and non academic scholarships given by the Yeditepe University **for up to four years**. The appropriate sanctions are determined by the Yeditepe University administration according to egregiousness of the Policy violation.



## COURSE LOCATIONS

COURSE CODES	COURSE NAMES	LOCATIONS
MED 302	Introduction to Clinical Sciences	<b>Lectures/Sessions/Panels:</b> Room Number: B309, Base Floor, Medical Faculty Block, Yeditepe University Campus. <b>Microbiology Laboratory:</b> Room Number: 934, 5th Floor, Medical Faculty Block, Yeditepe University Campus. <b>Pathology Laboratory:</b> Room Number: 929-930, 5th Floor, Medical Faculty Block, Yeditepe University Campus.
MED 303	Introduction to Clinical Practice	<b>ICP-CSL:</b> Room Number: 442, Base Floor, Medical Faculty Block, Yeditepe University Campus. <b>YH:</b> Yeditepe University Hospital.

**Yeditepe University Campus Address:** İnönü Mah. Kayışdağı Cad. 26 Ağustos Yerleşimi, 34755, Ataşehir, İstanbul.

**Yeditepe University Hospital Address:** İçerenköy Mah. Hastane Yolu Sok. No:102-104. Ataşehir, İstanbul.

## ACADEMIC CALENDAR of PHASE III 2016 - 2017

### COMMITTEE I

#### INFECTIOUS DISEASES (5 Weeks)

Beginning of Committee	September 05, 2016	Monday
End of Committee	October 07, 2016	Friday
<b>Committee Exam</b>	<b>October 07, 2016</b>	<b>Friday</b>
 <b>Religious Holiday</b>	 <b>September 12-16, 2016</b>	 <b>Monday-Friday</b>

### COMMITTEE II

#### CARDIOLOGY AND RESPIRATORY SYSTEM (7 Weeks)

Beginning of Committee	October 10, 2016	Monday
End of Committee	November 25, 2016	Friday
<b>Committee Exam</b>	<b>November 25, 2016</b>	<b>Friday</b>
 <b>National Holiday</b>	 <b>October 28<sup>1/2</sup>, 2016</b>	 <b>Friday</b>
<b>Commemoration of Atatürk</b>	<b>November 10, 2016</b>	<b>Thursday</b>

### COMMITTEE III

#### HEMATOPOIETIC SYSTEM (3 Weeks)

Beginning of Committee	November 28, 2016	Monday
End of Committee	December 16, 2016	Friday
<b>Committee Exam</b>	<b>December 16, 2016</b>	<b>Friday</b>

### COMMITTEE IV

#### GASTROINTESTINAL SYSTEM (4 Weeks)

Beginning of Committee	December 19, 2016	Monday
End of Committee	January 13, 2017	Friday
<b>Committee Exam</b>	<b>January 13, 2017</b>	<b>Friday</b>
 <b>New Year</b>	 <b>January 01, 2017</b>	 <b>Sunday</b>
<b>MIDTERM BREAK</b>	<b>January 16, 2017</b>	<b>January 27, 2017</b>

**COMMITTEE V****ENDOCRINE SYSTEM and REPRODUCTIVE SYSTEMS (5 Weeks)**

Beginning of Committee	January 30, 2017	Monday
End of Committee	March 03, 2017	Friday
<b>Committee Exam</b>	<b>March 03, 2017</b>	<b>Friday</b>
<b>OSCE I (Exam)</b>	<b>February 23-24, 2017</b>	<b>Thursday-Friday</b>
<b>Make-up Exam I (ICS)</b>	<b>February 2, 2017</b>	<b>Thursday</b>

**COMMITTEE VI****URINARY SYSTEM (4 Weeks)**

Beginning of Committee	March 06, 2017	Monday
End of Committee	March 31, 2017	Friday
<b>Committee Exam</b>	<b>March 31, 2017</b>	<b>Friday</b>
<b>ICP Make-up Exam</b>	<b>March 23, 2017</b>	<b>Thursday</b>
<b>Physicians' Day</b>	<b>March 14, 2017</b>	<b>Tuesday</b>

**COMMITTEE VII****NERVOUS SYSTEM and PSYCHIATRY (6 Weeks)**

Beginning of Committee	April 03, 2017	Monday
End of Committee	May 12, 2017	Friday
<b>Committee Exam</b>	<b>May 12, 2017</b>	<b>Friday</b>

<b>Labour's Day</b>	<b>May 01, 2017</b>	<b>Monday</b>
---------------------	---------------------	---------------

**COMMITTEE VIII****MUSCULOSKELETAL SYSTEM (4 Weeks)**

Beginning of Committee	May 15, 2017	Monday
End of Committee	June 09, 2017	Friday
<b>Committee Exam</b>	<b>June 09, 2017</b>	<b>Friday</b>
<b>OSCE II (Exam)</b>	<b>June 12-13, 2017</b>	<b>Monday-Tuesday</b>
<b>Make-up Exam II (ICS)</b>	<b>June 16, 2017</b>	<b>Friday</b>

<b>National Holiday</b>	<b>May 19, 2017</b>	<b>Friday</b>
-------------------------	---------------------	---------------

<b>Final Exam</b>	<b>June 30, 2017</b>	<b>Friday</b>
<b>Incomplete Exam (ICP)</b>	<b>July 28, 2017</b>	<b>Monday</b>
<b>Incomplete Exam (ICS)</b>	<b>July 28, 2017</b>	<b>Friday</b>

<b>1. Coordination Committee Meeting</b>	<b>October 20, 2016</b>	<b>Thursday</b>
<b>2. Coordination Committee Meeting</b>	<b>January 05, 2017</b>	<b>Thursday (with student participation)</b>
<b>3. Coordination Committee Meeting</b>	<b>May 10, 2017</b>	<b>Wednesday (with student participation)</b>
<b>4. Coordination Committee Meeting</b>	<b>July 04, 2017</b>	<b>Tuesday</b>

## RECOMMENDED TEXTBOOKS

### Biomedical Ethics & Deontology

1. Marcia Lewis , Carol D. Tamparo. Medical Law, Ethics, & Bioethics for the Health Professions, F.A. Davis Publishing House, 2012, ISBN: 0803627068
2. Michael Boylan. Medical Ethics, Wiley-Blackwell Publishing House, 2013, ISBN: 978-1118494752

### Biostatistics

1. Pagano, Marcello, Gauvreau, Kimberlee. Principles of Biostatistics. Duxbury Press, 2000 ISBN 0534229026, 9780534229023.
2. Glantz, Stanton A. Primer of Biostatistics. 7th Edition. McGraw Hill Professional, 2011. ISBN 0071447814, 9780071447812.

### Infectious Diseases and Clinical Microbiology

1. Murray, Patrick R, Rosenthal, Ken S, Pfaller, Michael A.. Medical Microbiology with STUDENT CONSULT Online Access. 7th Edition, 2012, ISBN-10: 0323086926, ISBN-13: 978-0323086929.

### Medical Genetics

1. Turnpenny, Peter D, Ellard, Sian. Emery's Elements of Medical Genetics. 14th Edition. Churchill Livingstone, 2012, ISBN: 9780702040436

### Neurosurgery

1. Microneurosurgery, Volume I to VolumeV, Thieme Kindle Edition by Mahmut Gazi Yasargil (Author)
2. Neurology and Neurosurgery Illustrated,5th Edition by Kenneth W. Lindsay PhD FRCS (Author), Ian Bone FRCP FACP (Author), Geraint Fuller MD FRCP (Author)
3. Handbook of NeurosurgeryFeb 22, 2010 by Mark S. Greenberg

### Pharmacology

1. Harvey, Richard A. Lippincott's Illustrated Review of Pharmacology. , Wolters Kluwer Health, 2012. ISBN-13: 978-1451113143; ISBN-10: 1451113145
2. Katzung, Bertram G., Masters, Susan B., Trevor Anthony J. Katzung's Basic & Clinical Pharmacology. 12th Edition. McGraw Hill Companies, 2012. ISBN-13: 978-0071825054; ISBN-10: 0071825053.
3. Brunton, Laurence, Chabner, Bruce, Knollman, Bjorn. Goodman&Gilman's The Pharmacological Basis of Therapeutics. Editors: 12th Edition. McGraw Hill Companies, 2011. ISBN-13: 978-0071624428

### Orthopedic Surgery

1. Ortopedik Fizik Muayane, çeviri ed. Uğur Şaylı, Güneş Tıp Kitapevi
2. Review of Orthopaedics, 6th edition (ed. Mark D. Miller)
3. AAOS Comprehensive Orthopaedic Review, 2nd edition (ed. Martin I. Boyer)

### Pathology

1. Abbas Aster, Kumar. Robbins Basic Pathology. 9th edition, Saunders, Elsevier Inc. 2013. ISBN:978-0-8089-2432-6

### Psychiatry

1. Öztürk O. Ruh Sağlığı ve Bozuklukları. 2. Baskı, Ankara 2011. ISBN: 9786058617292
2. Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock's Comprehensive Textbook of Psychiatry, 9. Ed. 2009, Lippincott Williams & Wilkins, PA, USA. ISBN: 9780781768993
3. Purves D, Augustine GJ. Fitzpatrick D. et al. Neuroscience. 5. Ed. 2012, Sinauer Assoc, Mass, USA. ISBN: 9780878936953

### General Surgery

1. Brunicaudi, F. Schwartz's Principles of Surgery, 10th edition, July 16, 2014, ISBN: 0071796754 / 9780071796750

### Urology

1. Campbell-Walsh Urology, 11th Edition 4-Volume Set. By Alan J. Wein, MD, FACS, PhD (hon), Louis R. Kavoussi, MD, Alan W. Partin, MD, PhD and Craig A. Peters, MD, FACS, FAAP. Imprint: Elsevier. ISBN: 978-1-4557-7567-5. Copyright: 2016

## COMMITTEES

In phase I, II and III, the formation of committees is based on a thematic structure. This structure corresponds to organizational levels of human body such that macromolecule, organelle, cell, tissue, organ systems and finally introduction to pathogenesis.

- Phase I: Normal structure and function of human body at molecular, cellular, tissue and organ level.
- Phase II: Normal structure and function of human body at system and multi-system level, and introduction to pathogenesis.
- Phase III: Physiopathological and pathological processes in human body.

Besides this thematic structure, there is a continuous clinical skills education in Phase I, II and III, as "Introduction to Clinical Practice -I, -II and -III" courses.

Therefore, the core medical courses are;

- Phase I: MED 104 Basic Medical Sciences I, MED 102 Introduction to Clinical Practice I, MED 103 Anatomical Drawing,
- Phase II: MED 201 Basic Medical Sciences II, MED 202 Introduction to Clinical Practice II,
- Phase III: MED 302 Introduction to Clinical Sciences, MED 303 Introduction to Clinical Practice III.

The learning objectives of the phase include learning objectives of core courses. The learning objectives of committees include learning objectives of core courses' components for the committee.

**COMMITTEE I - INFECTIOUS DISEASES**  
**DISTRIBUTION of LECTURE HOURS**  
**September 05, 2016 - October 07, 2016**  
**COMMITTEE DURATION: 5 WEEKS**

<b>MED 302</b>	<b>INTRODUCTION TO CLINICAL SCIENCES</b>	<b>ABBR.</b>	<b>THEO.</b>	<b>PRAC.</b>	<b>LAB/CSL</b>	<b>DISCUSSION</b>	<b>TOTAL</b>
<b>DISCIPLINE</b>	INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY	IDCM	18		2 (4 Groups)		<b>20</b>
	PHARMACOLOGY	PC	15				<b>15</b>
	PATHOLOGY	PT	8				<b>8</b>
	PUBLIC HEALTH	PH	8				<b>8</b>
	BIOMEDICAL ETHICS & DEONTOLOGY	BED	8				<b>8</b>
	BIOSTATISTICS	BS	4				<b>4</b>
	INTERNAL MEDICINE	IM	2				<b>2</b>
	PATHOPHYSIOLOGY	PP	2				<b>2</b>
	FAMILY MEDICINE	FM	2				<b>2</b>
	MEDICAL GENETICS	MG	2				<b>2</b>
	EMERGENCY MEDICINE	EM	1				<b>1</b>
	PEDIATRICS	PED	1				<b>1</b>
	SCIENTIFIC PROJECTS-III	SP	1				<b>1</b>
	INTERDISCIPLINARY	MCDP				2	<b>2</b>
<b>MED 303</b>	<b>INTRODUCTION TO CLINICAL PRACTICE III</b>	ICP III			3 (4 Groups)		<b>3</b>
<b>TOTAL</b>			<b>72</b>		<b>5</b>	<b>2</b>	<b>79</b>

**Coordination Committee**

<b>HEAD</b>	Meral Sönmezoğlu, MD, Prof.
<b>SECRETARY</b>	İ. Çağatay Acuner, MD, Assoc. Prof.
<b>MEMBER</b>	Yaşar Küçükardalı, MD, Prof.
<b>MEMBER</b>	Hale Arık Taşyikan, MD, Asst. Prof.

**COMMITTEE I - INFECTIOUS DISEASES  
LECTURERS**

<b>MED 302 INTRODUCTION TO CLINICAL SCIENCES</b>	
<b>DISCIPLINE</b>	<b>LECTURERS</b>
INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY	Meral Sönmezoğlu, MD, Prof. İ. Çağatay Acuner, MD, Assoc. Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Ferda Kaleağasıoğlu, MD, Prof.
PATHOLOGY	Ferda Özkan, MD, Prof. Işın Doğan Ekici, MD, Prof. Ahmet Sedat Çöloğlu, DMD, Prof.
PUBLIC HEALTH	Erol Sezer, MD, Prof Hale Arık Taşyikan, MD, Asst. Prof
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, Assoc. Prof.
PEDIATRICS	Suat Biçer, MD, Assoc. Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu, MD, Assoc. Prof.
FAMILY MEDICINE	Güldal İzbirak, MD, Assoc.Prof. Özlem Tanrıöver, MD, Assoc.Prof.
INTERNAL MEDICINE	Yaşar Küçükardalı, MD. Prof.
EMERGENCY MEDICINE	Mustafa Ferudun Çelikmen, MD, Asst Prof.
BIOSTATISTICS	Çiğdem Kaspar, PhD, Asst. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Asst. Prof.
SCIENTIFIC PROJECTS-III	Gülderen Yanıkkaya Demirel, MD, Assoc. Prof.

<b>MED 303 INTRODUCTION TO CLINICAL PRACTICE III</b>	
<b>DISCIPLINE</b>	<b>LECTURERS</b>
CLINICAL SKILLS LAB	Sezgin Sarıkaya, MD, Assoc. Prof. Mustafa Ferudun Çelikmen, MD, Asst. Prof. Pınar Tura, MD, Asst. Prof.

## COMMITTEE I - INFECTIOUS DISEASES

### AIMS and LEARNING OBJECTIVES

#### AIMS

*In evidence based manner,*

1. **to remind** knowledge on structures of agents that cause infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
2. **to convey** knowledge on epidemiology of infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
3. **to convey** knowledge on pathogenesis mechanisms of agents that cause infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
4. **to convey** necessary knowledge on prevention of infectious clinical conditions, and protection or improvement of health against these conditions,
5. **to convey** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
6. **to convey** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing infectious clinical conditions, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. **to convey** necessary knowledge on pharmacology of drugs used in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
8. **to convey** necessary knowledge on ethical problems encountered in health care service and utilization, and on principles of solutions,
9. **to convey** biostatistical knowledge required in design of medical research,
10. **to convey** necessary knowledge on genetical basis of clinical conditions,
11. **to equip with** basic clinical skills, (intravenous injection on phantom model), required at primary health care service level.

#### LEARNING OBJECTIVES

*At the end of this committee, student should be able to:*

- 1.0. **explain** basic characteristics of infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
- 2.1. **recall** structures, and
- 2.2. **explain** mechanisms of pathogenesis of agents (bacteria, viruses, fungi, parasites, prions) that cause infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
- 3.0. **classify** infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, based on causative agents and systems,
- 4.0. **explain** mechanisms of change in structure and function at molecular, cellular, tissue, system, multi-system and organismal levels in infectious clinical conditions which are frequent in community



- and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
- 5.0. **explain** mechanisms of host immune response to and consequences in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
  - 6.0. **explain** epidemiology of infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
  - 7.0. **explain** requirements for prevention of infectious clinical conditions, and protection or improvement of health against these conditions, in healthy or susceptible individual or community,
  - 8.0. **explain** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
  - 9.0. at multi-system level or related to a body system,
    - for healthy conditions in an individual or community with a request against infectious clinical conditions that pose risks,
    - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
    - for infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,**explain** in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,
    - health care processes, clinical decision making process, clinical decisions and clinical practices which are required for management at primary health care service level:
  - 9.1. practice of history taking and physical examination
  - 9.2. evaluation of emergency case (sepsis and septic shock-C1)
  - 9.3. approach to healthy individual or patient (fever-C1)
  - 9.4. laboratory tests/examinations (urine sample collection-C1, urine strip/dipstick test-C1, urine culture-C1)
  - 9.5. imaging tests/examinations (nuclear medicine tests in infectious diseases-C1)
  - 9.6. point of care testing (urine strip/dipstick test-C1)
  - 9.7. making preliminary diagnosis or definitive diagnosis decision
  - 9.8. making non-intervention or intervention decision
  - 9.9. practicing non-intervention or intervention
  - 9.10. referral/transport of healthy individual or patient
  - 10.1. **list** goals and principles of drug use,
  - 10.2. **describe** effects,
  - 10.3. **explain** mechanism of action (pharmacodynamics),
  - 10.4. **list** indications, contraindications, pharmacological features, pharmacokinetic characteristics, drug-drug interactions and side effects,
  - 10.5. **explain** resistance mechanisms of drugs (principles of antimicrobial chemotherapy, antibacterial, antifungal, antiviral, antiprotozoal, antihelmintic drugs, antiseptics and disinfectants) used in infectious clinical conditions,
  - 11.0. **explain** interactions of health conditions (healthy and clinical conditions) at individual, family and community levels in relation to infectious agents, and importance of infectious agents and infectious clinical conditions from the aspect of public health,
  - 12.0. **define** approaches (education, sanitation, hygiene, disinfection/antisepsis/sterilization, screening, surveillance, vaccination, prophylaxis, isolation, design/renovation) to control risks in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health,
  - 14.0. **explain** hereditary immune system disorders,
  - 15.0. **explain** ethical problems (violation of truthfulness, responsibilities of physician and patient, allocation of scarce resources) encountered in health care service and utilization, and principles of solutions,
  - 16.0. **define** biostatistical knowledge required in design of medical research (research design, planning medical research,

- 17.0. **perform** basic clinical skills, practiced on phantom models (intravenous injection-C1), required at primary health care service level.
- 18.0. **explain** ethical problems (violation of truthfulness, responsibilities of physician and patient, allocation of scarce resources) encountered in health care service and utilization, and principles of solutions,
- 19.0. **define** biostatistical knowledge required in design of medical research (research design, planning medical research,
- 20.0. **perform** basic clinical skills, practiced on phantom models (intravenous injection-C1), required at primary health care service level.

## COMMITTEE I - INFECTIOUS DISEASES

### COMMITTEE ASSESSMENT MATRIX

PHASE III						
COURSE: MD 320 INTRODUCTION TO CLINICAL SCIENCES						
COURSE COMPONENT: COMMITTEE I - INFECTIOUS DISEASES						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/ INSTRUCTOR	NUMBER OF QUESTIONS (MCQ)			
			CE	FE	IE	Total
1.0, 2.0.,3.0. (4.0.-12.0.)	IDCM	M. Sönmezoğlu	22	5	5	32
1.0.,3.0. (4.0.-12.0.)		İ.Ç.Acuner				
10.0.	PC	E.Genç	19	5	5	29
10.0.		F.Kaleağasıoğlu				
4.0.,5.0.	PT	F. Özkan	10	2	2	14
4.0.,5.0.		I. D. Ekici				
4.0., 5.0.		A.S.Çöloğlu				
6.0.,7.0.,11.0.,12.0.	PH	R.E. Sezer	10	2	2	14
6.0.,7.0.,11.0.,12.0.		H.A.Taşıyan				
15.0.	BED	E. Vatanoğlu	10	2	2	14
16.0.	BS	Ç. Kaspar	5	1	1	7
9.3. (6.0.-9.0.,11.0.,12.0.)	FM	Ö. Tanrıöver	3	1	1	5
9.3. (6.0.-9.0.,11.0.,12.0.)		G. İzbırak				
8.0.,9.0., 9.1.	IM	Y. Küçükardalı	3	1	1	5
4.0.,5.0.,8.0.	PP	M. Kaçar	3	1	1	5
14.0.	MG	A. Ç. Kuşkucu	3	1	1	5
9.2.	EM	S. Sarıkaya	1	1	1	3
8.0.,9.0., 9.1.	PED	M. Berber	1	0	0	1
TOTAL			90	22	22	134
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (EMQ)			
1.0, 2.0.,3.0. (4.0.-12.0.)	IDCM	M. Sönmezoğlu/ İ.Ç. Acuner	2	-	-	2
10.0.	PC	E.Genç/ F.Kaleağasıoğlu	2	-	-	2
4.0.,5.0.	PT	I. D. Ekici/ F. Özkan	1	-	-	1
TOTAL			5	-	-	5

**CS\*= 90 pts (MCQ) + 10 pts (EMQ) = 100 pts; pts:points**

\*Each MCQ has a value of 1 points; each EMQ question has a value of 2 points.

**MCQ:** Multiple Choice Question

**EMQ:** Extending Matching Question

**CE:** Committee Exam

**CS:** Committee Score

**FE:** Final Exam

**ICE:** Incomplete Exam

**\*\*22** out of 200 FE and ICE MCQs will be from Committee I (Each question is of worth **0.5** pts).

**COMMITTEE I - INFECTIOUS DISEASES**  
**WEEK I / 5-9 Sep 2016**

	<b>Monday 5-Sep-2016</b>	<b>Tuesday 6-Sep-2016</b>	<b>Wednesday 7-Sep-2016</b>	<b>Thursday 8-Sep-2016</b>	<b>Friday 9-Sep-2016</b>
<b>09.00- 09.50</b>	<b>Introductory Session</b> Introduction to Phase III <b>Phase III Coordination Committee</b> Introduction to Committee I <b>Head of Committee</b>	<b>Lecture</b> Pathology of Mycobacterial Infections I <b>A. S. Çöloğlu</b>	<b>Lecture</b> Semiology-I <b>Y. Küçükardalı</b>	<b>Lecture</b> Scientific Projects - III: Project Writing <b>G. Y. Demirel</b>	<b>Microbiology Laboratory (Antibacterial &amp; Susceptibility Testing)</b> <b>Microbiology Lecturers</b>
<b>10.00- 10.50</b>	<b>Lecture</b> Diagnosis of Infectious Diseases I <b>Microbiology Lecturer</b>	<b>Lecture</b> Pathology of Mycobacterial Infections II <b>A. S. Çöloğlu</b>	<b>Lecture</b> Semiology-II <b>Y. Küçükardalı</b>	<b>Microbiology Laboratory (Antibacterial &amp; Susceptibility Testing)</b> <b>Microbiology Lecturers</b>	<b>GROUP A IL</b> <b>GRUP B</b> <b>GROUP C</b> <b>GROUP D IL</b>
<b>11.00- 11.50</b>	<b>Lecture</b> Diagnosis of Infectious Diseases II <b>Microbiology Lecturer</b>	Antimicrobial Agents: Basic Concepts & Principles <b>İ.Ç.Acuner</b>	<b>Lecture</b> Introduction to Antimicrobial Chemotherapy <b>F. Kaleağasıoğlu</b>	<b>GROUP A</b> <b>GROUP A IL</b> <b>GROUP C IL</b> <b>GROUP D IL</b>	<b>GROUP A IL</b> <b>GRUP B</b> <b>GROUP C IL</b> <b>GROUP D</b>
<b>12.00- 12.50</b>	<b>Lecture</b> Tissue Response to Infections <b>A. S. Çöloğlu</b>	Antimicrobial Agents: Mechanisms of Resistance <b>İ.Ç.Acuner</b>	<b>Lecture</b> β Lactam Antibiotics I <b>F. Kaleağasıoğlu</b>	<b>GRUP B IL</b> <b>GRUP B</b> <b>GROUP C IL</b> <b>GROUP D IL</b>	<b>Independent Learning</b>
<b>12.50 - 14.00</b>	<b>LUNCH BREAK</b>				
<b>14.00- 14.50</b>	<b>Lecture</b> Pathology of Bacterial Infections <b>A. S. Çöloğlu</b>	<b>Lecture</b> Confidentiality and Truthfulness I <b>E. Vatanoğlu</b>	<b>Lecture</b> Planning Medical Studies I <b>Ç. Kaspar</b>	<b>Lecture</b> β Lactam Antibiotics II <b>F. Kaleağasıoğlu</b>	<b>Independent Learning</b>
<b>15.00- 15.50</b>	<b>Lecture</b> Introduction to the Course I <b>E.Vatanoğlu</b>	<b>Lecture</b> Confidentiality and Truthfulness II <b>E. Vatanoğlu</b>	<b>Lecture</b> Planning Medical Studies II <b>Ç. Kaspar</b>	<b>Lecture</b> Research Design I <b>Ç. Kaspar</b>	<b>Independent Learning</b>
<b>16.00- 16.50</b>	<b>Lecture</b> Introduction to the Course II <b>E.Vatanoğlu</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Lecture</b> Research Design II <b>Ç. Kaspar</b>	<b>Independent Learning</b>
<b>17.00-17.50</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

**COMMITTEE I - INFECTIOUS DISEASES**  
**WEEK II / 12-16 Sep 2016**

	Monday 12-Sep-2016	Tuesday 13-Sep-2016	Wednesday 14-Sep-2016	Thursday 15-Sep-2016	Friday 16-Sep-2016
09.00- 09.50	Independent Learning	Religious Holiday	Religious Holiday	Religious Holiday	Religious Holiday
10.00- 10.50					
11.00- 11.50					
12.00- 12.50					
12.50 – 14.00					
14.00- 14.50	Religious Holiday	Religious Holiday	Religious Holiday	Religious Holiday	Religious Holiday
15.00- 15.50					
16.00- 16.50					
17.00-17.50					

**COMMITTEE I - INFECTIOUS DISEASES**  
**WEEK III / 19-23 Sep 2016**

	Monday 19-Sep-2016	Tuesday 20-Sep-2016	Wednesday 21-Sep-2016	Thursday 22-Sep-2016	Friday 23-Sep-2016
09.00- 09.50	Independent learning	<b>Lecture</b> Vancomycin & Other Cell Wall Synthesis Inhibitors F. Kaleağasıoğlu	<b>Lecture</b> Tuberculosis & Other Mycobacterial Infections I İ.Ç. Acuner	<b>Lecture</b> Antimycobacterial Drugs E.Genç	<b>Lecture</b> Bacterial and Viral Skin & Soft Tissue Infections M. Sönmezoğlu
10.00- 10.50	Independent learning	<b>Lecture</b> Macrolides F. Kaleağasıoğlu	<b>Lecture</b> Tuberculosis & Other Mycobacterial Infections II M. Sönmezoğlu	<b>Microbiology Laboratory</b> (Techniques and Diagnostic Tests) Microbiology Lecturers	<b>Lecture</b> Parasitic Infections II M. Sönmezoğlu
11.00- 11.50	<b>Lecture</b> Parasitic Infections I Microbiology Lecturer	<b>Lecture</b> Pathology of the Parasitic Infections F. Özkan	<b>Lecture</b> Zoonotic Diseases I M. Sönmezoğlu	GROUP A GROUP B IL GROUP C IL GROUP D IL	<b>Lecture</b> Anthelmintic Drugs F. Kaleağasıoğlu
12.00- 12.50	<b>Lecture</b> Fungal and Parasitic Skin and Soft Tissue Infections Microbiology Lecturer	<b>Lecture</b> Pathology of Fungal Infections F. Özkan	<b>Lecture</b> Zoonotic Diseases II M. Sönmezoğlu	GROUP A IL GROUP B GROUP C GROUP D	<b>Lecture</b> Antiprotozoal Drugs F. Kaleağasıoğlu
12.50 – 14.00	LUNCH BREAK				
14.00- 14.50	<b>Lecture</b> Hospital Infection M. Sönmezoğlu	<b>Lecture</b> Aminoglycosides E.Genç	<b>ICP-CSL</b> (Intravenous Injection & iv Cannulation) S.Sarıkaya/P. Tura/M.F. Çelikmen	<b>Lecture</b> Approach to the Patient with Fever in Primary Care Ö. Tanrıöver	<b>Lecture</b> Occupational Health Hazards I Microbiology Lecturer
15.00- 15.50	<b>Lecture</b> Febrile Neutropenia M. Sönmezoğlu	<b>Lecture</b> Sulfonamides, Chloramphenicol & Tetracyclines E.Genç	Group A Group B IL Group C IL Group D IL	<b>Lecture</b> Quinolones F. Kaleağasıoğlu	<b>Lecture</b> Occupational Health Hazards II Microbiology Lecturer
16.00- 16.50	<b>Lecture</b> Principles of Autonomy and Informed Consent I E. Vatanoğlu	<b>Lecture</b> Introduction to Clinical Genetics A. Ç. Kuşkuç		<b>Lecture</b> Pathophysiology of Infectious Diseases I M. Kaçar	<b>Lecture</b> Public Health and Communicable Diseases-I R.E.Sezer
17.00-17.50	<b>Lecture</b> Principles of Autonomy and Informed Consent II E. Vatanoğlu	<b>Lecture</b> Inherited Immune System Disorders A. Ç. Kuşkuç	Independent Learning	<b>Lecture</b> Pathophysiology of Infectious Diseases II M. Kaçar	<b>Lecture</b> Public Health and Communicable Diseases-II R.E.Sezer

**COMMITTEE I - INFECTIOUS DISEASES**  
**WEEK IV / 26-30 Sep 2016**

	Monday 26-Sep-2016	Tuesday 27-Sep-2016	Wednesday 28-Sep-2016	Thursday 29-Sep-2016	Friday 30-Sep-2016
09.00- 09.50	Lecture Infections in Immuncompromised Host Microbiology Lecturer	Lecture Prevention and Control of Communicable Diseases I R.E. Sezer	Lecture Antifungal Drugs F. Kaleağasioğlu	Lecture Pathology of Viral Infections I I.D.Ekici	ICP-CSL (Intravenous Injection& iv Cannulation) S.Sarıkaya / P. Tura/ M.F. Çelikmen
10.00- 10.50	Lecture Vaccines Microbiology Lecturer	Lecture Prevention and Control of Communicable Diseases II R.E. Sezer	Lecture Antiseptics and Disinfectants F. Kaleağasioğlu	Lecture Pathology of Viral Infections II I.D.Ekici	Group A IL Group B IL Group C IL Group D
11.00- 11.50	Lecture Epidemiology of Communicable Diseases I H.A.Taşıyan	Lecture Antiviral Drugs F. Kaleağasioğlu	Lecture Investigation of a Disease Outbreak or Epidemic I H.A.Taşıyan	Microbiology Laboratory (Techniques and Diagnostic Tests) Microbiology Lecturers	
				Group A IL Group B IL Group C IL Group D IL	
12.00- 12.50	Lecture Epidemiology of Communicable Diseases II H.A.Taşıyan	Lecture Approach to the Pediatric Patient with Fever S. Biçer	Lecture Investigation of a Disease Outbreak or Epidemic II H.A.Taşıyan	Group A IL Group B IL Group C IL Group D	Independent Learning
12.50 – 14.00	LUNCH BREAK				
14.00- 14.50	ICP-CSL (Intravenous Injection & iv Cannulation) S.Sarıkaya/P. Tura/M.F. Çelikmen	Lecture Antimalarial Drugs F. Kaleağasioğlu	Lecture Physician-Patient Relationship I E.Vatanoğlu	ICP-CSL (Intravenous Injection& iv Cannulation) S.Sarıkaya/ P. Tura/ M.F.Çelikmen	Microbiology Laboratory Make-up (Antibacterial & Susceptibility Testing) Microbiology Lecturers
15.00- 15.50	Group A IL Group B Group C IL Group D IL	Lecture Introduction to the Program of Family Medicine G. İzbirak	Lecture Physician-Patient Relationship II E.Vatanoğlu	Group A IL Group B IL Group C Group D IL	Independent Learning
16.00- 16.50		Lecture Emergency Evaluation of Sepsis and Septic Shock M. F. Çelikmen	Multidisciplinary Case Discussion Panel		Independent Learning
17.00-17.50	Independent Learning	Independent Learning	Multidisciplinary Case Discussion Panel	Independent Learning	Independent Learning

# **COMMITTEE I - INFECTIOUS DISEASES**

**WEEK V / 3-7 Oct 2016**

WEEK V / 3-7 Oct 2016					
	Monday 3-Oct-2016	Tuesday 4-Oct-2016	Wednesday 5-Oct-2016	Thursday 6-Oct-2016	Friday 7-Oct-2016
09.00- 09.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning
10.00- 10.50					COMMITTEE EXAM
11.00- 11.50					
12.00- 12.50					
12.50 – 14.00	LUNCH BREAK				
14.00- 14.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Program Evaluation Session Committee I Coordination Committee Members
15.00- 15.50					Independent Learning
16.00- 16.50					
17.00-17.50					



## COMMITTEE II - CARDIOVASCULAR & RESPIRATORY SYSTEMS

**DISTRIBUTION of LECTURE HOURS**  
**October 10, 2016 – November 25, 2016**  
**COMMITTEE DURATION: 7 WEEKS**

MED 302	INTRODUCTION TO CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
<b>DISCIPLINE</b>	PHARMACOLOGY	PC	25				25
	PATHOLOGY	PT	24	1x3=3 (2 Groups)			27
	CHEST MEDICINE	CHM	17				17
	CARDIOLOGY	CRD	14				14
	PUBLIC HEALTH	PH	9				9
	BIOMEDICAL ETHICS & DEONTOLOGY	BED	9				9
	PATHOPHYSIOLOGY	PP	6				6
	INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	IDCM	5				5
	ENT DISEASES	ENT	4				4
	THORACIC SURGERY	TS	3				3
	FAMILY MEDICINE	FM	4				4
	MEDICAL GENETICS	MG	2				2
	BIOSTATISTICS	BS	4				4
	PEDIATRICS	PED	3				3
	RADIOLOGY	RAD	1				1
	EMERGENCY MEDICINE	EM	1				1
	SCIENTIFIC PROJECTS-III	SP	1				1
	INTERDISCIPLINARY	MCDP				2	2
MED 303	INTRODUCTION TO CLINICAL PRACTICE III	ICP III			2x3=6 (4 Groups)		6
<b>TOTAL</b>			<b>132</b>	<b>3</b>	<b>6</b>	<b>2</b>	<b>143</b>

### Coordination Committee

<b>HEAD</b>	Sevda Özdoğan, MD, Prof.
<b>SECRETARY</b>	Olçay Özveren, MD, Asst. Prof.
<b>MEMBER</b>	Hülya Sarıçoban, MD, Assoc. Prof.
<b>MEMBER</b>	Işın D. Ekici, MD, Prof.

## COMMITTEE II - CARDIOVASCULAR & RESPIRATORY SYSTEMS LECTURERS

MED 302 INTRODUCTION TO CLINICAL SCIENCES	
DISCIPLINE	LECTURERS
PHARMACOLOGY	Ece Genç, PhD, Prof. Ferda Kaleağasıoğlu, MD, Prof.
PATHOLOGY	Ferda Özkan, MD, Prof. Işın Doğan Ekici, MD Prof. Ahmet Sedat Çöloğlu, DMD, Prof.
CHEST MEDICINE	Emine Sevda Özdoğan, MD, Prof.
CARDIOLOGY	Muzaffer Değertekin, MD, Prof. Olca Özveren, MD, Asst. Prof. Ayça Türer Cabbar, MD Mustafa Aytek Şimşek, MD
PUBLIC HEALTH	Recep Erol Sezer, MD, Prof. Hale Arık Taşyikan, MD, Asst. Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu, MD, Assoc. Prof
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, Assoc. Prof.
INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	Meral Sönmezoğlu, MD, Prof. İbrahim Çağatay Acuner, MD, Assoc. Prof.
EAR- NOSE -THROAT (ENT)	Yavuz Selim Pata, MD, Prof. Müzeyyen Doğan, MD, Assoc. Prof.
THORACIC SURGERY	Sina Ercan, MD, Prof.
FAMILY MEDICINE	Güldal İzbirak, MD, Assoc.Prof. Özlem Tanrıöver, MD, Assoc.Prof.
PEDIATRICS	Hülya Sarıçoban, MD, Assoc. Prof. Mustafa Berber, MD, Asst. Prof. Fatma Tuba Coşkun, MD
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Asst. Prof.
RADIOLOGY	Neslihan Taşdelen, MD, Assoc.Prof.
EMERGENCY MEDICINE	Mustafa Ferudun Çelikmen, MD, Asst.Prof.
BIOSTATISTICS	Çiğdem Kaspar, PhD, Asst. Prof
SCIENTIFIC PROJECTS- III	Gülderen Yanıkkaya Demirel, MD, Assoc. Prof.

MED 303 INTRODUCTION TO CLINICAL PRACTICE III	
DISCIPLINE	LECTURERS
CLINICAL SKILLS LAB	Güldal İzbirak, MD, Assoc. Prof. Ferdi Menda MD, Assoc.Prof. Olca Özveren, MD, Asst. Prof. Serdar Özdemir, MD, Asst. Prof. Sevgi Bilgen, MD, Asst. Prof Ayça Türer Cabbar, MD Mustafa Aytek Şimşek, MD

## COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS

### AIMS and LEARNING OBJECTIVES

#### AIMS

*In evidence based manner,*

1. **to remind** knowledge on anatomy, histology and physiology of cardiovascular and respiratory systems,
2. **to convey** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
3. **to convey** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
4. **to convey** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to cardiovascular and respiratory systems,
5. **to convey** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
6. **to convey** necessary knowledge together **with performance measures** on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to cardiovascular and respiratory systems, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, **at the level of primary health care service,**
7. **to convey** knowledge on principles of prescription,
8. **to convey** necessary knowledge on pharmacology of drugs effective on cardiovascular system,
9. **to convey** necessary knowledge on radiation physics and biology and its use in oncology,
10. **to convey** necessary knowledge on ethical problems encountered in health care service and utilization, and on principles of solutions,
11. **to convey** knowledge on principles of biostatistical analysis,
12. **to equip with basic and advanced clinical skills** (advanced cardiac life support-C2, approach to patient with cardiovascular clinical condition-C2) required at primary health care service level.

#### LEARNING OBJECTIVES

**At the end of this committee, student should be able to:**

1. **recall** anatomy, histology and physiology of cardiovascular and respiratory systems,
2. **explain** etiopathogenesis of clinical conditions (*upper respiratory tract problems -nasal obstruction, etc.-, infectious clinical conditions with upper and lower respiratory tract and lung involvement - pneumonia, tuberculosis, etc.-, circulatory lung disorders -pulmonary embolism, etc.-, obstructive/restrictive lung diseases, respiratory insufficiency, tobacco use, lung tumors, other lung diseases; diseases of coronary circulation and coronary arteries, diseases of cardiac valves, myocardial and pericardial diseases, blood stream infections and sepsis, cardiac problems in adults and children, mediastinal diseases, nasopharyngeal and oropharyngeal diseases, nasal and paranasal sinus diseases, diseases of middle ear and eustachian tube, laryngeal diseases, voice disorders*) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
3. **explain** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,

4. **explain** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to cardiovascular and respiratory systems,
5. **describe** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
6. at multi-system level and/or related to cardiovascular and respiratory systems,
  - for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
  - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
  - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

**explain** in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes, health care processes, clinical decision making process, clinical decisions and clinical practices

  - which are required for management at primary health care service level:
- 6.1. practice of history taking and physical examination (cardiovascular-C2, pulmonary-C2)
- 6.2. evaluation of emergency case (dyspnea-C2)
- 6.3. approach to healthy individual or patient (cardiovascular disease-C2, chest pain-C2, cough and hemoptysis-C2, dyspnea-C2)
- 6.4. laboratory tests/examinations (cardiac markers-, coagulation tests-, blood gases-, pulmonary function tests-C2)
- 6.5. imaging tests/examinations (radionuclide ventriculography-C2, myocardial scintigraphy-C2, cardiac PET-C2, ventilation/perfusion scintigraphy-C2, PET in lung cancer-C2)
- 6.6. point of care testing (urine strip/dipstick test-C1)
- 6.7. making preliminary diagnosis or definitive diagnosis decision
- 6.8. making non-intervention or intervention decision
- 6.9. practicing non-intervention or intervention
- 6.10. referral/transport of healthy individual or patient
7. **define** radiation physics, biology and its use in oncology,
8. **explain** implementation of hypertension treatment guidelines,
9. **explain** pharmacology of drugs effective on cardiovascular system (autonomic system pharmacology, renin-angiotensin system pharmacology, calcium channel blockers, pharmacological approach to ischemic and congestive cardiovascular conditions, drugs effecting body fluids and volume, anti-hypertension drugs, hypolipidemic drugs, antiarrhythmic drugs, antiplatelet, antithrombotic and thrombolytic drugs, drugs used in the treatment of asthma and chronic obstructive pulmonary disease, antitussive, expectorant and surfactant drugs),
10. **explain** ethical problems (rejection of treatment, organ transplantation, paternalism, reproductive and negative rights),
11. **explain** principles of biostatistical analysis,
12. **perform** basic clinical skills, practiced on phantom models (advanced cardiac life support-C2), and advanced clinical skills, practiced on simulated/standardized patients (approach to patient with cardiovascular clinical condition-C2), required at primary health care service.<sup>96</sup>

## COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS COMMITTEE ASSESSMENT MATRIX

PHASE III						
COURSE: MD 320 INTRODUCTION TO CLINICAL SCIENCES						
COURSE COMPONENT: COMMITTEE II - CARDIOVASCULAR & RESPIRATORY SYSTEMS						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/ INSTRUCTOR	NUMBER OF QUESTIONS (MCQ)			
			CE	FE	IE	Total
8.0.,9.0.	PC	E. Genç	17	8	8	33
9.0.		F. Kaleağasıoğlu				
1.0.,2.0.	PT	F. Özkan	16	7	7	30
1.0.,2.0.		I D. Ekici				
1.0.,2.0.,5.0.,6.0.,6.1.,6.4.,6.5.,6.6.	CHM	S. Özdoğan	12	5	5	22
1.0.,2.0.,5.0.,6.0.6.4.	CRD	M.Değertekin	10	4	4	18
1.0.,2.0., 5.0., 6.0.6.1.,6.3.		Z.Küçükurmaz				
1.0.,2.0.,5.0.,6.0.6.4.		O. Özveren				
3.0.,4.0.	PH	R.E. Sezer	6	3	3	12
3.0.,4.0.		H.A.Taşıyan				
10.0.	BED	E. Vatanoğlu	6	3	3	12
2.0.,5.0.	PP	M. Kaçar	4	2	2	8
2.0.,5.0.,6.0.	IDCM	M. Sönmezoğlu	3	2	2	7
2.0.,5.0.,6.4.		İ. Ç. Acuner				
1.0.,2.0.,5.0.,6.0.	ENT	M. Doğan	3	1	1	5
1.0.,2.0.,5.0.,6.0.	FM	G.İzbirak	3	1	1	5
1.0.,2.0.,5.0.,6.0.		Ö. Tanrıöver				
1.0.,2.0.,5.0.,6.0.	BS	Ç. Kaspar	3	1	1	5
2.0.,5.0.	PED	S. Sarıçoban	2	1	1	4
6.3.		M. Berber				
6.3.	TS	S. Ercan	2	1	1	4
6.2.	MG	A.Ç. Kuşkuç	1	1	1	3
6.5.	RAD	N. Taşdelen	1	1	1	3
11.0.	EM	F. Çelikmen	1	0	0	1
TOTAL			90	41	41	172
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0.,2.0.,5.0.,6.0.,6.1.,6.4.,6.5.,6.6.	CHM	S. Özdoğan	1	-	-	1
1.0.,2.0.,5.0.,6.0.,6.3.,6.4.	PT	ID. Ekici	2	-	-	2
8.0.,9.0.	PC	F. Kaleağasıoğlu	2	-	-	2
TOTAL			5	-	-	5

**CS\* = 90 pts (MCQ) + 10 pts (EMQ) = 100 pts; pts:points**

\*Each MCQ has a value of 1 points; each EMQ question has a value of 2 points.

**MCQ:** Multiple Choice Question

**EMQ:** Extending Matching Question

**CE:** Committee Exam

**CS:** Committee Score

**FE:** Final Exam

**ICE:** Incomplete Exam

**\*\*41** out of 200 FE and ICE MCQs will be from Committee II (Each question is of worth **0.5** pts).

**COMMITTEE II - CARDIOVASCULAR AND RESPIRATORY SYSTEMS**  
**WEEK I / 10-14 Oct 2016**

	<b>Monday 10-Oct-2016</b>	<b>Tuesday 11-Oct-2016</b>	<b>Wednesday 12-Oct-2016</b>	<b>Thursday 13-Oct-2016</b>	<b>Friday 14-Oct-2016</b>
<b>09.00- 09.50</b>	<b>Introductory Session</b> Introduction to Committee II <i>Head of Committee</i>	<b>Lecture</b> Congestive Heart Failure <i>A. S. Çöloğlu</i>	<b>Lecture</b> Examination of the Heart <i>M. Değertekin</i> <i>M. A. Şimşek</i>	<b>ICP-CSL</b> (Advanced Cardiac Life Support) <i>F.Menda/S.Bilgen</i>	<b>Lecture</b> Electrocardiography I <i>M. Değertekin</i> <i>M. A. Şimşek</i>
<b>10.00- 10.50</b>	<b>Lecture</b> Pathophysiology of Cardiovascular System Disorders I <i>M. Kaçar</i>	<b>Lecture</b> Congestive Heart Failure & Pericardium <i>A. S. Çöloğlu</i>	Coronary Artery Disease I <i>M. Değertekin</i> <i>M. A. Şimşek</i>	<b>Group A</b>  <b>Group B IL</b>  <b>Group C IL</b>  <b>Group D IL</b>	<b>Lecture</b> Electrocardiography II <i>M. Değertekin</i> <i>M. A. Şimşek</i>
<b>11.00- 11.50</b>	<b>Lecture</b> Pathophysiology of Cardiovascular System Disorders II <i>M. Kaçar</i>	<b>Lecture</b> Myocardium <i>A. S. Çöloğlu</i>	<b>Lecture</b> Coronary Artery Disease II <i>M. Değertekin</i> <i>M. A. Şimşek</i>		<b>Lecture</b> Parasympatholytic Drugs <i>E. Genç</i>
<b>12.00- 12.50</b>	<b>Lecture</b> Pathophysiology of Cardiovascular System Disorders III <i>M. Kaçar</i>	<b>Lecture</b> Introduction to Autonomic System Pharmacology <i>E. Genç</i>	<b>Lecture</b> Acetylcholine and Directly Acting Parasympathomimetic Drugs <i>E. Genç</i>	<b>Lecture</b> Hypertension Treatment Guidelines <i>F. Kaleağasıoğlu</i>	<b>Lecture</b> Sympathomimetic Drugs: Catecholamines & Noncatecholamines <i>E. Genç</i>
<b>12.50 – 14.00</b>	<b>LUNCH BREAK</b>				
<b>14.00- 14.50</b>	<b>Lecture</b> Principles of Beneficence and Nonmaleficence I <i>E.Vatanoğlu</i>	<b>Lecture</b> Pharmacology of ReninAngiotensin System <i>F. Kaleağasıoğlu</i>	<b>Lecture</b> Acetylcholinesterase Inhibitors <i>E. Genç</i>	<b>Lecture</b> Approach to the Patient with Cardiovascular System Diseases <i>M. Değertekin</i> <i>M. A. Şimşek</i>	<b>Lecture</b> General Signs and Principal Symptoms in Cardiovascular System Diseases <i>O.Özveren</i> <i>A.Türer Cabbar</i>
<b>15.00- 15.50</b>	<b>Lecture</b> Principles of Beneficence and Nonmaleficence II <i>E.Vatanoğlu</i>	<b>Lecture</b> Ischemic Heart Disease I <i>F. Özkan</i>	<b>Lecture</b> Preparing to Analyse Data I <i>Ç.Kaspar</i>	<b>Lecture</b> Cardiac Arrhythmias I <i>M. Değertekin</i> <i>M. A. Şimşek</i>	<b>Lecture</b> Congestive Heart Failure I <i>O.Özveren</i> <i>A.Türer Cabbar</i>
<b>16.00- 16.50</b>	<b>Lecture</b> End of Life Decisions I <i>E.Vatanoğlu</i>	<b>Lecture</b> Ischemic Heart Disease II <i>F. Özkan</i>	<b>Lecture</b> Preparing to Analyse Data II <i>Ç.Kaspar</i>	<b>Lecture</b> Cardiac Arrhythmias II <i>M. Değertekin</i> <i>M. A. Şimşek</i>	<b>Lecture</b> Congestive Heart Failure II <i>O.Özveren</i> <i>A.Türer Cabbar</i>
<b>17.00-17.50</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

**COMMITTEE II - CARDIOVASCULAR AND RESPIRATORY SYSTEMS**  
**WEEK II / 17-21 Oct 2016**

	<b>Monday 17-Oct-2016</b>	<b>Tuesday 18-Oct-2016</b>	<b>Wednesday 19-Oct-2016</b>	<b>Thursday 20-Oct-2016</b>	<b>Friday 21-Oct-2016</b>
<b>09.00- 09.50</b>	<b>Lecture</b> Pathology of Endocardium & Heart Valves I I.D.Ekici	<b>Lecture</b> Atherosclerosis & Hypertension I A. S. Çöloğlu	<b>Lecture</b> Infective Endocarditis and Acute Rheumatic Fever O. Özveren A.Türer Cabbar	<b>ICP-CSL</b> (Advanced Cardiac Life Support) F.Menda/S.Bilgen	<b>Lecture</b> Respiratory Muscles and Surgical Anatomy of Thorax S. Ercan
<b>10.00- 10.50</b>	<b>Lecture</b> Pathology of Endocardium & Heart Valves II I.D.Ekici	<b>Lecture</b> Atherosclerosis & Hypertension II A. S. Çöloğlu	<b>Lecture</b> Aortic Valvular Heart Diseases O. Özveren A.Türer Cabbar	<b>Group A IIL</b>  <b>Group B</b>  <b>Group C IIL</b>  <b>Group D IIL</b>	<b>Lecture</b> Surgical Disorders of Mediastinum and the Diaphragm S. Ercan
<b>11.00- 11.50</b>	<b>Lecture</b> Adrenergic Receptor Blockers E. Genç	<b>Lecture</b> Bloodstream Invasion & Sepsis I Microbiology Lecturer	<b>Lecture</b> Mitral Valvular Heart Diseases O. Özveren A.Türer Cabbar		<b>Lecture</b> Surgical Treatment of Pulmonary Diseases S. Ercan
<b>12.00- 12.50</b>	<b>Lecture</b> Adrenergic Neuron Blockers E. Genç	<b>Lecture</b> Upper and Lower Respiratory System Infections I Microbiology Lecturer	<b>Lecture</b> Pharmacology Case Studies F. Kaleağasioğlu	<b>Lecture</b> Drugs Used in the Treatment of Angina Pectoris F. Kaleağasioğlu	<b>Lecture</b> Epidemiology and Prevention of Cardiovascular Diseases I H.A.Taşıyikan
<b>12.50 - 14.00</b>	<b>LUNCH BREAK</b>				
<b>14.00- 14.50</b>	<b>Lecture</b> Diuretic Agents I F. Kaleağasioğlu	<b>Lecture</b> Diuretic Agents II F. Kaleağasioğlu	<b>Lecture</b> Rheumatic Heart Disease I. D. Ekici	<b>Lecture</b> Drugs Used in Cardiac Arrhythmias I F. Kaleağasioğlu	<b>Lecture</b> Epidemiology and Prevention of Cardiovascular Diseases II H.A.Taşıyikan
<b>15.00- 15.50</b>	<b>Lecture</b> End of Life Decisions II E.Vatanoğlu	<b>Lecture</b> Anti-hypertensive Drugs I F. Kaleağasioğlu	<b>Lecture</b> CVS Tumors I .D. Ekici	<b>Lecture</b> Drugs Used in Cardiac Arrhythmias II F. Kaleağasioğlu	<b>Lecture</b> Epidemiology and Prevention of Cardiovascular Diseases III H.A.Taşıyikan
<b>16.00- 16.50</b>	<b>Lecture</b> End of Life Decisions III E.Vatanoğlu	<b>Lecture</b> Anti-hypertensive Drugs II F. Kaleağasioğlu	<b>Lecture</b> Approach to Patient with Chest Pain in Primary Care I G. İzbirak	<b>Independent Learning</b>	<b>Lecture</b> Public Health and Chronic Non-Communicable Diseases H.A. Taşıyikan
<b>17.00-17.50</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Lecture</b> Approach to Patient with Chest Pain in Primary Care II G. İzbirak	<b>Independent Learning</b>	<b>Independent Learning</b>

**COMMITTEE II - CARDIOVASCULAR AND RESPIRATORY SYSTEMS**  
**WEEK III / 24-28 Oct 2016**

	Monday 24-Oct-2016	Tuesday 25-Oct-2016	Wednesday 26-Oct-2016	Thursday 27-Oct-2016	Friday 28-Oct-2016
09.00- 09.50	<b>Lecture</b> Congenital Heart Disease I I.D. Ekici	<b>Lecture</b> Drugs Used in the Treatment of Dyslipidemias I F. Kaleağasıoğlu	<b>Independent Learning</b>	<b>ICP-CSL</b> (Advanced Cardiac Life Support) F.Menda/S.Bilgen	<b>Independent Learning</b>
10.00- 10.50	<b>Lecture</b> Congenital Heart Disease II I.D. Ekici	<b>Lecture</b> Drugs Used in the Treatment of Dyslipidemias II F. Kaleağasıoğlu	<b>Lecture</b> Pathology of Upper Respiratory Tract F. Özkan	Group A IL Group B IL Group C Group D IL	<b>Independent Learning</b>
11.00- 11.50	<b>Lecture</b> Drugs Used in Congestive Heart Disease I F. Kaleağasıoğlu	<b>Lecture</b> Congenital Heart Disease in Pediatrics M. Berber / F.T.Coşkun	<b>Lecture</b> Asthma Bronchiale F. Özkan		<b>Independent Learning</b>
12.00- 12.50	<b>Lecture</b> Drugs Used in Congestive Heart Disease II F. Kaleağasıoğlu	<b>Lecture</b> Inherited Cardiovascular Disorders A.Ç. Kuşkucu	<b>Lecture</b> Congenital Lung Anomalies & Atalectasis F. Özkan	<b>Independent Learning</b>	<b>Independent Learning</b>
12.50 – 14.00	<b>LUNCH BREAK</b>				
14.00- 14.50	<b>Lecture</b> Anticoagulant, Antiplatelet & Thrombolytic drugs F. Kaleağasıoğlu	<b>Lecture</b> Pathophysiology of Respiratory System Disorders I M. Kaçar	<b>Lecture</b> History and Symptoms in Pulmonary Diseases S. Özdoğan	<b>Lecture</b> Pulmonary Infections I A. S. Çöloğlu	<b>Republic Day</b>
15.00- 15.50	<b>Lecture</b> Ethics of Distribution I E.Vatanoğlu	<b>Lecture</b> Pathophysiology of Respiratory System Disorders II M. Kaçar	<b>Lecture</b> Physical Examination and Signs in Pulmonary Diseases S. Özdoğan	<b>Lecture</b> Pulmonary Infections II A. S. Çöloğlu	
16.00- 16.50	<b>Lecture</b> Ethics of Distribution II E.Vatanoğlu	<b>Lecture</b> Pathophysiology of Respiratory System Disorders III M. Kaçar	<b>Lecture</b> Respiratory Failure S. Özdoğan	<b>Lecture</b> Chronic Obstructive Pulmonary Diseases A. S. Çöloğlu	
17.00-17.50	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	



**COMMITTEE II - CARDIOVASCULAR AND RESPIRATORY SYSTEMS**

**WEEK IV/ 31 Oct-4 Nov 2016**

	Monday 31-Oct-2016	Tuesday 1-Nov-2016	Wednesday 2-Nov-2016	Thursday 3-Nov-2016				Friday 4-Nov-2016
09.00- 09.50	Lecture Diagnostic Methods in Pulmonary Medicine S. Özdoğan	Lecture Pneumonia S. Özdoğan	Lecture Sleep Apnea Syndrome S. Özdoğan	ICP-CSL (Advanced Cardiac Life Support) F.Menda/S.Bilgen				Independent Learning
10.00- 10.50	Lecture Clinical Application of Pulmonary Function Tests S. Özdoğan	Lecture Interstitial Lung Diseases S. Özdoğan	Lecture Lung Cancer S. Özdoğan	Group A IL	Group B IL	Group C IL	Group D	
11.00- 11.50	Lecture Pulmonary Tuberculosis S. Özdoğan	Lecture Pleural Diseases S. Özdoğan	Lecture Tracheobronchitis S. Özdoğan					
12.00- 12.50	Lecture X-Ray Examination of the Lungs N. Taşdelen	Lecture Treatment of Cough & Drugs Used in the Treatment of Common Cold F. Kaleağasıoğlu	Lecture Emergency Evaluation of Dyspnea M.F. Çelikmen	Independent Learning				
12.50 – 14.00	LUNCH BREAK							
14.00- 14.50	Lecture Inherited Respiratory System Disorders A.Ç.Kuşkucu	Lecture Palliative Care Ethics I E. Vatanoğlu	Lecture Laryngeal and Voice Diseases M. Doğan	Independent Learning				Independent Learning
15.00- 15.50	Lecture Diseases of the Nose and Paranasal Sinuses Y. S. Pata	Lecture Palliative Care Ethics II E. Vatanoğlu	Lecture Diseases of the Middle Ear and Eustachian Tube M. Doğan					
16.00- 16.50	Lecture Nasopharyngeal and Oropharyngeal Diseases Y. S. Pata	Independent Learning	Lecture Principals of Statistical Analysis Ç. Kaspar					
17.00-17.50	Independent Learning	Independent Learning	Lecture Principals of Statistical Analysis Ç. Kaspar					

**COMMITTEE II - CARDIOVASCULAR AND RESPIRATORY SYSTEMS**  
**WEEK V / 7-11 Nov 2016**

	Monday 7-Nov-2016	Tuesday 8-Nov-2016			Wednesday 9-Nov-2016			Thursday 10-Nov-2016	Friday 11-Nov-2016				
09.00- 09.50	Lecture Pulmonary Hypertension S. Özdoğan	Lecture Tobacco Control and Chronic Non-Communicable Diseases I R.E. Sezer			Lecture Scientific Projects- III: Project Writing G. Y. Demirel			Commomeration of Atatürk (Rectorate Building, Inan Kırac Conference Hall)	Independent Learning				
10.00- 10.50	Lecture Special Pulmonary Problems S. Özdoğan	Lecture Tobacco Control and Chronic Non-Communicable Diseases II R.E. Sezer			Lecture Tumors of the Respiratory System I I.D. Ekici								
11.00- 11.50	Lecture Approach to the Pediatric Patient with Pneumonia H. Sarıçoban	Lecture Tobacco Control and Chronic Non-Communicable Diseases III R.E. Sezer			Lecture Tumors of the Respiratory System II I.D. Ekici								
12.00- 12.50	Lecture Chest Medicine Case Reports H. Sarıçoban	Independent Learning			Lecture Pathology of Pleural and Mediastinal Diseases I.D. Ekici			Lecture Drugs Used in the Treatment of Asthma & Chronic Obstructive Lung Disease F. Kaleağasıoğlu					
12.50 – 14.00	LUNCH BREAK												
14.00- 14.50	ICP-CSL (History taking & examination of cardiovascular system) O. Özveren / A.Türer Cabbar/ S. Özdemir/ G. İzbirak				ICP-CSL (History taking & examination of cardiovascular system) O. Özveren / M. A. Şimşek / S. Özdemir/ G. İzbirak			Lecture Pulmonary Embolism S. Özdoğan	Independent Learning				
15.00- 15.50	Group A	Group B IL	Group C IL	Group D IL	Group A IL	Group B	Group C IL	Group D IL		Pathology Laboratory (Cardiovascular and Respiratory Systems) F. Özkan/ I.D. Ekici	Group A	Group B IL	Lecture Bronchial Hyperreactivity and Asthma S. Özdoğan
16.00- 16.50													Lecture Chronic Obstructive Pulmonary Disease S. Özdoğan
17.00-17.50	Independent Learning				Independent Learning			Independent Learning					

**COMMITTEE II - CARDIOVASCULAR AND RESPIRATORY SYSTEMS**  
**WEEK VI / 14-18 Nov 2016**

	Monday 14-Nov-2016	Tuesday 15-Nov-2016	Wednesday 16-Nov-2016				Thursday 17-Nov-2016				Friday 18-Nov-2016	
09.00- 09.50	<b>Lecture</b> Approach to the Patient with Cough and Heameoptysis in Primary Care Ö. Tanrıöver	<b>Independent Learning</b>	<b>ICP-CSL</b> (History taking & examination of cardiovascular system) O. Özveren / A.Türer Cabbar / S. Özdemir/G. İzbırak				<b>ICP-CSL</b> (History taking & examination of cardiovascular system) O. Özveren / M. A. Şimşek / / S. Özdemir/G. İzbırak				<b>Independent Learning</b>	
10.00- 10.50	<b>Lecture</b> Approach to the Patient with Dyspnea in Primary Care Ö. Tanrıöver		<b>Lecture</b> Chronic Restrictive Pulmonary Diseases I A. S. Çöloğlu	Group A IL	Group B IL	Group C	Group D IL	Group A IL	Group B IL	Group C IL		Group D
11.00- 11.50	<b>Lecture</b> Tobacco Control and Chronic Non-Communicable Diseases IV R.E. Sezer											
12.00- 12.50	<b>Lecture</b> Epidemiology, Prevention and Control of Chronic Non-Communicable Respiratory Diseases R.E. Sezer	<b>Lecture</b> Pharmacology and Toxicology of Tobacco F. Kaleağasıoğlu	<b>Independent Learning</b>				<b>Independent Learning</b>					
12.50 – 14.00	<b>LUNCH BREAK</b>											
14.00- 14.50	<b>Lecture</b> Upper and Lower Respiratory System Infections II M. Sönmezoğlu	<b>Multidisciplinary Case Discussion Panel</b>	<b>Independent Learning</b>				<b>Independent Learning</b>				<b>Independent Learning</b>	
15.00- 15.50	<b>Lecture</b> Bloodstream Invasion & Sepsis II M. Sönmezoğlu	<b>Multidisciplinary Case Discussion Panel</b>										
16.00- 16.50	<b>Lecture</b> Cardiac Infections M. Sönmezoğlu	<b>Independent Learning</b>										
17.00-17.50	<b>Independent Learning</b>	<b>Independent Learning</b>										

**COMMITTEE II - CARDIOVASCULAR AND RESPIRATORY SYSTEMS**  
**WEEK VII /21-25 Nov 2016**

WEEK VII/21-25 NOV 2016					
	Monday 21-Nov-2016	Tuesday 22-Nov-2016	Wednesday 23-Nov-2016	Thursday 24-Nov-2016	Friday 25-Nov-2016
09.00- 09.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning
10.00- 10.50					COMMITTEE EXAM
11.00- 11.50					
12.00- 12.50					
14.00- 14.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Program Evaluation Session Committee II Coordination Committee Members
15.00- 15.50					Independent Learning
16.00- 16.50					
17.00-17.50					

# COMMITTEE III - HEMATOPOIETIC SYSTEM

## DISTRIBUTION of LECTURE HOURS

November 28, 2016 – December 16, 2016

COMMITTEE DURATION: 3 WEEKS

MED 302	INTRODUCTION TO CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	HEMATOLOGY	HEM	17				17
	PATHOLOGY	PT	10				10
	PHARMACOLOGY	PC	9				9
	PEDIATRICS	PED	7				7
	INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	IDCM	4				4
	MEDICAL GENETICS	MG	3				3
	PHYTOTHERAPY	PHY	3				3
	ONCOLOGY	ONC	3				3
	RADIATION ONCOLOGY	RONC	2				2
	PATHOPHYSIOLOGY	PP	2				2
	BIOSTATISTICS	BS	4				4
	BIOMEDICAL ETHICS&DEONTOLOGY	BED	2				2
	FAMILY MEDICINE	FM	1				1
	SCIENTIFIC PROJECTS- III	SP	1				1
	INTERDISCIPLINARY	MCDP				2	2
MED 303	INTRODUCTION TO CLINICAL PRACTICE III	ICP III			1X3=3 (4 Groups)		3
TOTAL			68		3	2	73

## Coordination Committee

HEAD	Işın D. Ekici, MD, Prof
SECRETARY	Orhan Önder Eren, MD, Asst. Prof
MEMBER	Atilla Özkan , MD, Assoc. Prof
MEMBER	Ferda Kaleağasıoğlu, MD, Prof

## COMMITTEE III - HEMATOPOIETIC SYSTEM

### LECTURERS

MED 302 INTRODUCTION TO CLINICAL SCIENCES	
DISCIPLINE	LECTURERS
HEMATOLOGY	Atilla Özkan, MD, Assoc.Prof.
PATHOLOGY	Ferda Özkan, MD, Prof. A.İşin Doğan Ekici, MD, Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Ferda Kaleağasıoğlu, MD, Prof.
PEDIATRICS	Sabri Kemahlı, MD, Prof Hülya Sarıçoban, MD, Assoc. Prof. Sema Yılmaz, MD, Assoc. Prof.
INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	Meral Sönmezoğlu, MD, Prof. İbrahim Çağatay Acuner, MD, Assoc. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Asst. Prof.
PHYTOTHERAPY	Erdem Yeşilada, PhD, Prof.
ONCOLOGY	Orhan Önder Eren, MD, Asst. Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, Assoc. Prof.
RADIATION ONCOLOGY	Halim Aydın, MD, Assoc. Prof.
BIostatISTICS	Çiğdem Kaspar, PhD, Asst. Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu, MD, Assoc. Prof.
FAMILY MEDICINE	Hülya Akan, MD, Assoc. Prof.
SCIENTIFIC PROJECTS - III	Gülderen Yanıkkaya Demirel, MD., Assoc. Prof.

MED 303 INTRODUCTION TO CLINICAL PRACTICE III	
DISCIPLINE	LECTURERS
CLINICAL SKILLS LAB	Müzeyyen Doğan, MD, Assoc. Prof. Vildan Öztürk, MD, Asst. Prof Feridun Çelikmen, MD, Asst. Prof. Uğur Anıl Bingöl, MD, Prof

## COMMITTEE III - HEMATOPOIETIC SYSTEM

### AIMS and LEARNING OBJECTIVES

#### AIMS

##### *In evidence based manner,*

1. **to remind** knowledge on anatomy, histology and physiology of hematopoietic system,
2. **to convey** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
3. **to convey** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
4. **to convey** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to hematopoietic system,
5. **to convey** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
6. **to convey** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to hematopoietic system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. **to convey** knowledge on pharmacology of drugs that are effective on hematopoietic system or on clinical conditions involving hematopoietic system,
8. **to convey** knowledge on phytotherapeutic agents that have immune-modulatory effects,
9. **to convey** basic knowledge on phytotherapy
10. **to convey** knowledge on comparative biostatistical analysis of study groups,
11. **to equip with** basic and advanced clinical skills (arterial blood sample collection-C3) required at primary health care service level.

#### LEARNING OBJECTIVES

##### *At the end of this committee, student should be able to:*

1. **recall** anatomy, histology and physiology of hematopoietic system,
2. **explain** etiopathogenesis of clinical conditions (hematological syndromes, disorders and diseases, lenforeticular infections) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
3. **explain** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
4. **explain** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to hematopoietic system,
5. **describe** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
6. at multi-system level and/or related to hematopoietic system,

- for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
  - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
  - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
- explain** in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,
- health care processes, clinical decision making process, clinical decisions and clinical practices which are required for management at primary health care service level:
- 6.1. practice of history taking and physical examination
  - 6.2. evaluation of emergency case
  - 6.3. approach to healthy individual or patient (anemia-C3, lymphadenopathy-C3)
  - 6.4. laboratory tests/examinations (peripheral/venous blood collection for hematology tests-C3, hematology tests for anemia-C3)
  - 6.5. imaging tests/examinations (nuclear medicine tests in hematology-C3)
  - 6.6. point of care testing (hematology-peripheral blood smear examination-C3, hematology-complete blood count-)
  - 6.7. making preliminary diagnosis or definitive diagnosis decision
  - 6.8. making non-intervention or intervention decision
  - 6.9. practicing non-intervention or intervention
  - 6.10. referral/transport of healthy individual or patient
7. **classify** blood products and blood groups,
  8. **define** principles of transfusion,
  9. **explain** pharmacology of drugs (antianemic drugs, antineoplastic drugs, hematostatic drugs and blood products, immunomodulators) that are effective on hematopoietic system or on clinical conditions involving hematopoietic system,
  10. **explain** mechanisms of bone marrow toxicity of drugs and other chemicals,
  11. **list** principles of cancer chemotherapy,
  12. **explain** chemotherapy in leukemia and lymphoma,
  13. **list** phytotherapeutic agents with immunomodulatory effects,
  14. **list** principles of comparative biostatistical analysis of study groups,
  15. **perform** basic clinical skills, practiced on phantom models (arterial blood sample collection-C3), required at primary health care service.
  16. **explain** basic knowledge on phytotherapy (basic concepts and terms, uses in modern medicine, regulations, standardization and quality control),



## COMMITTEE III - HEMATOPOIETIC SYSTEM COMMITTEE ASSESSMENT MATRIX

PHASE III						
COURSE: MD 320 INTRODUCTION TO CLINICAL SCIENCES						
COURSE COMPONENT: COMMITTEE III - HEMATOPOIETIC SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER / INSTRUCTOR	NUMBER OF QUESTIONS (MCQ)			
			CE	FE	IE	Total
1.0.-6.0.	HEM	A.Özkan	23	5	5	33
2.0.,5.0.,6.4.	PT	I.D. Ekici	13	3	3	19
9.0.-12.0.	PC	E. Genç	13	3	3	19
9.0.-12.0.		F. Kaleağasıoğlu				
1.0.-6.0.	PED	S. Kemahlı	9	2	2	13
1.0.-6.0.		H. Sarıçoban				
1.0.-6.0.		S. Yılmaz				
2.0.-6.0.	IDCM	M. Sönmezoğlu	5	1	1	7
2.0.-6.4.		İ.Ç. Acuner				
2.0.	BS	Ç. Kaspar	5	1	1	7
	MG	A. Ç. Kuşkucu	4	1	1	6
1.0.-6.0.	PHR	E. Yeşilada	4	1	1	6
2.0.,5.0.	IM-ONC	O. Ö. Eren	4	1	1	6
10.0	ROC	Halim Aydın	3	1	1	5
14.0.	PP	M. Kaçar	3	1	1	5
	BED	E. Vatanoğlu	3	1	1	5
6.3.	FM	H. Akan	1	1	1	3
TOTAL			90	22	22	134
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER / INSTRUCTOR	NUMBER OF QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0.-6.0.	HEM	A.Özkan	2	-	-	2
1.0.-6.0.	PC	E. Genç/F. Kaleağasıoğlu	1	-	-	1
2.0.,5.0.,6.4.	PT	I.D. Ekici	2	-	-	2
TOTAL			5	-	-	5

**CS\* = 90 pts (MCQ) + 10 pts (EMQ) = 100 pts; pts: points**

\*Each MCQ has a value of 1 points; each EMQ question has a value of 2 points.

**MCQ:** Multiple Choice Question

**EMQ:** Extending Matching Question

**CE:** Committee Exam

**CS:** Committee Score

**FE:** Final Exam

**ICE:** Incomplete Exam

**pts:** Points

**\*\*22** out of 200 FE and ICE MCQs will be from Committee III (Each question is of worth 0.5 pts).

**COMMITTEE III - HEMATOPOIETIC SYSTEM**  
**WEEK I / 28 Nov-2 Dec 2016**

	Monday 28-Nov-2016	Tuesday 29-Nov-2016	Wednesday 30-Nov-2016	Thursday 1-Dec-2016				Friday 2-Dec-2016			
09.00- 09.50	<b>Introductory Session</b> Introduction to Committee III <i>Head of Committee</i>	<b>Lecture</b> Introduction to Hematology, Signs and Symptoms in Hematological Diseases <i>A.Özkan</i>	<b>Lecture</b> Thalassemias and Hemoglobinopathies (Sickle Cell Anemia and Others) <i>A.Özkan</i>	<b>Independent Learning</b>				<b>Lecture</b> Approach to the Patient with Anemia and Laboratory Tests in Diagnosis with Anemia <i>A.Özkan</i>			
10.00- 10.50	<b>Lecture</b> Pathology of Bone Marrow-1 <i>I D. Ekici</i>	<b>Lecture</b> Classification of Anemias <i>A.Özkan</i>	<b>Lecture</b> Aplastic and Hypoplastic Anemias <i>A.Özkan</i>	<b>ICP-CSL</b> (Suturing technique) <i>M. Doğan</i>				<b>Lecture</b> Hematopoiesis: Stem Cell and Bone Marrow <i>A.Özkan</i>			
11.00- 11.50	<b>Lecture</b> Pathology of Bone Marrow-2 <i>I D. Ekici</i>	<b>Lecture</b> Immune Acquired Hemolytic Anemias / Non Immune Acquired Hemolytic Anemias <i>A . Özkan</i>	<b>Lecture</b> Iron Metabolism and Iron Deficiency Anemia <i>A.Özkan</i>	<b>Group A</b>	<b>Group B IL</b>	<b>Group C IL</b>	<b>Group D IL</b>	<b>Lecture</b> Non/Hodgkin's Lymphoma I <i>I D. Ekici</i>			
12.00- 12.50	<b>Lecture</b> Pathophysiology of Hematopoietic System Disorders I <i>M. Kaçar</i>	<b>Lecture</b> Antianemic Drugs <i>E. Genç</i>	<b>Lecture</b> Vitamin B <sub>12</sub> and Folic acid Metabolism and Megaloblastic Anemias <i>A.Özkan</i>					<b>Lecture</b> Non/Hodgkin's Lymphoma II <i>I D. Ekici</i>			
12.50 – 14.00	<b>LUNCH BREAK</b>										
14.00- 14.50	<b>Lecture</b> Pathophysiology of Hematopoietic System Disorders II <i>M. Kaçar</i>	<b>Lecture</b> Introduction to Anemias in Childhood <i>S. Kemahlı</i>	<b>Lecture</b> Hodgkin's Lymphoma <i>I D. Ekici</i>	<b>ICP-CSL</b> (Suturing technique) <i>V. Öztürk</i>				<b>Lecture</b> Non/Hodgkin's Lymphoma III <i>I D. Ekici</i>			
15.00- 15.50	<b>Lecture</b> Introduction to Radiation Oncology <i>H. Aydın</i>	<b>Lecture</b> Introduction to Hemolytic Anemias <i>S. Kemahlı</i>	<b>Lecture</b> Disorders of White Blood Cells& Leukemia I <i>I D. Ekici</i>	<b>Group A IL</b>	<b>Group B</b>	<b>Group C IL</b>	<b>Group D IL</b>	<b>Lecture</b> Introduction to Clinical Oncology I <i>O .Ö.Eren</i>			
16.00- 16.50	<b>Lecture</b> Basics of Radiation Biology and Radiation Physics <i>H. Aydın</i>	<b>Lecture</b> Pharmacological Basis of Cancer Therapy I <i>F. Kaleağasıoğlu</i>	<b>Lecture</b> Disorders of White Blood Cells& Leukemia II <i>I D. Ekici</i>					<b>Lecture</b> Introduction to Clinical Oncology II <i>O .Ö.Eren</i>			
17.00-17.50	<b>Independent Learning</b>	<b>Lecture</b> Pharmacological Basis of Cancer Therapy II <i>F. Kaleağasıoğlu</i>	<b>Independent Learning</b>	<b>Independent Learning</b>				<b>Lecture</b> Treatment Approaches of Cancer <i>O .Ö.Eren</i>			

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

**COMMITTEE III - HEMATOPOIETIC SYSTEM**  
**WEEK II / 5-9 Dec 2016**

	<b>Monday 5-Dec-2016</b>	<b>Tuesday 6-Dec-2016</b>	<b>Wednesday 7-Dec-2016</b>	<b>Thursday 8-Dec-2016</b>	<b>Friday 9-Dec-2016</b>
<b>09.00- 09.50</b>	<b>Lecture</b> Coagulation Defects A.Özkan	<b>Lecture</b> Lymphoma A.Özkan	<b>Lecture</b> Antineoplastic Drugs II F. Kaleağasıoğlu	<b>ICP-CSL</b> (Suturing technique) U.A.Bingöl	<b>Lecture</b> Hemophilia and other Coagulopathies in Childhood I S. Yılmaz
<b>10.00- 10.50</b>	<b>Lecture</b> Quantitative and Qualitative Platelet Disorders A.Özkan	<b>Lecture</b> Acute Leukemias A.Özkan	<b>Lecture</b> Antineoplastic Drugs III F. Kaleağasıoğlu	<b>Group A</b> IL <b>Group B</b> IL <b>Group C</b> IL <b>Group D</b>	<b>Lecture</b> Hemophilia and other Coagulopathies in Childhood II S. Yılmaz
<b>11.00- 11.50</b>	<b>Lecture</b> Hypercoagulability A.Özkan	<b>Lecture</b> Myeloproliferative Diseases A.Özkan	<b>Lecture</b> Comparing Groups-categorical Data I Ç. Kaspar		<b>Lecture</b> Congenital Hemolytic Anemias I S. Yılmaz
<b>12.00- 12.50</b>	<b>Lecture</b> Multiple Myelom A.Özkan	<b>Lecture</b> Chronic Leukemia A.Özkan	<b>Lecture</b> Comparing Groups-categorical Data II Ç. Kaspar	<b>Lecture</b> Approach to the Patient with LAP H. Akan	<b>Lecture</b> Congenital Hemolytic Anemias II S. Yılmaz
<b>12.50-14.00</b>	<b>LUNCH BREAK</b>				
<b>14.00- 14.50</b>	<b>Lecture</b> Congenital Immunodeficiency Disease H. Sarıçoban	<b>Lecture</b> Antineoplastic Drugs I F. Kaleağasıoğlu	<b>Lecture</b> Lymphoreactive Disease I D. Ekici	<b>Lecture</b> Lenforeticular Infections I Microbiology Lecturer	<b>Lecture</b> Immunomodulators F. Kaleağasıoğlu
<b>15.00- 15.50</b>	<b>ICP-CSL</b> (Suturing technique) M. F. Çelikmen	<b>Lecture</b> Molecular Basis of Hemoglobinopathies A. Ç. Kuşkucu	<b>Lecture</b> Pathology of Spleen I D. Ekici	<b>Lecture</b> Lenforeticular Infections II M. Sönmezoğlu	<b>Lecture</b> Phytotherapy I E. Yeşilada
<b>16.00- 16.50</b>	<b>Group A</b> IL <b>Group B</b> IL <b>Group C</b> <b>Group D</b> IL	<b>Lecture</b> Genetics of Oncology I A.Ç. Kuşkucu	<b>Lecture</b> Responsible Biomedical Research I E. Vatanoğlu	<b>Lecture</b> Blood Components and Transfusion Indications M. Sönmezoğlu	<b>Lecture</b> Phytotherapy II E. Yeşilada
<b>17.00-17.50</b>		<b>Lecture</b> Genetics of Oncology II A.Ç. Kuşkucu	<b>Lecture</b> Responsible Biomedical Research II E. Vatanoğlu	<b>Lecture</b> Blood Groups M. Sönmezoğlu	<b>Lecture</b> Phytotherapy III E. Yeşilada

**COMMITTEE III - HEMATOPOIETIC SYSTEM**  
**WEEK III / 12-16 Dec 2016**

	Monday 12-Dec-2016	Tuesday 13-Dec-2016	Wednesday 14-Dec-2016	Thursday 15-Dec-2016	Friday 16-Dec-2016
09.00-09.50	Lecture Scientific Projects- III: Project Writing G. Yanikkaya Demirel	Independent Learning	Independent Learning	Independent Learning	Independent Learning
10.00-10.50	Lecture Comparing Groups-Continous Data II Ç. Kaspar				COMMITTEE EXAM
11.00-11.50	Lecture Comparing Groups-Continous Data I Ç. Kaspar				
12.00-12.50	Lecture Hematostatic Drugs and Hematostatic Blood Products I E. Genç				
12.50-14.00	LUNCH BREAK				
14.00-14.50	Lecture Hematostatic Drugs and Hematostatic Blood Products II E. Genç	Independent Learning	Independent Learning	Independent Learning	Program Evaluation Session Committee III Coordination Committee Members
15.00-15.50	Multidisciplinary Case Discussion Panel				Independent Learning
16.00-16.50	Multidisciplinary Case Discussion Panel				
17.00-17.50	Independent Learning				

## COMMITTEE IV - GASTROINTESTINAL SYSTEM

### DISTRIBUTION of LECTURE HOURS

December 19, 2016 - January 13, 2017

COMMITTEE DURATION: 4 WEEKS

MED 302	INTRODUCTION TO CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
	GASTROENTEROHEPATOLOGY	GE	20				20
	PATHOLOGY	PT	13		1x3=3 (2 Groups)		16
	PHARMACOLOGY	PC	5				5
	BIOMEDICAL ETHICS&DEONTOLOGY	BED	4				4
	PUBLIC HEALTH	PH	4				4
	INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	IDCM	4				4
	INTERNAL MEDICINE	IM	3				3
	PHYTOTHERAPY	PHY	3				3
	PATHOPHYSIOLOGY	PP	2				2
	BIOSTATISTICS	BS	4				4
	FAMILY MEDICINE	FM	2				2
	PEDIATRICS	PED	1				1
	PEDIATRIC SURGERY	PEDS	1				1
	RADIOLOGY	RAD	1				1
	MEDICAL GENETICS	MG	1				1
	SURGERY	GS	1				1
	EMERGENCY MEDICINE	EM	1				1
	INTERDISCIPLINARY	MCDP				2	2
MED 303	INTRODUCTION TO CLINICAL PRACTICE III	ICP III			1X3=3 (4 Groups)		3
<b>TOTAL</b>			<b>70</b>		<b>6</b>	<b>2</b>	<b>78</b>

### Coordination Committee

<b>HEAD</b>	Meltem Ergün, MD, Assoc. Prof.
<b>SECRETARY</b>	Atakan Yeşil , MD, Assoc. Prof
<b>MEMBER</b>	Ferda Özkan, MD, Prof.
<b>MEMBER</b>	Meltem Uğraş, MD, Assoc. Prof.

## COMMITTEE IV - GASTROINTESTINAL SYSTEM LECTURERS

MED 302 INTRODUCTION TO CLINICAL SCIENCES	
DISCIPLINE	LECTURERS
GASTROENTEROHEPATOLOGY	Meltem Ergün, MD, Assoc. Prof. Atalay Yeşil, MD, Prof.
PATHOLOGY	Ferda Özkan, MD, Prof. Işın Doğan Ekici, MD, Prof. Ahmet Sedat Çöloğlu, DMD, Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Ferda Kaleağasıoğlu, MD, Prof.
PUBLIC HEALTH	Erol Sezer, MD, Prof. Hale Arık Taşyikan, MD, Asst. Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu, MD, Assoc. Prof.
INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY	Meral Sönmezoğlu, MD, Prof. İbrahim Çağatay Acuner, MD, Assoc. Prof.
INTERNAL MEDICINE	Yaşar Küçükardalı, MD, Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, Assoc. Prof.
PHYTOTHERAPY	Erdem Yeşilada, PhD, Prof.
FAMILY MEDICINE	Hülya Akan, MD, Assoc. Prof. Özlem Tanrıöver, MD, Assoc. Prof.
BIOSTATISTICS	Çiğdem Kaspar, PhD, Asst. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Asst. Prof.
EMERGENCY MEDICINE	Mustafa Ferudun Çelikmen, MD, Asst. Prof.
PEDIATRICS	Meltem Uğraş, MD, Prof.
PEDIATRIC SURGERY	Selami Sözübir, MD, Prof.
GENERAL SURGERY	Onur Yaprak, MD, Assoc. Prof.
RADIOLOGY	Neslihan Taşdelen, MD, Assoc. Prof. Osman Melih Topçuoğlu, MD
SCIENTIFIC PROJECTS	Gülderen Yanıkkaya Demirel, MD, Prof.

MED 303 INTRODUCTION TO CLINICAL PRACTICE III	
DISCIPLINE	LECTURERS
CLINICAL SKILLS LAB	Zehra Eren, MD, Assoc. Prof. Atakan Yeşil, MD, Assoc. Prof. Orhan Önder Ören, MD, Assoc. Prof. Özlem Tanrıöver, MD, Assoc. Prof. Hülya Akan, MD, Assoc. Prof. Serdar Özdemir, MD, Asst., Prof.

## COMMITTEE IV - GASTROINTESTINAL SYSTEM

### AIMS and LEARNING OBJECTIVES

#### AIMS

##### *In evidence based manner,*

1. **to remind** knowledge on anatomy, histology and physiology of gastrointestinal system,
2. **to convey** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
3. **to convey** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
4. **to convey** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to gastrointestinal system,
5. **to convey** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
6. **to convey** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to gastrointestinal system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. **to convey** knowledge on pharmacology of drugs that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,
8. **to convey** knowledge on phytotherapeutic agents that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,
9. **to convey** knowledge on biostatistical analysis of association between variables,
10. **to convey** necessary knowledge on legal regulations and ethical principles for end-of-life decisions,
11. **to equip with** basic and advanced clinical skills (approach to patient with gastrointestinal clinical condition-C4) required at primary health care service level.
12. **to convey** knowledge on use of phytotherapy in an evidence based manner and drug interactions in phytotherapy,

#### LEARNING OBJECTIVES

##### *At the end of this committee, student should be able to:*

- 1.0. **recall** anatomy, histology and physiology of gastrointestinal system,
- 2.0. **explain** etiopathogenesis of clinical conditions (infections, nutritional disorders, bleedings, clinical conditions related to gastrointestinal organs) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
- 3.0. **explain** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,

- 4.0. **explain** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to gastrointestinal system,
- 5.0. **explain** importance of healthy nutrition, principles of balanced diet, and measurement of nutritional status,
- 6.0. **describe** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
- 7.0. at multi-system level and/or related to gastrointestinal system,
  - for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
  - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
  - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
- explain** in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,
  - health care processes, clinical decision making process, clinical decisions and clinical practices which are required for management at primary health care service level:
- 7.1. practice of history taking and physical examination (gastrointestinal-C4)
- 7.2. evaluation of emergency case (acute abdominal pain-C4)
- 7.3. approach to healthy individual or patient (diarrhea-C4)
- 7.4. laboratory tests/examinations
- 7.5. imaging tests/examinations (scintigraphy of liver/spleen-C4, PET in gastrointestinal system tumors-C4)
- 7.6. point of care testing
- 7.7. making preliminary diagnosis or definitive diagnosis decision
- 7.8. making non-intervention or intervention decision
- 7.9. practicing non-intervention or intervention
- 7.10. referral/transport of healthy individual or patient
8. **list** differences of gastrointestinal clinical conditions that may occur in children,
9. **explain** liver transplantation (indications, contraindications, conditions, risks, methods, patient care, results and monitorization),
10. **explain** pharmacology of drugs (agents used in the treatment of peptic ulcer, emetic and antiemetic agents, laxatives) that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,
11. **explain** genetics of gastrointestinal system,
12. **explain** phytotherapeutic agents that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,
13. **define** biostatistical analysis of association between variables,
14. **tell** legal regulations and ethical principles for end-of-life decisions,
15. **perform** basic clinical skills, practiced on phantom models and advanced clinical skills, practiced on simulated/standardized patients (approach to patient with gastrointestinal clinical condition-C4), required at primary health care service.
16. **to convey** knowledge on use of phytotherapy in an evidence based manner and drug interactions in phytotherapy.



## COMMITTEE IV - GASTROINTESTINAL SYSTEM

### COMMITTEE ASSESSMENT MATRIX

PHASE III						
COURSE: MD 320 INTRODUCTION TO CLINICAL SCIENCES						
COURSE COMPONENT: COMMITTEE IV - GASTROINTESTINAL SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/ INSTRUCTOR	NUMBER OF QUESTIONS (MCQ)			
			CE	FE	IE	Total
1.0.,2.0.,3.0.,4.0.,6.0.,7.0.	GE	M. Ergün	26	6	6	38
		A. Yeşil				
2.0.,6.0.	PT	I. D. Ekici	17	4	4	25
2.0.,6.0.,7.4.		F. Özkan				
2.0, 6.0, 7.4		A.S.Çöloğlu				
10.0.	PC	E. Genç	7	2	2	11
10.0.		F. Kaleağasıoğlu				
3.0.,4.0.,5.0.	PH	R.E. Sezer	5	1	1	7
3.0.,4.0.,5.0.		H.A.Taşyikan				
14.0.	BED	E. Vatanoglu	5	1	1	7
2.0.,3.0.,4.0.,6.0.,7.0.	IDCM	M. Sönmezoğlu	5	1	1	7
2.0.,3.0.,4.0.,6.0.,7.4.		I.Ç.Acuner				
13.0.	BS	Ç. Kaspar	5	1	1	7
1.0.,2.0.,3.0.,4.0.,6.0.,6.0.,7.1.	IM	Y. Küçükardalı	4	1	1	6
12.0	PHR (PHY)	E. Yeşilada	4	1	1	6
2.0.,6.0.	PP	M. Kaçar	3	1	1	5
7.3.	FM	H. Akan	3	1	1	5
7.3.		Ö. Tanrıöver				
5.0.	PED	M. Ugras	1	0	0	1
1.0.,2.0.,3.0.,4.0.,6.0.,7.0.	PEDS	S. Sözübir	1	1	1	3
7.5.	RAD	N. Taşdelen	1	0	0	1
11.0.	MG	A.Ç. Kuşkucu	1	0	0	1
9.0.	GS	O.Yaprak	1	0	0	1
2.0.,3.0.,4.0.,6.0.,7.3.	EM	F. Çelikmen	1	0	0	1
TOTAL			90	15	15	120
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0.,2.0.,3.0.,4.0.,6.0.,7.0.	GE	M.Ergün	3	-	-	3
2.0.,6.0.,7.4.	PT	F. Özkan/ I.D.Ekici	2	-	-	2
TOTAL			5	-	-	5

**CS\*= 90 pts (MCQ) + 10 pts (EMQ) = 100 pts; pts: Points**

\*Each MCQ has a value of 1 points; each EMQ question has a value of 2 points.

**MCQ:** Multiple Choice Question

**EMQ:** Extending Matching Question

**CE:** Committee Exam

**CS:** Committee Score

**FE:** Final Exam

**ICE:** Incomplete Exam

**\*\*15** out of 200 FE and ICE MCQs will be from Committee IV (Each question is of worth **0.5** pts).

**COMMITTEE IV - GASTROINTESTINAL SYSTEM**  
**WEEK I / 19-23 Dec 2016**

	<b>Monday 19-Dec-2016</b>	<b>Tuesday 20-Dec-2016</b>	<b>Wednesday 21-Dec-2016</b>	<b>Thursday 22-Dec-2016</b>	<b>Friday 23-Dec-2016</b>
<b>09.00- 09.50</b>	<b>Introductory Session</b> Introduction to Committee IV <i>Head of Committee</i>	<b>Lecture</b> Oral Pathology <i>A. S. Çöloğlu</i>	<b>Lecture</b> Pathology of Stomach I <i>F. Özkan</i>	<b>ICP-CSL</b> (History taking and physical examination of gastrointestinal system) <i>Z.Eren / S. Özdemir / H. Akan</i>	<b>Lecture</b> Pathology of Liver I <i>F. Özkan</i>
<b>10.00- 10.50</b>	<b>Lecture</b> Semiology I <i>Y. Küçükardalı</i>	<b>Lecture</b> Pathology of Esophagus I <i>F. Özkan</i>	<b>Lecture</b> Pathology of Stomach II <i>F. Özkan</i>	<b>Group A</b> <b>Group B</b> IL <b>Group C</b> IL <b>Group D</b> IL	<b>Lecture</b> Pathology of Liver I <i>F. Özkan</i>
<b>11.00- 11.50</b>	<b>Lecture</b> Semiology II <i>Y. Küçükardalı</i>	<b>Lecture</b> Pathology of Esophagus II <i>F. Özkan</i>	<b>Lecture</b> Pathology of Intestinal Diseases I <i>F. Özkan</i>		<b>Lecture</b> Acute Gastroenteritis <i>M. Sönmezoğlu</i>
<b>12.00- 12.50</b>	<b>Lecture</b> Pathophysiology of Gastro-intestinal Disorders I <i>M. Kaçar</i>	<b>Lecture</b> Laxatives <i>F. Kaleağasıoğlu</i>	<b>Lecture</b> Pathology of Intestinal Diseases II <i>F. Özkan</i>	<b>Lecture</b> Food poisoning <i>Microbiology Lecturer</i>	<b>Lecture</b> Hepatitis II <i>M. Sönmezoğlu</i>
<b>12.50 – 14.00</b>	<b>LUNCH BREAK</b>				
<b>14.00- 14.50</b>	<b>Lecture</b> Pathophysiology of Gastro-intestinal Disorders II <i>M. Kaçar</i>	<b>Lecture</b> Relation Between Several Variables I <i>Ç. Kaspar</i>	<b>Lecture</b> Approach to the Patient with Abdominal Pain Regarding to Primary Care <i>Ö. Tanrıöver</i>	<b>Lecture</b> Malabsorption <i>A. Yeşil</i>	<b>Independent Learning</b>
<b>15.00- 15.50</b>	<b>Lecture</b> Relation Between Two Variables I <i>Ç. Kaspar</i>	<b>Lecture</b> Relation Between Several Variables II <i>Ç. Kaspar</i>	<b>Lecture</b> Approach to the Patient with Diarrhea Regarding to Primary Care <i>H. Akan</i>	<b>Lecture</b> Inflammatory Bowel Disease <i>A. Yeşil</i>	<b>Independent Learning</b>
<b>16.00- 16.50</b>	<b>Lecture</b> Relation Between Two Variables II <i>Ç. Kaspar</i>	<b>Lecture</b> Clinical Approach to the Patient with Acute Abdominal Pain <i>S. Sarıkaya</i>	<b>Lecture</b> The Ethics of Testing and Screening I <i>E. Vatanoglu</i>	<b>Lecture</b> Functional GI Disorders & Irritable Bowel Disease <i>A. Yeşil</i>	<b>Independent Learning</b>
<b>17.00-17.50</b>	<b>Independent Learning</b>	<b>Lecture</b> Gastrointestinal Bleedings in Children <i>S. Sözübir</i>	<b>Lecture</b> The Ethics of Testing and Screening II <i>E. Vatanoglu</i>	<b>Lecture</b> Tumors of Esophagus, Stomach and Small Intestine <i>A. Yeşil</i>	<b>Independent Learning</b>

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

**COMMITTEE IV - GASTROINTESTINAL SYSTEM WEEK II / 26-30 Dec 2016**

	Monday 26-Dec-2016	Tuesday 27-Dec-2016	Wednesday 28-Dec-2016	Thursday 29-Dec-2016				Friday 30-Dec-2016					
09.00- 09.50	Lecture Gastritis and Helicobacter Pylori M. Ergün	Lecture Pathology of Liver & Biliary System I I. D. Ekici	Lecture Hepatitis I Microbiology Lecturer	ICP-CSL (History taking and physical examination of gastrointestinal system) Z. Eren / S. Özdemir /H. Akan				ICP-CSL (History taking and physical examination of gastrointestinal system) A.Yeşil / S. Özdemir / Ö. Tanrıöver					
10.00- 10.50	Lecture Gastroesophegeal Reflux (GE) and Esophageal Motility Disorder M. Ergün	Lecture Pathology of Liver & Biliary System II I. D. Ekici	Lecture Jaundice M. Ergün	Group A IL	Group B	Group C IL	Group D IL	Group A IL	Group B IL	Group C	Group D IL		
11.00- 11.50	Lecture Agents used in the Treatment of Peptic Ulcer I E. Genç	Lecture Pathology of Liver & Biliary System III I. D. Ekici	Lecture Chronic Viral Hepatitis M. Ergün										
12.00- 12.50	Lecture Agents used in the Treatment of Peptic Ulcer II E. Genç	Lecture Pathology of Liver & Biliary System IV I. D. Ekici	Lecture Cirrhosis and Complications M. Ergün	Lecture Pathology of Appendix & Peritoneum F. Özkan				Lecture Premalignant Lesion of the Colon M. Ergün					
12.50 – 14.00	LUNCH BREAK												
14.00- 14.50	Lecture Peptic Ulcer Disease A.Yeşil	Pathology Laboratory (Gastrointestinal System) F. Özkan/ I.D. Ekici	Group A	Group B IL	Lecture Epidemiology, Prevention and Control of Obesity I H.A.Taşyikan		Pathology Laboratory (Gastrointestinal System) F. Özkan/ I.D. Ekici	Group A	Group B IL	Lecture Malignant Lesions of the Colon M. Ergün			
15.00- 15.50	Lecture Autoimmune Hepatitis A.Yeşil				Lecture Epidemiology, Prevention and Control of Obesity II H.A.Taşyikan					Group A IL	Group B	Lecture Acute Liver Failure A. Yeşil	
16.00- 16.50	Independent Learning				Lecture Public Health and Nutrition I R.E. Sezer							Lecture Disease of the Bile Duct and Gall Bladder A. Yeşil	
17.00-17.50	Independent Learning	Independent Learning	Lecture Public Health and Nutrition II R.E. Sezer	Independent Learning				Independent Learning					

**COMMITTEE IV - GASTROINTESTINAL SYSTEM**  
**WEEK III / 2-6 Jan 2017**

	Monday 2-Jan-2017	Tuesday 3-Jan-2017	Wednesday 4-Jan-2017	Thursday 5-Jan-2017				Friday 6-Jan-2017
09.00- 09.50	<b>Lecture</b> Wilson Disease and Hemochromatosis A. Yeşil	<b>Lecture</b> Emetic & Antiemetic Agents F. Kaleağasıoğlu	<b>Lecture</b> Drug Induced Liver Disease M. Ergün	<b>ICP-CSL</b> (History taking and physical examination of gastrointestinal system) A.Yeşil / S. Özdemir / Ö. Tanrıöver				Independent learning
10.00- 10.50	<b>Lecture</b> Acute and Chronic Pancreatitis A. Yeşil	<b>Lecture</b> Digestive & Antidiarrheal Drugs F. Kaleağasıoğlu	<b>Lecture</b> Mass Lesions of the Liver M. Ergün	Group A IL	Group B IL	Group C IL	Group D	
11.00- 11.50	<b>Lecture</b> Tumors of the Bile Ducts and Pancreas A.Yeşil	<b>Lecture</b> Complex diseases-Inherited Gastrointestinal System Disorders A.Ç. Kuşkucu	<b>Multidisciplinary Case Discussion Panel</b>					
12.00- 12.50	<b>Lecture</b> Alcoholic and Nonalcoholic Liver Disease Y. Küçükardalı	<b>Lecture</b> Clinical Nutrition M. Uğraş	<b>Multidisciplinary Case Discussion Panel</b>	Independent Learning				
12.50 – 14.00	LUNCH BREAK							
14.00- 14.50	<b>Lecture</b> Transplantation of Liver O. Yaprak	<b>Lecture</b> Phytotherapy-IV E. Yeşilada	Independent Learning		2 <sup>nd</sup> Coordination Committee Meeting			Independent learning
15.00- 15.50	<b>Lecture</b> Radiology of Gastrointestinal System N. Taşdelen/O.M.Topçuoğlu	<b>Lecture</b> Phytotherapy-V E. Yeşilada						
16.00- 16.50	<b>Lecture</b> Organ Transplantation and Ethics I E. Vatanoğlu	<b>Lecture</b> Phytotherapy-VI E. Yeşilada						
17.00-17.50	<b>Lecture</b> Organ Transplantation and Ethics II E. Vatanoğlu	Independent Learning			Independent Learning			

**COMMITTEE IV - GASTROINTESTINAL SYSTEM**  
**WEEK IV / 9-13 Jan 2017**

	Monday 9-Jan-2017	Tuesday 10-Jan- 2017	Wednesday 11-Jan-2017	Thursday 12-Jan-2017	Friday 13-Jan-2017
09.00- 09.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning
10.00- 10.50					COMMITTEE EXAM
11.00- 11.50					
12.00- 12.50					
12.50 – 14.00	LUNCH BREAK				
14.00- 14.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Program Evaluation Session Committee IV Coordination Committee Members
15.00 -15.50					Independent Learning
16.00 - 16.50					
17.00 - 17.50					

## COMMITTEE V - ENDOCRINOLOGY and REPRODUCTIVE SYSTEMS

### DISTRIBUTION of LECTURE HOURS

January 30, 2017 – March 3, 2017

COMMITTEE DURATION: 5 WEEKS

MED 302	INTRODUCTION TO CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	PATHOLOGY	PT	20				20
	OBST & GYNEC	OBS-GYN	16				16
	ENDOCRINOLOGY	END	13				13
	INTERNAL MEDICINE	IM	2				2
	PHARMACOLOGY	PC	11				11
	MEDICAL GENETICS	MG	6				6
	INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	IDCM	3		1x2=2 (2 Groups)		5
	PATHOPHYSIOLOGY	PP	5				5
	BIOMEDICAL ETHICS&DEONTOLOGY	BED	4				4
	PUBLIC HEALTH	PH	4				4
	FAMILY MEDICINE	FM	4				4
	PEDIATRICS	PED	3				3
	BIOSTATISTICS	BS	4				4
	PHYTOTHERAPY	PHR (PHY)	2				2
	RADIOLOGY	RAD	1				1
	HISTOLOGY	HST	1				1
	SCIENTIFIC PROJECTS- III	SP	1				1
	INTERDISCIPLINARY	MCDP				2	2
MED 303	INTRODUCTION TO CLINICAL PRACTICE III	ICP III			1x3=3 (4 Groups)		3
TOTAL			100		5	2	107

### Coordination Committee

HEAD	Hasan Aydın, MD, Prof.
SECRETARY	Oluş Api, MD, Assoc. Prof.
MEMBER	Ayşegül Kuşkucu, MD, Asst. Prof.
MEMBER	Ece Genç, PhD, Prof.

**COMMITTEE V - ENDOCRINE SYSTEM and REPRODUCTIVE SYSTEM  
LECTURERS**

<b>MED 302 INTRODUCTION TO CLINICAL SCIENCES</b>	
<b>DISCIPLINE</b>	<b>LECTURERS</b>
<b>PATHOLOGY</b>	Ferda Özkan, MD, Prof. Işın Doğan Ekici, MD, Prof. Ahmet Sedat Çöloğlu, DMD, Prof.
<b>OBSTETRICS and GYNECOLOGY</b>	N. Cem Fıçıcıoğlu, MD, Prof. Meral Aban, MD, Prof. Selçuk Özden, MD, Prof.0 Oluş Api, MD, Assoc. Prof. Rukset Attar, MD, Assoc. Prof. Gazi Yıldırım, MD, Assoc. Prof.
<b>ENDOCRINOLOGY</b>	Hasan Aydın, MD, Assoc. Prof.
<b>INTERNAL MEDICINE</b>	Yaşar Küçükardalı, MD, Prof.
<b>PHARMACOLOGY</b>	Ece Genç, PhD, Prof. Ferda Kaleağasıoğlu, MD, Prof.
<b>MEDICAL GENETICS</b>	Ayşegül Çınar Kuşkucu, MD, Asst. Prof.
<b>INFECTIOUS DISEASES &amp; CLINICAL MICROBIOLOGY</b>	Meral Sönmezoğlu, MD Prof. İbrahim Çağatay Acuner, MD, Assoc. Prof.
<b>PATHOPHYSIOLOGY</b>	Mehtap Kaçar, MD, Assoc. Prof.
<b>BIOMEDICAL ETHICS&amp;DEONTOLOGY</b>	Elif Vatanoğlu, MD, Assoc. Prof.
<b>PUBLIC HEALTH</b>	Recep Erol Sezer, MD, Prof. Hale Arık Taşyikan, MD, Asst. Prof.
<b>FAMILY MEDICINE</b>	Özlem Tanrıöver, MD, Assoc. Prof. Ayşe Arzu Akalın, MD, Asst. Prof.
<b>PEDIATRICS</b>	Mustafa Berber, MD, Asst. Prof. F. T. Coşkun, MD
<b>BIOSTATISTICS</b>	Çiğdem Kaspar, PhD, Asst. Prof.
<b>RADIOLOGY</b>	Neslihan Taşdelen, MD, Assoc. Prof.
<b>PHYTOTHERAPY</b>	Erdem Yeşilada, MD, Prof.
<b>RADIOLOGY</b>	Neslihan Taşdelen, MD, Assoc. Prof.
<b>HISTOLOGY &amp; EMBRYOLOGY</b>	Oya Alagöz, MD, Asst. Prof.
<b>SCIENTIFIC PROJECTS- III</b>	Gülderen Yanıkkaya Demirel, MD, Assoc. Prof.

<b>MED 303 INTRODUCTION TO CLINICAL PRACTICE III</b>	
<b>DISCIPLINE</b>	<b>LECTURERS</b>
<b>CLINICAL SKILLS LAB</b>	Oluş Api, MD, Assoc. Prof. Rukset Attar, MD, Assoc. Prof. Gazi Yıldırım, MD, Assoc. Prof.

## COMMITTEE V - ENDOCRINE SYSTEM and REPRODUCTIVE SYSTEM

### AIMS and LEARNING OBJECTIVES

#### AIMS

##### In evidence based manner,

1. **to remind** knowledge on anatomy, embryology, histology and physiology of endocrine and reproductive systems,
2. **to convey** knowledge on health care service practices related to reproductive care,
3. **to convey** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
4. **to convey** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
5. **to convey** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to endocrine and reproductive systems,
6. **to convey** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
7. **to convey** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to endocrine and reproductive systems, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
8. **to convey** knowledge on pharmacology of drugs that are effective on endocrine and reproductive systems or on clinical conditions involving endocrine and reproductive systems,
9. **to convey** knowledge on genetics of endocrine and reproductive systems,
10. **to convey** knowledge on phytotherapeutic agents that are effective on endocrine system or on clinical conditions involving endocrine system,
11. **to convey** knowledge on design and biostatistical analysis of survival research,
12. **to convey** knowledge on legal regulations and ethical principles related to reproductive care,
13. **to equip with** basic and advanced clinical skills (*normal spontaneous vaginal delivery on phantom model-C5*) required at primary health care service level.

#### LEARNING OBJECTIVES

##### ***At the end of this committee, student should be able to:***

- 1.0. **recall** anatomy, embryology, histology and physiology of endocrine and reproductive systems,
- 2.0. **explain** physiology of normal spontaneous vaginal delivery,
- 3.0. **define** practice of reproductive care,
- 4.0. **explain** etiopathogenesis of clinical conditions (menstrual cycle/developmental conditions/congenital and sexually transmitted infections) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
- 5.0. **explain** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
- 6.0. **explain** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to endocrine and reproductive systems,



- 7.0. **describe** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
- 8.0. at multi-system level and/or related to endocrine and reproductive systems,
  - for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
  - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
  - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
- explain** in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,
  - health care processes, clinical decision making process, clinical decisions and clinical practices which are required for management at primary health care service level:
- 8.1. practice of history taking and physical examination (gynecological-C5, breast-C5)
- 8.2. evaluation of emergency case
- 8.3. approach to healthy individual or patient (pregnancy-C5)
- 8.4. laboratory tests/examinations (venous blood collection-C5, throat swab specimen-C5, sputum sample collection-C5, thyroid function tests-C5, diabetes tests-C5, rapid screening [antigen/antibody] tests-C5, throat culture-C5, sputum culture-C5)
- 8.5. imaging tests/examinations (radiological examinations in gynecology-C5, breast imaging-C5, radioisotope imaging of thyroid and parathyroid-C5)
- 8.6. point of care testing (diabetes tests-C5, rapid screening [antigen/antibody] tests-C5)
- 8.7. making preliminary diagnosis or definitive diagnosis decision
- 8.8. making non-intervention or intervention decision
- 8.9. practicing non-intervention or intervention
- 8.10. referral/transport of healthy individual or patient
- 9.0. **explain** pharmacology of drugs (hypothalamic and pituitary hormones, drugs effecting functions and action of oxytocin and ADH, thyroid and antithyroid drugs, adrenocortical hormones and drugs, insulin and oral antidiabetic drugs, estrogens, progestines and inhibitors) that are effective on endocrine and reproductive systems or on clinical conditions involving endocrine and reproductive systems,
- 10.0. **explain** genetics of endocrine and reproductive systems,
- 11.0. **explain** mechanisms of action for phytotherapeutic agents that are effective on endocrine system or in clinical conditions related to endocrine system,
- 12.0. **define** design and biostatistical analysis of survival research,
- 13.0. **explain** legal regulations and ethical principles related to reproductive care,
- 14.0. **perform** basic clinical skills, practiced on phantom models (normal spontaneous vaginal delivery-C5), and advanced clinical skills, practiced on simulated/standardized patients required at primary health care service.

**COMMITTEE V - ENDOCRINE SYSTEM and REPRODUCTIVE SYSTEM  
COMMITTEE ASSESSMENT MATRIX**

PHASE III						
COURSE: MD 320 INTRODUCTION TO CLINICAL SCIENCES						
COURSE COMPONENT: COMMITTEE V - ENDOCRINE SYSTEM and REPRODUCTIVE SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/ INSTRUCTOR	NUMBER OF QUESTIONS			
			(MCQ)			
			CE	FE	IE	Total
1.0, 4.0, 7.0, 8.4	PT	F. Özkan	17	6	6	29
1.0, 4.0, 7.0, 8.4		I.D. Ekici				
1.0, 4.0, 7.0, 8.4		A.Sedat Çöloğlu				
1.0-8.0	OBS-GYN	C. Fıçıcıoğlu	14	5	5	24
1.0-8.0		O. Api				
1.0-8.0		R. Attar				
1.0-8.0		G.Yıldırım				
1.0, 4.0-8.0	END	H. Aydın	11	4	4	19
9.0	PC	E. Genç	10	3	3	16
9.0		F.Kaleağasıoğlu				
10.0	MG	A. Ç. Kuşkucu	5	2	2	9
4.0, 7.0	PP	M. Kaçar	5	2	2	9
10.0	BED	E.Vatanoğlu	4	1	1	6
5.0, 6.0	PH	R.E. Sezer	4	1	1	6
5.0, 6.0		H.A.Taşyikan				
6.0, 8.0,8.1, 8.3	FM	A Akalın	4	1	1	6
8.3		Ö. Tanrıöver				
12.0	BS	Ç. Kaspar	4	1	1	6
4.0, 5.0, 6.0, 7.0, 8.0	IDCM	M. Sönmezoğlu	3	1	1	5
4.0, 5.0, 6.0, 7.0, 8.4		İ.Ç.Acuner				
1.0, 4.0-8.0	PED	M. Berber	3	1	1	5
		F. T. Coşkun				
1.0, 4.0-8.0	IM	Y. Küçükardalı	2	1	1	4
	PHR (PHY)	E. Yeşilada	2	1	1	4
8.5,	RAD	N. Taşdelen	1	1	1	3
1.0	HST	O. Akçin	1	0	0	1
TOTAL			90	31	31	152
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/ INSTRUCTOR	NUMBER OF QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0, 4.0-8.0	END	H. Aydın	1	-	-	1
1.0-8.0	OBS-GYN	O.Api	2	-	-	2
1.0, 4.0, 7.0, 8.4	PT	F. Özkan	2	-	-	2
TOTAL			5	-	-	5

**CS\*= 90 pts (MCQ) + 10 pts (EMQ) = 100 points**

\*Each MCQ has a value of 1 points; each EMQ question has a value of 2 points.

**MCQ:** Multiple Choice Question

**EMQ:** Extending Matching Question

**CE:** Committee Exam

**CS:** Committee Score

**FE:** Final Exam

**ICE:** Incomplete Exam

**pts:** Points

**\*\*31** out of 200 FE and ICE MCQs will be from Committee V (Each question is of worth **0.5** pts).

**COMMITTEE V - ENDOCRINOLOGY and REPRODUCTIVE SYSTEMS**  
**WEEK I / 30 Jan-3 Feb 2017**

	<b>Monday 30-Jan-2017</b>	<b>Tuesday 31-Jan-2017</b>	<b>Wednesday 1-Feb-2017</b>	<b>Thursday 2-Feb-2017</b>	<b>Friday 3-Feb-2017</b>
<b>09.00- 09.50</b>	<b>Introductory Session</b> Introduction to Committee V Head of Committee	<b>Lecture</b> Pathology of Endocrine System: Introduction A. S. Çöloğlu	<b>Lecture</b> Thyroid Function Tests H. Aydın	<b>ICP-CSL</b> (Follow-up of pregnancy & stages of normal labour & Gynecological examination, PAP smear obtaining) R. Attar /G. Yıldırım/ Oluş Api	<b>Lecture</b> Hypocalcemic Diseases H. Aydın
<b>10.00- 10.50</b>	<b>Lecture</b> Pathophysiology of Endocrine System Diseases I M. Kaçar	<b>Lecture</b> Pathology of Pituitary Gland I A. S. Çöloğlu	<b>Lecture</b> Thyroid Disorders H. Aydın	<b>Group A</b>	<b>Lecture</b> Adrenal Disorders H. Aydın
<b>11.00- 11.50</b>	<b>Lecture</b> Pathophysiology of Endocrine System Diseases II M. Kaçar	<b>Lecture</b> Pathology of Pituitary Gland II A. S. Çöloğlu	<b>Lecture</b> Calcium Metabolism H. Aydın		<b>Lecture</b> Hypoglycemia H. Aydın
<b>12.00- 12.50</b>	<b>Lecture</b> Pathophysiology of Endocrine System Diseases III M. Kaçar	<b>Lecture</b> Introduction to Endocrine Pharmacology E. Genç	<b>Lecture</b> Hypercalcemic Diseases H. Aydın	<b>Lecture</b> Design of Survival Studies I Ç. Kaspar	<b>Lecture</b> Congenital Adrenal Hyperplasia M. Berber
<b>12.50 – 14.00</b>	<b>LUNCH BREAK</b>				
<b>14.00- 14.50</b>	<b>Lecture</b> Introduction to Endocrinology H. Aydın	<b>Lecture</b> Hypothalamic and Pituitary Hormones I F. Kaleağasıoğlu	<b>Lecture</b> Thyroid and Antithyroid Drugs I E. Genç	<b>Lecture</b> Design of Survival Studies II Ç. Kaspar	<b>Independent learning</b>
<b>15.00- 15.50</b>	<b>Lecture</b> Hyperfunctioning Disorders of Anterior Pituitary Gland H. Aydın	<b>Lecture</b> Hypothalamic and Pituitary Hormones II F. Kaleağasıoğlu	<b>Lecture</b> Thyroid and Antithyroid Drugs II E. Genç	<b>Lecture</b> Pathology of Adrenal Gland I A. S. Çöloğlu	
<b>16.00- 16.50</b>	<b>Lecture</b> Disorders of Posterior Pituitary Gland H. Aydın	<b>Lecture</b> Pathology of Thyroid & Parathyroid I F. Özkan	<b>Lecture</b> Imaging of Thyroid Glands N. Taşdelen	<b>Lecture</b> Pathology of Adrenal Gland II A. S. Çöloğlu	
<b>17.00-17.50</b>	<b>Lecture</b> Hypopituitarism H. Aydın	<b>Lecture</b> Pathology of Thyroid & Parathyroid II F. Özkan	<b>Independent Learning</b>	<b>Independent Learning</b>	

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

**COMMITTEE V - ENDOCRINOLOGY and REPRODUCTIVE SYSTEMS**

**WEEK II / 6-10 Feb 2017**

	<b>Monday 6-Feb-2017</b>	<b>Tuesday 7-Feb-2017</b>	<b>Wednesday 8-Feb-2017</b>	<b>Thursday 9-Feb-2017</b>	<b>Friday 10-Feb-2017</b>
<b>09.00- 09.50</b>	<b>Lecture</b> Pathology of Pancreas I <b>A. S. Çöloğlu</b>	<b>Lecture</b> Introduction to Diabetes Mellitus <b>Y. Küçükardalı</b>	<b>Lecture</b> Chromosomal Disorders I <b>A. Ç. Kuşkucu</b>	<b>ICP-CSL</b> (Follow-up of pregnancy & stages of normal labour & Gynecological examination, PAP smear obtaining) <b>R. Attar /G. Yıldırım/ Oluş Api</b>	<b>Lecture</b> Puerperal Infections <b>Oluş Api</b>
<b>10.00- 10.50</b>	<b>Lecture</b> Pathology of Pancreas II <b>A. S. Çöloğlu</b>	<b>Lecture</b> Clinical and Laboratory Findings of Diabetes Mellitus <b>Y. Küçükardalı</b>	<b>Lecture</b> Chromosomal Disorders II (Sex chromosomes and their abnormalities) <b>A. Ç. Kuşkucu</b>	<b>Group A IL</b> <b>Group B</b> <b>Group C IL</b> <b>Group D IL</b>	<b>Lecture</b> Normal and Abnormal Labor <b>Oluş Api</b>
<b>11.00- 11.50</b>	<b>Lecture</b> Obesity <b>H. Aydın</b>	<b>Lecture</b> Insulin and Oral Antidiabetic Drugs I <b>E. Genç</b>	<b>Lecture</b> Pathophysiology of Reproductive System Diseases I <b>M. Kaçar</b>		<b>Lecture</b> Pathology of Cervix Uteri I <b>F. Özkan</b>
<b>12.00- 12.50</b>	<b>Lecture</b> Diffuse Hormonal Systems and Endocrine Tumor Syndromes <b>H. Aydın</b>	<b>Lecture</b> Insulin and Oral Antidiabetic Drugs II <b>E. Genç</b>	<b>Lecture</b> Pathophysiology of Reproductive System Diseases II <b>M. Kaçar</b>	<b>Independent Learning</b>	<b>Lecture</b> Pathology of Cervix Uteri II <b>F. Özkan</b>
<b>12.50-14.00</b>	<b>LUNCH BREAK</b>				
<b>14.00- 14.50</b>	<b>Lecture</b> Adrenocortical Hormones and Drugs I <b>E. Genç</b>	<b>Lecture</b> Epidemiology, Prevention and Control of Type II Diabetes Mellitus <b>R. E. Sezer</b>	<b>Lecture</b> Pathology of Breast I <b>F. Özkan</b>	<b>Lecture</b> Conditions affecting Vulva & Vagina <b>M. Aban</b>	<b>Lecture</b> Inborn Errors of Metabolism I <b>A.Ç. Kuşkucu</b>
<b>15.00- 15.50</b>	<b>Lecture</b> Adrenocortical Hormones and Drugs II <b>E. Genç</b>	<b>Independent Learning</b>	<b>Lecture</b> Pathology of Breast II <b>F. Özkan</b>	<b>Lecture</b> The Gynecological History and Examination <b>G. Yıldırım</b>	<b>Lecture</b> Inborn Errors of Metabolism II <b>A.Ç. Kuşkucu</b>
<b>16.00- 16.50</b>	<b>Lecture</b> Delivery of Family Planning Services I <b>A. Akalın</b>	<b>Independent Learning</b>	<b>Lecture</b> Pathology of Vulva & Vagina <b>F. Özkan</b>	<b>Lecture</b> Endometriosis & Adenomyosis <b>G. Yıldırım</b>	<b>Independent Learning</b>
<b>17.00-17.50</b>	<b>Lecture</b> Delivery of Family Planning Services II <b>A. Akalın</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>

**COMMITTEE V - ENDOCRINOLOGY and REPRODUCTIVE SYSTEMS**  
**WEEK III / 13-17 Feb 2017**

	Monday 13-Feb-2017	Tuesday 14-Feb-2017	Wednesday 15-Feb-2017	Thursday 16-Feb-2017	Friday 17-Feb-2017
09.00-09.50	<b>Lecture</b> Pathology of Pregnancy & Placenta F. Özkan	<b>Lecture</b> Antenatal Care S. Özden	<b>Lecture</b> Normal Pubertal Development M. Berber Belma Haliloğlu	<b>ICP-CSL</b> (Follow-up of pregnancy & stages of normal labour & Gynecological examination, PAP smear obtaining) R. Attar /G. Yıldırım/ Oluş Api	<b>ICP-CSL</b> (Follow-up of pregnancy & stages of normal labour & Gynecological examination, PAP smear obtaining) R. Attar/ G.Yıldırım/Oluş Api
10.00-10.50	<b>Lecture</b> Pathology of Uterus I F. Özkan	<b>Lecture</b> Disorders of Early Pregnancy (Miscarriage; Ectopic; GTD) S. Özden	<b>Lecture</b> Pubertal Disorders M. Berber Belma Haliloğlu	Group A IL Group B IL Group C Group D IL	Group A IL Group B IL Group C IL Group D
11.00-11.50	<b>Lecture</b> Pathology of Uterus II F. Özkan	<b>Lecture</b> Genetic disorders of gonadal development A. Ç. Kuşku	<b>Lecture</b> The Menstrual Cycle and Disorders of the Menstrual Cycle R. Attar		
12.00-12.50	<b>Lecture</b> Analysis of Survival Studies I Ç. Kaspar	<b>Lecture</b> Prenatal genetic diagnosis and genetic counseling A. Ç. Kuşku	<b>Lecture</b> Normal and Abnormal Sexual Development & Puberty R. Attar	<b>Lecture</b> Scientific Projects- III: Writing Project G. Y. Demirel	<b>Independent Learning</b>
12.50-14.00	<b>LUNCH BREAK</b>				
14.00-14.50	<b>Lecture</b> Analysis of Survival Studies II Ç. Kaspar	<b>Lecture</b> Medical History for Breast Diseases in Primary Care & Clinical Breast Examination A. Akalın	<b>Lecture</b> Estrogens, Progestins and Inhibitors I F. Kaleağasıoğlu	<b>Lecture</b> Pathology of Ovary I F. Özkan	<b>Lecture</b> Reproductive, Maternal and Child Health I H. A. Taşyikan
15.00-15.50	<b>Microbiology Laboratory</b> (Diagnostic tests of urogenital specimens) I.Ç. Acuner	<b>Microbiology Laboratory</b> (Diagnostic tests of urogenital specimens) I.Ç. Acuner	<b>Lecture</b> Estrogens, Progestins and Inhibitors II F. Kaleağasıoğlu	<b>Lecture</b> Pathology of Ovary II F. Özkan	<b>Lecture</b> Reproductive, Maternal and Child Health II H. A. Taşyikan
16.00-16.50			<b>Lecture</b> Embryology O. Alagöz	<b>Lecture</b> Pathology of Treponemal Infections F. Özkan	<b>Lecture</b> Reproductive, Maternal and Child Health III H. A. Taşyikan
17.00-17.50	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>

**COMMITTEE V - ENDOCRINOLOGY and REPRODUCTIVE SYSTEMS**

**WEEK IV / 20-24 Feb 2017**

	Monday 20-Feb-2017	Tuesday 21-Feb-2017	Wednesday 22-Feb-2017	Thursday 23-Feb-2017	Friday 24-Feb-2017
09.00- 09.50	Lecture Menopause C. Fişicioğlu	Lecture Malign Diseases of the Uterus and the Cervix M. Aban	Lecture Benign Diseases of the Uterus and the Cervix R. Attar	OSCE-I EXAM	OSCE-I EXAM
10.00- 10.50	Lecture Fertility Control C. Fişicioğlu	Lecture Malign Diseases of the Ovary M. Aban	Lecture Benign Diseases of the Ovary R. Attar		
11.00- 11.50	Lecture Infertility C. Fişicioğlu	Lecture Phytotherapy-VII E. Yeşilada	Multidisciplinary Case Discussion Panel		
12.00- 12.50	Lecture General Approach to the Pregnant Woman Ö. Tannöver	Lecture Phytotherapy-VIII E. Yeşilada	Multidisciplinary Case Discussion Panel		
12.50 – 14.00	LUNCH BREAK				
14.00- 14.50	Lecture Reproductive Ethics I E. Vatanoğlu	Lecture Congenital Infections and Sexually Transmitted Diseases, Genital Infections I Microbiology Lecturer	Independent Learning	OSCE-I EXAM	OSCE-I EXAM
15.00- 15.50	Lecture Reproductive Ethics II E. Vatanoğlu	Lecture Congenital Infections and Sexually Transmitted Diseases, Genital Infections II Microbiology Lecturer			
16.00- 16.50	Lecture Reproductive Ethics III E. Vatanoğlu	Lecture Congenital Infections and Sexually Transmitted Diseases, Genital Infections III M. Sönmezoğlu			
17.00-17.50	Lecture Reproductive Ethics IV E. Vatanoğlu	Independent Learning			

**COMMITTEE V - ENDOCRINOLOGY and REPRODUCTIVE SYSTEMS**

**WEEK V / 27 Feb-3 Mar 2017**

WEEK V / 27-Feb-3-Mar-2017					
	Monday 27-Feb-2017	Tuesday 28-Feb-2017	Wednesday 1-Mar-2017	Thursday 2-Mar-2017	Friday 3-Mar-2017
09.00- 09.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning
10.00- 10.50					COMMITTEE EXAM
11.00- 11.50					
12.00- 12.50					
12.50 – 14.00	LUNCH BREAK				
14.00- 14.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Program Evaluation Session Committee V Coordination Committee Members
15.00- 15.50					Independent Learning
16.00- 16.50					
17.00-17.50					

## COMMITTEE VI - URINARY SYSTEM

### DISTRIBUTION of LECTURE HOURS

March 6, 2017 – March 31, 2017

COMMITTEE DURATION: 4 WEEKS

MED 302	INTRODUCTION TO CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	UROLOGY	URO	7				7
	NEPHROLOGY	NE	11				11
	PATHOLOGY	PT	12		1x2=2 (2 Groups)		14
	PATHOPHYSIOLOGY	PP	2				2
	PHARMACOLOGY	PC	3				3
	PEDIATRICS	PED	3				3
	PUBLIC HEALTH	PH	2				2
	RADIOLOGY	RAD	1				1
	MEDICAL GENETICS	MG	1				1
	INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	IDCM	2		1x2=2 (2 Groups)		4
	PEDIATRIC SURGERY	PED-S	1				1
	GENERAL SURGERY	GS	1				1
	BIOSTATISTICS	BS	4				4
	FAMILY MEDICINE	FM	1				1
	INTERDISCIPLINARY	MCDP				2	2
MED 303	INTRODUCTION TO CLINICAL PRACTICE III	ICP III			1x2=2 (4 Groups) 1x3=3 (4 Groups)		5
TOTAL			51		9	2	62

### Coordination Committee

HEAD	Gülçin Kantarcı, MD, Prof.
SECRETARY	Zehra Eren, MD, Assoc. Prof.
MEMBER	Işın Doğan Ekici, MD, Prof.
MEMBER	Ahmet Tunç Özdemir, MD, Assoc. Prof.



**COMMITTEE VI - URINARY SYSTEM**  
**LECTURERS**

<b>MED 302 INTRODUCTION TO CLINICAL SCIENCES</b>	
<b>DISCIPLINE</b>	<b>LECTURERS</b>
PATHOLOGY	Işın Doğan Ekici, MD, Prof. Ahmet Sedat Çöloğlu, DMD, Prof
NEPHROLOGY	Gülçin Kantarcı, MD, Prof. Zehra Eren, MD, Assoc. Prof.
UROLOGY	Faruk Yencilek, MD, Prof. Ahmet Tunç Özdemir, MD, Assoc. Prof. Hasbey Hakan Koyuncu, MD, Asst. Prof.
BIOSTATISTICS	Çiğdem Kaspar, PhD, Asst. Prof.
PEDIATRICS	Filiz Bakar, MD, Prof. E. Romano, MD
PHARMACOLOGY	Ece Genç, PhD, Prof.
PUBLIC HEALTH	Hale Arık Taşyikan, MD, Asst. Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, Assoc. Prof.
INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	Meral Sönmezoğlu, MD, Assoc. Prof. İbrahim Çağatay Acuner, MD, Assoc. Prof.
RADIOLOGY	Ayşegül Sarsılmaz, MD, Asst. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Asst. Prof.
PEDIATRIC SURGERY	Selami Sözübir, MD, Prof.
GENERAL SURGERY	Onur Yaprak, MD, Assoc. Prof. Altan Alim, MD
FAMILY MEDICINE	Hülya Akan, MD, Assoc. Prof.

<b>MED 303 INTRODUCTION TO CLINICAL PRACTICE III</b>	
<b>DISCIPLINE</b>	<b>LECTURERS</b>
CLINICAL SKILLS LAB	Filiz Bakar, MD, Prof Güldal İzbirak, MD, Assoc. Prof. Suat Biçer, MD, Assoc. Prof. Ayşe Arzu Akalın, MD, Asst. Prof. Mustafa Berber, MD, Asst., Prof

## COMMITTEE VI - URINARY SYSTEM

### AIMS and LEARNING OBJECTIVES

#### AIMS

##### In evidence based manner,

1. **to remind** knowledge on anatomy, histology and physiology of urinary system,
2. **to convey** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,
3. **to convey** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,
4. **to convey** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to urinary system,
5. **to convey** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system
6. **to convey** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to urinary system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, **at the** level of primary health care service,
7. **to convey** knowledge on pharmacology of drugs that are effective on urinary system or on clinical conditions involving urinary system,
8. **to convey** knowledge on genetics of urinary system,
9. **to convey** knowledge on phytotherapeutic agent that are effective on urinary system or on clinical conditions involving urinary system,
10. **to convey** knowledge on use of biostatistical software and presentation of results,
11. **to convey** knowledge on legal regulations and ethical principles related to reproductive care,
12. **to equip with** basic and advanced clinical skills (*gynecological examination-C6, "Pap-smear" collection-C6, intrauterine device placement-C6, breast examination-C6, physical examination in neonate, infant and prepubertal/pubertal child-C6*) required at primary health care service level.

#### LEARNING OBJECTIVES

##### At the end of this committee, student should be able to:

1. **recall** anatomy, histology and physiology of urinary system,
2. **explain** etiopathogenesis of clinical conditions (renal hemodynamics, acid-base equilibrium, renal clinical conditions, urinary system stones, urinary system infections) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,
3. **explain** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
4. **explain** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to urinary system,
5. **describe** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,

6. at multi-system level and/or related to urinary system,
  - for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
  - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
  - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

**explain** in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

  - health care processes, clinical decision making process, clinical decisions and clinical practices which are required for management at primary health care service level:
  - 6.1. practice of history taking and physical examination (neonatal, prepubertal/pubertal-C6)
  - 6.2. evaluation of emergency case (urological emergencies-C6)
  - 6.3. approach to healthy individual or patient (urethral-vaginal-cervical discharge/swab specimen-C6, fecal specimen collection-C6)
  - 6.4. laboratory tests/examinations (urethral-vaginal-cervical discharge culture-C6, fecal culture-C6)
  - 6.5. imaging tests/examinations (uroradiology-C6, renal scintigraphy (GFR, ERPF, Renogram)-C6)
  - 6.6. point of care testing
  - 6.7. making preliminary diagnosis or definitive diagnosis decision
  - 6.8. making non-intervention or intervention decision
  - 6.9. practicing non-intervention or intervention
  - 6.10. referral/transport of healthy individual or patient
7. **explain** pharmacology of drugs that are effective on urinary system or on clinical conditions involving urinary system,
8. **explain** pharmacology of androgens and anabolic steroids, and drugs that affect bone mineral homeostasis,
9. **explain** genetics of urinary system,
10. **explain** mechanisms of action for action for phytotherapeutic agents that are effective on urinary system or in clinical conditions related to urinary system,
11. **define** use of biostatistical software and presentation of results,
12. **perform** basic clinical skills, practiced on phantom models, and advanced clinical skills, practiced on simulated/standardized patients (gynecological examination-C6, "Pap-smear" collection-C6, intrauterine device placement-C6, breast examination-C6, physical examination in neonate, infant and prepubertal/pubertal child-C6), required at primary health care service.

## COMMITTEE VI - URINARY SYSTEM

### COMMITTEE ASSESSMENT MATRIX

PHASE III						
COURSE: MD 320 INTRODUCTION TO CLINICAL SCIENCES						
COURSE COMPONENT: COMMITTEE VI - URINARY SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (MCQ)			
			CE	FE	IE	Total
1.0., 2.0., 5.0., 6.4.	PT	I D. Ekici	20	4	4	28
		A.S. Çöloğlu				
1.0.-6.0.	NE	G. Kantarcı	19	3	3	25
1.0.-6.0.		Z. Eren				
1.0.-6.0.	URO	F. Yencilek	12	2	2	16
1.0.-6.0.		H . Koyuncu				
1.0.-6.0.		A.T.Özdemir				
11.0.	BS	Ç. Kaspar	7	1	1	9
1.0.-6.0.	PED	F. Bakar	5	1	1	7
		M. Berber				
7.0., 8.0.	PC	E. Genç	5	1	1	7
3.0., 4.0.	PH	H. A. Taşyikan	4	1	1	6
2.0., 5.0.	PP	M. Kaçar	4	1	1	6
2.0.-6.0.	IDCM	M. Sönmezoğlu	4	1	1	6
2.0.-5.0., 6.4.		İ.Ç.Acuner				
6.5.	RAD	A.Sarsılmaz	2	0	0	2
9.0.	MG	A.Ç. Kuşkuçcu	2	0	0	2
1.0.-6.0.	PED-S	S. Sözübir	2	0	0	2
1.0.-6.0.	GS	O.Yaprak/A.Alım	2	1	1	4
6.3.	FM	H. Akan	2	0	0	2
TOTAL			90	16	16	122
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0.-6.0.	URO	A.T.Özdemir	1	-	-	1
1.0.-6.0.	NE	G. Kantarcı	2	-	-	2
1.0., 2.0., 5.0., 6.4.	PT	I D. Ekici	2			2
TOTAL			5	-	-	5

**CS\* = 90 pts (MCQ) + 10 pts (EMQ) = 100 points**

\*Each MCQ has a value of 1 points; each EMQ question has a value of 2 points.

**MCQ:** Multiple Choice Question

**EMQ:** Extending Matching Question

**CE:** Committee Exam

**CS:** Committee Score

**FE:** Final Exam

**ICE:** Incomplete Exam

**pts:** Points

**\*\*16** out of 200 FE and ICE MCQs will be from Committee VI (Each question is of worth **0.5** pts).

# COMMITTEE VI - URINARY SYSTEM

WEEK I / 6-10 Mar 2017

	Monday 6-Mar-2017	Tuesday 7-Mar-2017	Wednesday 8-Mar-2017	Thursday 9-Mar-2017				Friday 10-Mar-2017
09.00- 09.50	<b>Introductory Session</b> Introduction to Committee VI Head of Committee	<b>Lecture</b> Urolithiasis-I F. Yencilek	<b>Lecture</b> Pathology of Tubulointerstitial Disease I I. D. Ekici	<b>ICP-CSL</b> (Clinical breast examination) A.Akalın/ G.Izbırak		<b>ICP-CSL</b> (Physical examination of the newborn and child patient) F. Bakar/S. Biçer /M.Berber		<b>Lecture</b> Physical examination of newborn patient M. Berber
10.00- 10.50	<b>Lecture</b> Pathophysiology of Urinary System Diseases I M. Kaçar	<b>Lecture</b> Urolithiasis-II F. Yencilek	<b>Lecture</b> Pathology of Tubulointerstitial Disease II I. D. Ekici	Group A	Group B IL	Group C1 YH	Group C2 & D IL	<b>Lecture</b> Physical examination of child patient M. Berber
11.00- 11.50	<b>Lecture</b> Pathophysiology of Urinary System Diseases II M. Kaçar	<b>Lecture</b> Pathology of Male Genital System I I. D. Ekici	<b>Lecture</b> Upper and Lower Urinary Tract Infections I Microbiology Lecturer			Group C1 IL		<b>Lecture</b> Nephritic and Nephrotic Syndrome F. Bakar E. Romano
12.00- 12.50	<b>Lecture</b> Renovascular Pathology A. S. Çöloğlu	<b>Lecture</b> Pathology of Male Genital System II I. D. Ekici	<b>Lecture</b> Upper and Lower Urinary Tract Infections II M. Sönmezoğlu	<b>Lecture</b> Androgens & Anabolic Steroids E. Genç				<b>Lecture</b> Agents Effecting Bone Mineral Homeostasis I E. Genç
12.50-14.00	LUNCH BREAK							
14.00- 14.50	<b>Lecture</b> Renal Cystic Disease A. S. Çöloğlu	<b>Lecture</b> The Presentation of the Results I Ç. Kaspar	<b>Lecture</b> Clinical study of renal functions and urinary findings Z. Eren	<b>Lecture</b> Pathology of Glomerular Diseases I I. D. Ekici				<b>Lecture</b> Agents Effecting Bone Mineral Homeostasis II E. Genç
15.00- 15.50	<b>Lecture</b> Epidemiology, Prevention and Control of Sexually Transmitted Diseases I H.A. Taşyikan	<b>Lecture</b> The Presentation of the Results II Ç. Kaspar	<b>Lecture</b> Tubulointerstitial Diseases Z. Eren	<b>Lecture</b> Pathology of Glomerular Diseases II I. D. Ekici				<b>Lecture</b> Nephritic Syndrome Z. Eren
16.00- 16.50	<b>Lecture</b> Epidemiology, Prevention and Control of Sexually Transmitted Diseases II H.A. Taşyikan	<b>Lecture</b> Imaging of Urinary System A.Sarsılmaz	<b>Lecture</b> Approach to the Urinary Tract Infections H. Akan	<b>Lecture</b> Pathology of Glomerular Diseases III I. D. Ekici				<b>Lecture</b> Nephrotic Syndrome Z.Eren
17.00-17.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning				Independent Learning

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

**COMMITTEE VI - URINARY SYSTEM WEEK II / 13-17 Mar 2017**

	Monday 13-Mar-2017	Tuesday 14-Mar-2017	Wednesday 15-Mar-2017	Thursday 16-Mar-2017	Friday 17-Mar-2017
09.00- 09.50	<b>Lecture</b> Fluid, Electrolyte I G.Kantarci	PYHSICIANS'DAY	<b>Lecture</b> Acid/Base Balance I Z. Eren	<b>Lecture</b> Acute Kidney Injury G.Kantarci	<b>Microbiology Laboratory</b> (Diagnostic tests for urinary specimens) I.Ç.Acuner
10.00- 10.50	<b>Lecture</b> Fluid, Electrolyte II G.Kantarci		<b>Lecture</b> Acid/Base Balance II Z. Eren	<b>ICP-CSL</b> (Clinical breast examination) A.Akalın/G.Izbrak	
11.00- 11.50	<b>Lecture</b> Urologic Oncology I A. T. Özdemir		<b>Lecture</b> Congenital Anomalies of The Urinary System S. Sözübir	Group A IL	<b>Microbiology Laboratory</b> (Diagnostic tests for urinary specimens) I.Ç.Acuner
12.00- 12.50	<b>Lecture</b> Urologic Oncology II A. T. Özdemir		<b>Lecture</b> Polygenic Disorders A. Ç. Kuşkucu	Group B	Group A & B IL
				Group C & D IL	Group C IL
12.50 -14.00	<b>LUNCH BREAK</b>				
14.00- 14.50	<b>Lecture</b> Pathology of Bladder I. D. Ekici	PYHSICIANS'DAY	<b>ICP-CSL</b> (Physical examination of the newborn and child patient) F. Bakar/S. Biçer /M.Berber	<b>ICP-CSL</b> (Clinical breast examination) A.Akalın/ G.Izbrak	<b>ICP-CSL</b> (Physical examination of the newborn and child patient) F. Bakar/S. Biçer /M.Berber
15.00- 15.50	<b>Lecture</b> Pathology of Urinary System Tumors I. D. Ekici		Group A, B2 IL	Group B1 YH	<b>Lecture</b> Chronic Kidney Disease G. Kantarci
16.00- 16.50	<b>Lecture</b> Congenital Anomalies of Urinary System I. D. Ekici				<b>Lecture</b> The Kidney Systemic Disease and Inherited Disorders G. Kantarci
17.00-17.50	<b>Independent Learning</b>		Group C IL	Group D	Group A, B, C & D2 IL
			Group B1 IL	Group 1 IL	Group D1 YH
			<b>Independent Learning</b>		<b>Independent Learning</b>
			<b>Independent Learning</b>		<b>Independent Learning</b>

**COMMITTEE VI - URINARY SYSTEM WEEK III / 20-24 Mar 2017**

	Monday 20-Mar-2017				Tuesday 21-Mar-2017			Wednesday 22-Mar-2017				Thursday 23-Mar-2017				Friday 24-Mar-2017	
09.00- 09.50	Lecture Benign Prostatic Hyperplasia-I H. Koyuncu				Pathology Laboratory (Urinary System) I. D. Ekici/F. Özkan	Group A IL	Group B	Lecture Using Statistical Programs I Ç. Kaspar				ICP-CSL (Physical examination of the newborn and child patient) F. Bakar/S. Biçer / M.Berber				Independent Learning	
10.00- 10.50	Lecture Benign Prostatic Hyperplasia-II H. Koyuncu							Lecture Using Statistical Programs II Ç. Kaspar				A IL	B2 YH	C IL	D IL		
11.00- 11.50	Lecture Urologic Emergencies H. Koyuncu					Group A	Group B IL	Multidisciplinary Case Discussion Panel		ICP-CSL (Physical examination of the newborn and child patient) F. Bakar/S. Biçer/M.Berber							
12.00- 12.50	Lecture Transplantation of Kidney O. Yaprak/ A. Alim				Independent Learning			Multidisciplinary Case Discussion Panel		A2 YH	B IL	C IL	D IL				
12.50- 14.00	LUNCH BREAK																
14.00- 14.50	ICP-CSL (Physical examination of the newborn and child patient) F. Bakar/S.Biçer/ M.Berber		ICP-CSL (Clinical breast examination) A.Akalın/ G.İzbırak		Pathology Laboratory (Urinary System) I. D. Ekici/F. Özkan	Group A	Group B IL	ICP-CSL (Physical examination of the newborn and child patient) F. Bakar/S. Biçer/M.Berber				Independent Learning			Independent Learning		
15.00- 15.50	Group A1 YH	Group A2 & B IL	Group C	Group D IL				A IL	B IL	C IL	D2 YH	Independent Learning			Independent Learning		
16.00- 16.50	Group A1 IL					Group A IL	Group B	ICP-CSL (Physical examination of the newborn and child patient) F.Bakar/S.Biçer/M.Berber				Independent Learning			Independent Learning		
17.00-17.50	Independent Learning					Independent Learning			A IL	B IL	C2 YH	D IL	Independent Learning			Independent Learning	

**COMMITTEE VI - URINARY SYSTEM WEEK IV / 27-31 Mar 2017**

	Monday 27-Mar-2017	Tuesday 28-Mar-2017	Wednesday 29-Mar-2017	Thursday 30-Mar-2017	Friday 31-Mar-2017
09.00- 09.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning
10.00- 10.50					COMMITTEE EXAM
11.00- 11.50					
12.00- 12.50					
12.50 – 14.00	LUNCH BREAK				
14.00- 14.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Program Evaluation Session Committee VI Coordination Committee Members
15.00- 15.50					Independent Learning
16.00- 16.50					
17.00-17.50					



## COMMITTEE VII - NERVOUS SYSTEM AND PSYCHIATRY

### DISTRIBUTION of LECTURE HOURS

Nisan 3, 2017 – May 12, 2017

COMMITTEE DURATION: 6 WEEKS

MED 302	INTRODUCTION TO CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
<b>DISCIPLINE</b>	NEUROLOGY	NR	13	1x4=4 (2 Groups)			17
	PSYCHIATRY	PCH	13				13
	CHILD PSYCHIATRY	C-PCH	3				3
	NEUROSURGERY	NRS	16	1x2=2 (2 Groups)			18
	PATHOLOGY	PT	11		1x2=2 (2 Groups)		13
	PATHOPHYSIOLOGY	PP	2				2
	PHARMACOLOGY	PC	17				17
	PEDIATRICS	PED	4				4
	PUBLIC HEALTH	PH	4				4
	FAMILY MEDICINE	FM	4				4
	RADIOLOGY	RAD	1				1
	MEDICAL GENETICS	MG	3				3
	INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	IDCM	2				2
	OPHTHALMOLOGY	OPT	3				3
	BIOSTATISTICS	BS	4				4
	SCIENTIFIC PROJECTS- III	SP	1				1
	INTERDISCIPLINARY	MCDP				2	2
MED 303	INTRODUCTION TO CLINICAL PRACTICE III	ICP III			2x3=6 (4 Groups)		6
<b>TOTAL</b>			<b>101</b>	<b>6</b>	<b>8</b>	<b>2</b>	<b>117</b>

### Coordination Committee

<b>HEAD</b>	Berrin Aktekin, MD, Prof.
<b>SECRETARY</b>	Burcu Örmeci, MD, Assoc. Prof
<b>MEMBER</b>	Vildan Öztürk, MD, Asst. Prof.
<b>MEMBER</b>	Oğuzhan Zahmacıoğlu, MD, Asst. Prof

**COMMITTEE VII - NERVOUS SYSTEM and PSYCHIATRY  
LECTURERS**

<b>MED 302 INTRODUCTION TO CLINICAL SCIENCES</b>	
<b>DISCIPLINE</b>	<b>LECTURERS</b>
<b>NEUROLOGY</b>	Berrin Aktekin, MD, Prof. Burcu Örmeci, MD, Assoc. Prof.
<b>PSYCHIATRY</b>	N. Berfu Akbaş, MD, Asst. Prof.
<b>CHILD PSYCHIATRY</b>	Oğuzhan Zahmacıoğlu, MD, Asst. Prof
<b>NEUROSURGERY</b>	M.Gazi Yaşargil, MD, Prof. Uğur Türe, MD, Prof. Başar Atalay, MD, Prof.
<b>PATHOLOGY</b>	Ferda Özkan, MD, Prof Işın Doğan Ekici, MD, Prof. Ahmet Sedat Çöloğlu, DMD, Prof.
<b>PATHOPHYSIOLOGY</b>	Mehtap Kaçar, MD, Assoc. Prof.
<b>PHARMACOLOGY</b>	Ece Genç, PhD, Prof. Ferda Kaleağasıoğlu, MD, Prof.
<b>PEDIATRICS</b>	Mustafa Berber, MD, Asst. Prof.
<b>PUBLIC HEALTH</b>	Recep Erol Sezer, MD, Prof
<b>FAMILY MEDICINE</b>	Güldal İzbirak, MD, Assoc. Prof. Hülya Akan, MD, Assoc. Prof. Ayşe Arzu Akalın, MD, Asst. Prof
<b>RADIOLOGY</b>	Ayşegül Sarsılmaz, MD, Asst.Prof.
<b>MEDICAL GENETICS</b>	Ayşegül Çınar Kuşkucu, MD, Asst. Prof.
<b>INFECTIOUS DISEASES &amp; CLINICAL MICROBIOLOGY</b>	Meral Sönmezoğlu, MD, Prof. İbrahim Çağatay Acuner, MD, Assoc. Prof.
<b>OPHTHALMOLOGY</b>	Vildan Öztürk, MD, Asst. Prof.
<b>BIostatISTICS</b>	Çiğdem Kaspar, PhD, Asst. Prof.
<b>SCIENTIFIC PROJECTS- III</b>	Gülderen Yanıkkaya Demirel, MD, Assoc. Prof.

<b>MED 303 INTRODUCTION TO CLINICAL PRACTICE III</b>	
<b>DISCIPLINE</b>	<b>LECTURERS</b>
<b>CLINICAL SKILLS LAB</b>	Başar Atalay, MD, Prof. Berrin Aktekin, MD, Prof. Güldal İzbirak, MD, Assoc. Prof. Burcu Örmeci, MD, Assoc. Prof. Naz Berfu Akbaş, MD, Asst. Prof Oğuzhan Zahmacıoğlu, MD Asst. Prof Serdar Özdemir, MD, Asst. Prof.

## COMMITTEE VII - NERVOUS SYSTEM and PSYCHIATRY

### AIMS and LEARNING OBJECTIVES

#### AIMS

##### In evidence based manner,

1. **to remind** knowledge on anatomy, histology and physiology of nervous system,
2. **to convey** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
3. **to convey** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
4. **to convey** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to nervous system and psychiatry,
5. **to convey** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
6. **to convey** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to nervous system and psychiatry, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. **to convey** necessary knowledge on drugs that are effective on nervous system or on clinical conditions related to nervous system and psychiatry ,
8. **to convey** necessary knowledge on professional standards, organizational ethics, and ethics of psychiatry,
9. **to convey** necessary knowledge on common problems in medical research,
10. **to convey** knowledge on phytotherapeutic agents,
11. **to equip with** basic and advanced clinical skills (*suturing and tying-C7, neuropsychiatric evaluation-C7*) required at primary health care service level.

#### LEARNING OBJECTIVES

##### ***At the end of this committee, student should be able to:***

- 1.0. **recall** anatomy, histology and physiology of nervous system,
- 2.0. **define** biochemical and psychodynamical basis of behavior,
- 3.0. **grade** physical, psychosocial and cognitive development of child,
- 4.0. **explain** etiopathogenesis of clinical conditions (central and peripheral nervous system disorders, epilepsy, organic brain syndromes, CNS tumors, psychiatric disorders/diseases) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
- 5.0. **explain** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
- 6.0. **explain** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to nervous system and psychiatry,
- 7.0. **describe** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for

- individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
- 8.0. at multi-system level and/or related to cardiovascular and respiratory systems system,
    - for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
    - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
    - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
  - explain** in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,
    - health care processes, clinical decision making process, clinical decisions and clinical practices which are required for management at primary health care service level:
  - 8.1. practice of history taking and physical examination (neurological/neuropsychiatric-C7)
  - 8.2. evaluation of emergency case (neurological emergencies-C7)
  - 8.3. approach to healthy individual or patient (neurological symptoms-C7, headache-C7, depression-C7, dementia-C7)
  - 8.4. laboratory tests/examinations
  - 8.5. imaging tests/examinations (conventional neuroradiological examinations-C7, spinal neuroradiology-C7, cranial CT-C7, cranial MRI-C7, brain perfusion scintigraphy-C7, brain PET-C7)
  - 8.6. point of care testing
  - 8.7. making preliminary diagnosis or definitive diagnosis decision
  - 8.8. making non-intervention or intervention decision
  - 8.9. practicing non-intervention or intervention
  - 8.10. referral/transport of healthy individual or patient
  - 9.0. **explain** pharmacology of drugs (parkinsonism and other movement disorders, antiepileptics, CNS stimulants and hallucinogenic drugs, sedative/hypnotic drugs, opioid analgesics and antagonists, general/local anesthetics, antipsychotic drugs, bipolar disease and lithium, antidepressant drugs, alcohols, drug dependence and abuse) that are effective on nervous system or on clinical conditions related to nervous system and psychiatry,
  - 10.0. **describe** professional standards, organizational ethics, and ethics in psychiatry,
  - 11.0. **describe** phytotherapeutic agents ("HMPs, Nutraceuticals"),
  - 12.0. **list** common problems in medical research,
  - 13.0. **perform** basic clinical skills, practiced on phantom models (suturing and tying-C7), and advanced clinical skills, practiced on simulated/standardized patients (neuropsychiatric evaluation-C7), required at primary health care service.

**COMMITTEE VII - NERVOUS SYSTEM and PSYCHIATRY**  
**COMMITTEE ASSESSMENT MATRIX**

PHASE III						
COURSE: MD 320 INTRODUCTION TO CLINICAL SCIENCES						
COURSE COMPONENT: COMMITTEE VII - NERVOUS SYSTEM and PSYCHIATRY						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/ INSTRUCTOR	NUMBER OF QUESTIONS (MCQ)			
			CE	FE	IE	Total
9.0.	PC	E. Genç	15	5	5	25
9.0.		F.Kaleağasıoğlu				
1.0., 4.0.-8.0.	NRS	M.G.Yaşargil	14	5	5	24
1.0., 4.0.-8.0.		B. Atalay				
1.0., 4.0.-8.0.		U. Türe				
1.0., 4.0.-8.0.	NR	B. Aktekin	11	4	4	19
1.0., 4.0.-8.0.		B. Örmeci				
1.0., 2.0., 4.0.-8.0., 10.0.	PCH	B.Akbas	11	4	4	19
1.0., 4.0., 7.0.	PT	F. Özkan	9	3	3	15
1.0., 4.0., 7.0.		I.D. Ekici				
1.0., 3.0.-8.0.	PED	M. Berber	4	1	1	6
5.0., 6.0.	PH	R.E. Sezer	4	1	1	6
8.3.	FM	H. Akan	4	1	1	6
8.3.		G. İzbırak				
8.3.		A.Akalın				
12.0.	BS	Ç. Kaspar	4	1	1	6
2.0.	MG	A.Ç. Kuşkucu	3	1	1	5
2.0.-8.0., 10.0.	C-PCH	O. Zahmacioglu	3	1	1	5
1.0., 4.0.-8.0.	OPT	V. Öztürk	3	1	1	5
4.0., 7.0.	PP	M. Kaçar	2	1	1	4
4.0.-7.0, 8.4.	IDCM	M. Sönmezoğlu	2	1	1	4
4.0.-8.0.		İ.Ç.Acuner				
8.5.	RAD	A.Sarsılmaz	1	1	1	3
<b>TOTAL</b>			<b>90</b>	<b>31</b>	<b>31</b>	<b>152</b>
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0., 4.0.-8.0.	NR	B. Örmeci	1	-	-	1
1.0., 2.0., 4.0.-8.0., 10.0.	PCH	B. Akbaş	1	-	-	1
	PC	E. Genç	1			1
1.0., 4.0.-8.0.	NRS	B. Atalay	2			2
<b>TOTAL</b>			<b>5</b>	<b>-</b>	<b>-</b>	<b>5</b>

**CS\* = 90 pts (MCQ) + 10 pts (EMQ) = 100 points**

\*Each MCQ has a value of 1 points; each EMQ question has a value of 2 points.

**MCQ:** Multiple Choice Question

**EMQ:** Extending Matching Question

**CE:** Committee Exam

**CS:** Committee Score

**FE:** Final Exam

**ICE:** Incomplete Exam

**pts:** Points

**\*\*31** out of 200 FE and ICE MCQs will be from Committee VII (Each question is of worth 0.5 points).

**COMMITTEE VII - NERVOUS SYSTEM AND PYSCHIATRY**  
**WEEK I / 3-7 Apr 2017**

	Monday 3-Apr-2017	Tuesday 4-Apr-2017	Wednesday 5-Apr-2017	Thursday 6-Apr-2017	Friday 7-Apr-2017
09.00- 09.50	Introduction to Commitee VII Head of Committee	Lecture Pathology of Myelin & Neuronal Storage Diseases I I. D. Ekici	Lecture Neurodegenerative Disorders I F. Özkan	Independent Learning	Lecture Clinical Presentation, Anatomic Concepts and Diagnosis in a Neurosurgical Patient B. Atalay
10.00- 10.50	Lecture Signs and Symptoms in Neurology B. Aktekin	Lecture Pathology of Myelin & Neuronal Storage Diseases II I. D. Ekici	Lecture Neurodegenerative Disorders II F. Özkan		Lecture Pediatric Neurosurgery B. Atalay
11.00- 11.50	Lecture Cranial Nerves I B. Aktekin	Lecture Developmental Disorders of CNS I. D. Ekici	Lecture Degenerative Diseases of the Spine and the Spinal Cord I B. Atalay		Lecture Hydrocephalus B. Atalay
12.00- 12.50	Lecture Cranial Nerves II B. Aktekin	Lecture Introduction to Central Nervous System Pharmacology E. Genç	Lecture Degenerative Diseases of the Spine and the Spinal Cord II B. Atalay		Lecture Pharmacological Approach to Parkinsonism & Other Movement Disorders I E. Genç
12.50 – 14.00	LUNCH BREAK				
14.00- 14.50	Lecture Pathophysiology of Nervous System Diseases I M. Kaçar	Lecture Demyelinating Disorders I B. Örmeci	Lecture Neurodegenerative Disorders M. Berber	Lecture Dementia B. Örmeci	Lecture Pharmacological Approach to Parkinsonism & Other Movement Disorders II E. Genç
15.00- 15.50	Lecture Pathophysiology of Nervous System Diseases I M. Kaçar	Lecture Demyelinating Disorders II B. Örmeci	Lecture Cerebral Lobes and their Disorders B. Örmeci	Lecture Extrapyramidal System Disorders B. Örmeci	Lecture Public Health and Aging I R. E. Sezer
16.00- 16.50	Lecture Headache in Primary Care A. Akalın	Independent Learning	Lecture Cerebrovascular Disease B. Örmeci	Lecture Conventional Neuroradiological Examinations A. Sarsılmaz	Lecture Public Health and Aging II R. E. Sezer
17.00-17.50	Independent Learning		Independent Learning	Independent Learning	Independent Learning

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

**COMMITTEE VII - NERVOUS SYSTEM AND PYSCHIATRY**  
**WEEK II / 10-14 Apr 2017**

	Monday 10-Apr-2017	Tuesday 11-Apr -2017	Wednesday 12-Apr -2017				Thursday 13-Apr -2017				Friday 14-Apr-2017
09.00- 09.50	Lecture Peripheral Nerve Disorders B. Aktekin	Lecture Headache in Neurologic Patient B. Örmeci	Neurology Clinical Training B. Aktekin				Neurology Clinical Training B. Örmeci				Lecture Cerebral Malformations M. Berber
10.00- 10.50	Lecture Epilepsy B. Aktekin	Lecture Neurological Emergencies B. Örmeci	Group A	Group B	Group C IL	Group D IL	Group A IL	Group B IL	Group C	Group D	Lecture Mental and Motor Development M. Berber
11.00- 11.50	Lecture Cranial Trauma & Intracranial Hemorrhage I A.S. Çöloğlu	Lecture Antimigraine Drugs F. Kaleağasioğlu									Lecture Infectious Disease of the Nervous System M. Berber
12.00- 12.50	Lecture Cranial Trauma & Intracranial Hemorrhage II A.S. Çöloğlu	Independent Learning									Lecture Acute and Chronic Meningitis, Encephalitis I Microbiology Lecturer
12.50 – 14.00	LUNCH BREAK										
14.00- 14.50	Lecture Neurosurgical Infections B. Atalay	Lecture Surgical Neuroanatomy U. Türe	Lecture Antiepileptics E. Genç				Lecture Paralytic Strabismus and Nistagmus V. Öztürk				Lecture Acute and Chronic Meningitis, Encephalitis II M. Sönmezoğlu
15.00- 15.50	Lecture Spinal Cord Compression and Spinal Tumors B. Atalay	Lecture Cerebrovascular Diseases in Neurosurgery I U. Türe	Lecture Some Common Problems in Medical Research I Ç. Kaspar				Lecture Infectious Diseases of CNS I A.S. Çöloğlu				Lecture Diseases of Optic Nerves and Visual Fields V. Öztürk
16.00- 16.50	Lecture Peripheral Nerve Compression Syndromes B. Atalay	Lecture Cerebrovascular Diseases in Neurosurgery II U. Türe	Lecture Some Common Problems in Medical Research II Ç. Kaspar				Lecture Infectious Diseases of CNS II A.S. Çöloğlu				Lecture Pupilla V. Öztürk
17.00-17.50	Independent Learning	Independent Learning	Independent Learning				Independent Learning				Independent Learning

**COMMITTEE VII - NERVOUS SYSTEM AND PYSCHIATRY**  
**WEEK III / 17-21 Apr 2017**

	Monday 17-Apr-2017	Tuesday 18-Apr -2017	Wednesday 19-Apr -2017				Thursday 20-Apr -2017		Friday 21-Apr-2017				
09.00- 09.50	<b>Lecture</b> Tumors of CNS I <b>I. D. Ekici</b>	<b>Lecture</b> Scientific Projects- III: Writing Project <b>G. Y. Demirel</b>	<b>Neurosurgery Clinical Trainig</b> <b>B. Atalay</b>				<b>Pathology Laboratory</b> (Nervous System) <b>I. D. Ekici/F. Özkan</b>	<b>Group A IL</b>	<b>Group B</b>	<b>Neurosurgery Clinical Trainig</b> <b>B. Atalay</b>			
10.00- 10.50	<b>Lecture</b> Tumors of CNS II <b>I. D. Ekici</b>	<b>Lecture</b> Functional Neurosurgery <b>B. Atalay</b>	<b>Group A</b>	<b>Group B</b>	<b>Group C IL</b>	<b>Group D IL</b>				<b>Group A IL</b>	<b>Group B IL</b>	<b>Group C</b>	<b>Group D</b>
11.00- 11.50	<b>Lecture</b> Intracranial tumors II <b>M. Gazi Yaşargil</b>	<b>Lecture</b> Spinal Trauma in Neurosurgery <b>B. Atalay</b>	<b>Lecture</b> Power analysis and sample size calculation I <b>Ç. Kaspar</b>					<b>Group A</b>	<b>Group B IL</b>	<b>Lecture</b> Organic Brain Syndromes <b>B. Akbaş</b>			
12.00- 12.50	<b>Lecture</b> Intracranial tumors I <b>M. Gazi Yaşargil</b>	<b>Lecture</b> Cranial Trauma in Neurosurgery <b>B. Atalay</b>	<b>Lecture</b> Power analysis and sample size calculation II <b>Ç. Kaspar</b>							<b>Lecture</b> Drug Addiction & Alcoholism <b>B. Akbaş</b>			
12.50 – 14.00	<b>LUNCH BREAK</b>												
14.00- 14.50	<b>Lecture</b> Opioid Analgesics & Antagonists I <b>E. Genç</b>	<b>Lecture</b> Opioid Analgesics & Antagonists II <b>E. Genç</b>	<b>Lecture</b> Local Anesthetics <b>E. Genç</b>				<b>Lecture</b> Developmental Psychopathology: Risk and Protective Factors in Mental Development <b>Psychiatry Lecturer</b>		<b>Lecture</b> Drug Dependence & Abuse <b>E. Genç</b>				
15.00- 15.50	<b>Lecture</b> Culture, Health and Illness <b>R. E Sezer</b>	<b>Lecture</b> Introduction to Psychiatry <b>Psychiatry Lecturer</b>	<b>Lecture</b> General Anesthetics <b>E. Genç</b>				<b>Lecture</b> Neuroscience I <b>Psychiatry Lecturer</b>		<b>Lecture</b> The Alcohols <b>E. Genç</b>				
16.00- 16.50	<b>Lecture</b> Behavioral Determinants of Health and Disease <b>R. E. Sezer</b>	<b>Lecture</b> Signs and Symptoms in Psychiatry <b>Psychiatry Lecturer</b>	<b>Independent Learning Lecture</b> Genetic Aspects of Psychiatric Disorders <b>A. Ç. Kuşku</b>				<b>Lecture</b> Neuroscience II <b>Psychiatry Lecturer</b>		<b>Lecture</b> Approach to Smoking Patient in Primary Care <b>H. Akan</b>				
17.00-17.50	<b>Independent Learning</b>	<b>Independent Learning</b>	<b>Independent Learning</b>				<b>Independent Learning</b>		<b>Independent Learning</b>				



**COMMITTEE VII - NERVOUS SYSTEM AND PYSCHIATRY**  
**WEEK IV / 24-28 Apr 2017**

	Monday 24-Apr-2017	Tuesday 25-Apr -2017	Wednesday 26-Apr -2017	Thursday 27-Apr -2017				Friday 28-Apr-2017				
09.00- 09.50	Lecture Schizophrenia and Psychosis I Psychiatry Lecturer	Lecture Mood Disorders B. Akbaş	Lecture Introduction to Child and Adolescent Psychiatry Oğuzhan Zahmacioğlu	ICP-CSL (Neurological examination & psychiatric examination) N.B.Akbaş/O.Zahmacioğlu/B.Örmeci				Lecture Approach to the Patient with Dementia in Primary Care H. Akan				
10.00- 10.50	Lecture Schizophrenia and Psychosis II Psychiatry Lecturer	Lecture Anxiety Disorders I B. Akbaş	Lecture Common Childhood Psychiatric Problems Oğuzhan Zahmacioğlu	Group A IL	Group B	Group C IL	Group D IL	Lecture Depression in Primary Care G. İzbirak				
11.00- 11.50	Lecture Antipsychotic Drugs F. Kaleağasioğlu	Lecture Anxiety Disorders II B. Akbaş	Lecture Mental Development in Childhood and Adolescence Oğuzhan Zahmacioğlu					Lecture Sedative / Hypnotic Drugs I E. Genç				
12.00- 12.50	Lecture Bipolar Disease & Lithium F. Kaleağasioğlu	Lecture Antidepressant Drugs E. Genç	Lecture CNS stimulants and Hallusinogenic Drugs E. Genç	Independent Learning				Lecture Sedative / Hypnotic Drugs II E. Genç				
12.50 – 14.00	LUNCH BREAK											
14.00- 14.50	Pathology Laboratory (Nervous System) I. D. Ekici/F. Özkan	Group A IL	Group B	Lecture Genetic Etiology of Mental Retardation I A. Ç. Kuşkucu		ICP-CSL (Neurological examination & psychiatric examination) N.B.Akbaş/O.Zahmacioğlu/B.Örmeci		ICP-CSL (General Physical Examination) G. İzbirak/S.Özdemir		Multidisciplinary Case Discussion Panel		
15.00- 15.50				Lecture Genetic Etiology of Mental Retardation II A. Ç. Kuşkucu		Group A	Group B IL	Group C IL	Group D IL	Group A IL	Group B	Group C IL
16.00- 16.50		Group A	Group B IL	Lecture General Physical Exam G.İzbirak								
17.00-17.50				Independent Learning		Independent Learning		Independent Learning				

**COMMITTEE VII - NERVOUS SYSTEM AND PYSCHIATRY**  
**WEEK V / 1-5 May 2017**

	Monday 1-May-2017	Tuesday 2-May-2017				Wednesday 3-May-2017				Thursday 4-May-2017				Friday 5-May-2017	
09.00- 09.50	LABOUR'S DAY SPRING FEST	ICP-CSL (Neurological examination & psychiatric examination) N.B.Akbaş/ O.Zahmacioğlu/B.Örmeci/				ICP-CSL (Neurological examination & psychiatric examination) N.B.Akbaş/ O.Zahmacioğlu/B.Örmeci/				ICP-CSL (General Physical Examination) G. İzbırak/S.Özdemir				Independent Learning SPRING FEST	
10.00- 10.50		Group A IL	Group B IL	Group C	Group D IL	Group A IL	Group B IL	Group C IL	Group D	Group A	Group B IL	Group C IL	Group D IL		
11.00- 11.50															
12.00- 12.50											Independent Learning SPRING FEST				
12.50 – 14.00	LUNCH BREAK														
14.00- 14.50	LABOUR'S DAY SPRING FEST	ICP-CSL (General Physical Examination) G. İzbırak/S.Özdemir				ICP-CSL (General Physical Examination) G. İzbırak/S.Özdemir				Independent Learning SPRING FEST				Independent Learning SPRING FEST	
15.00- 15.50		Group A IL	Group B IL	Group C	Group D IL	Group A IL	Group B IL	Group C IL	Group D						
16.00- 16.50															
17.00-17.50		Independent Learning SPRING FEST				Independent Learning SPRING FEST									

**COMMITTEE VII - NERVOUS SYSTEM AND PYSCHIATRY**  
**WEEK VI / 8-12 May 2017**

	Monday 08-May-2017	Tuesday 09-May-2017	Wednesday 10-May-2017	Thursday 11-May-2017	Friday 12-May-2017
09.00- 09.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning
10.00- 10.50					COMMITTEE EXAM
11.00- 11.50					
12.00- 12.50					
12.50 – 14.00	LUNCH BREAK				
14.00- 14.50	Independent Learning	Independent Learning	3 <sup>rd</sup> Coordination Committee Meeting	Independent Learning	Program Evaluation Session Committee VII Coordination Committee Members
15.00- 15.50			Independent Learning		
16.00- 16.50					
17.00-17.50					

## COMMITTEE VIII - MUSCULOSKELETAL SYSTEM

### DISTRIBUTION of LECTURE HOURS

May 15, 2017 – June 9, 2017

COMMITTEE DURATION: 4 WEEKS

MED 302	INTRODUCTION TO CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	ORTHOPAEDICS & TRAUMATOLOGY	ORT	22				22
	PHYSICAL THERAPY & REHABILITATION	PTR	4				4
	RHEUMATOLOGY	RHE	8				8
	PATHOLOGY	PT	11		1x2=2 (4 Groups)		13
	PATHOPHYSIOLOGY	PP	2				2
	PHARMACOLOGY	PC	5				5
	PUBLIC HEALTH	PH	4				4
	FAMILY MEDICINE	FM	2				2
	MEDICAL GENETICS	MG	2				2
	RADIOLOGY	RAD	1				1
	BIOMEDICAL ETHICS & DEONTOLOGY	BED	2				2
	EMERGENCY MEDICINE	EM	1				1
	BIOSTATISTICS	BS	4				4
	INTERDISCIPLINARY	MCDP				2	2
MED 303	INTRODUCTION TO CLINICAL PRACTICE III	ICP III			1x3=3 (4 Groups)		3
TOTAL			68	0	5	2	75

### Coordination Committee

HEAD	Uğur Şaylı, MD, Prof.
SECRETARY	Müge Bıçakçıl, MD, Assoc. Prof
MEMBER	Melih Güven, MD, Assoc. Prof
MEMBER	Ece Aydoğ, MD, Prof.

**COMMITTEE VIII - MUSCULOSKELETAL SYSTEM**  
**LECTURERS**

<b>MED 302 INTRODUCTION TO CLINICAL SCIENCES</b>	
<b>DISCIPLINE</b>	<b>FACULTY</b>
ORTHOPAEDICS & TRAUMATOLOGY	Faik Altıntaş, MD, Prof. Uğur Şaylı, MD, Prof. Turhan Özler, MD, Assoc Prof. Melih Güven, MD, Assoc.Prof. Çağatay Uluçay, MD, Assoc. Prof. Budak Akman, MD
PHYSICAL THERAPY & REHABILITATION	Ece Aydoğ, MD, Prof.
RHEUMATOLOGY	Müge Bıçakçığıl, MD, Assoc. Prof
PATHOLOGY	Ferda Özkan, MD, Prof Işın Doğan Ekici, MD, Prof. Ahmet Sedat Çöloğlu, DMD, Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, Assoc. Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Ferda Kaleağasıoğlu, MD, Prof.
PUBLIC HEALTH	Recep Erol Sezer, MD, Prof Hale Arık Taşyikan, MD, Asst. Prof
FAMILY MEDICINE	Özlem Tanrıöver, MD, Assoc. Prof Hülya Akan, MD, Assoc. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Asst. Prof.
RADIOLOGY	Neslihan Taşdelen, MD, Assoc. Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu, MD, Assoc. Prof.
EMERGENCY MEDICINE	Sezgin Sarıkaya, MD, Assoc.Prof
BIOSTATISTICS	Çiğdem Kaspar, PhD, Asst. Prof.

<b>MED 303 INTRODUCTION TO CLINICAL PRACTICE III</b>	
<b>DISCIPLINE</b>	<b>LECTURERS</b>
CLINICAL SKILLS LAB	Çağatay Uluçay, MD, Assoc. Prof.Turhan Özler, MD, Assoc. Prof. Serdar Özdemir, MD, Asst. Prof Budak Akman, MD

## COMMITTEE VIII - MUSCULOSKELETAL SYSTEM

### AIMS and LEARNING OBJECTIVES

#### AIMS

##### *In evidence based manner,*

1. **to remind** knowledge on anatomy, histology and physiology of musculoskeletal system,
2. **to convey** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
3. **to convey** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
4. **to convey** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to musculoskeletal system,
5. **to convey** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
6. **to convey** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to musculoskeletal system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. **to convey** necessary knowledge on pharmacology of drugs that are effective on musculoskeletal system or on clinical conditions related to musculoskeletal system,
8. **to convey** necessary knowledge on ethics in biomedical research,
9. **to convey** necessary knowledge on clinical research methods and searching medical literature,
10. **to convey** necessary knowledge on phytotherapeutic agents,
11. **to equip with** basic and advanced clinical skills (peripheral venous catheter insertion-C8, physical examination of musculoskeletal system-C8) required at primary health care service level.

#### LEARNING OBJECTIVES

##### *At the end of this committee, student should be able to:*

- 1.0. **recall** anatomy, histology and physiology of musculoskeletal system,
- 2.0. **explain** etiopathogenesis of clinical conditions (congenital, traumatic, metabolic, degenerative, oncological conditions of bone, rheumatological disorders, diseases/disorders of connective tissue, vascular diseases, pathological posture, pain) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
- 3.0. **explain** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
- 4.0. **explain** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to musculoskeletal system,
- 5.0. **describe** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for

- individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
- 6.0. at multi-system level and/or related to cardiovascular and respiratory systems system,
    - for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
    - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
    - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
- explain** in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,
- health care processes, clinical decision making process, clinical decisions and clinical practices which are required for management at primary health care service level:
- 6.1. practice of history taking and physical examination (musculoskeletal-C8)
  - 6.2. evaluation of emergency case (trauma-C8)
  - 6.3. approach to healthy individual or patient (musculoskeletal dysfunction-C8)
  - 6.4. laboratory tests/examinations (monitorization of drug therapy-C8)
  - 6.5. imaging tests/examinations (radiological imaging of musculoskeletal system-C8, radiological examinations in benign ve malign tumors of bones-C8, bone scintigraphy-C8)
  - 6.6. point of care testing
  - 6.7. making preliminary diagnosis or definitive diagnosis decision
  - 6.8. making non-intervention or intervention decision
  - 6.9. practicing non-intervention or intervention
  - 6.10. referral/transport of healthy individual or patient
  - 7.0. **explain** pharmacology of drugs (non-opioid analgesics, skeletal muscle relaxants, disease modifying antirheumatic drugs) that are effective on musculoskeletal system or on clinical conditions related to musculoskeletal system,
  - 8.0. **explain** effects of phytotherapeutic agents on musculoskeletal system or on clinical conditions related to musculoskeletal system,
  - 9.0. **list** ethical principles in biomedical research,
  - 10.0. **explain** use of biostatistics in clinical research and for evidence search in medical literature,
  - 11.0. **perform** basic clinical skills, practiced on phantom models (peripheral venous catheter insertion-C8), and advanced clinical skills, practiced on simulated/standardized patients (physical examination of musculoskeletal system-C8), required at primary health care service.

**COMMITTEE VIII - MUSCULOSKELETAL SYSTEM**  
**COMMITTEE ASSESSMENT MATRIX**

COURSE: MD 320 INTRODUCTION TO CLINICAL SCIENCES COURSE COMPONENT: COMMITTEE VIII - MUSCULOSKELETAL SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/ INSTRUCTOR	NUMBER OF QUESTIONS			
			(MCQ)			
			CE	FE	IE	Total
1.0.-6.0.	ORT	F. Altıntaş	28	7	7	42
1.0.-6.0.		T. Özler				
1.0.-6.0.		Ç. Uluçay				
1.0.-6.0.		M. Güven				
1.0., 2.0., 5.0.	PT	F. Özkan	15	3	3	21
		I.D.Ekici				
		A.S. Çöloğlu				
1.0.-6.0.	RHE	M. Bıçakçığıl	11	2	2	15
7.0.	PC	E. Genç	7	2	2	11
7.0.		F.Kaleağasıoğlu				
3.0., 4.0.	PH	R.E. Sezer	5	1	1	7
3.0., 4.0.		H.A.Taşıykan				
1.0.-6.0.	PTR	E. Aydoğ	5	1	1	7
10.0.	BS	Ç. Kaspar	5	1	1	7
1.0., 2.0., 5.0.	PP	M. Kaçar	3	1	1	5
2.0.	MG	A.Ç.Kuşkucu	3	1	1	5
6.3.	FM	H. Akan	3	1	1	5
6.3.		Ö. Tanrıöver				
9.0.	BED	E. Vatanoğlu	3	1	1	5
6.2.	EM	S.Sarıkaya	1	1	1	3
6.5.	RAD	N.Taşdelen	1	0	0	1
TOTAL			90	22	22	134
LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS			
			(EMQ)			
			CE	FE	IE	Total
1.0.-6.0.	RHE	M. Bıçakçığıl	1	-	-	1
1.0.-6.0.	ORT	M.Güven	2	-	-	2
1.0.-6.0.	PTR	E. Aydoğ	2	-	-	2
TOTAL			5	-	-	5

**CS\*= 90 pts (MCQ) + 10 pts (EMQ) = 100 points**

\*Each MCQ has a value of 1 points; each EMQ question has a value of 2 points.

**MCQ:** Multiple Choice Question

**EMQ:** Extending Matching Question

**CE:** Committee Exam

**CS:** Committee Score

**FE:** Final Exam

**ICE:** Incomplete Exam

**pts:** Points

**\*\*22** out of 200 FE and ICE MCQs will be from Committee VIII (Each question is of worth **0.5** pts).



**COMMITTEE VIII - MUSCULOSKELETAL SYSTEM**  
**WEEK I / 15-19 May 2017**

	<b>Monday 15-May-2017</b>	<b>Tuesday 16-May-2017</b>	<b>Wednesday 17-May-2017</b>	<b>Thursday 18-May-2017</b>	<b>Friday 19-May-2017</b>
<b>09.00- 09.50</b>	Introduction to Committee VIII <b>Head of Committee</b>	<b>Lecture</b> Public Health and Physical Activity I <b>R. E. Sezer</b>	<b>Lecture</b> Spondylarthropaties <b>M. Bıçakçığıl</b>	<b>ICP-CSL</b> (Physical examination of the musculoskeletal system) <b>T. Özler/B.Akman</b>	<b>NATIONAL HOLIDAY</b>
<b>10.00- 10.50</b>	<b>Lecture</b> Introduction to Musculoskeletal System <b>F. Altıntaş</b>	<b>Lecture</b> Public Health and Physical Activity II <b>R. E. Sezer</b>	<b>Lecture</b> Inflammatory Polyarthritis & Rheumatoid Arthritis <b>M. Bıçakçığıl</b>	<b>Group A</b>	
<b>11.00- 11.50</b>	<b>Lecture</b> Degenerative Osteoarthritis <b>F. Altıntaş</b>	<b>Lecture</b> Epidemiology, Prevention and Control of Occupational Diseases and Injuries I <b>H.A. Taşyikan</b>	<b>Lecture</b> Osteoporosis and Osteoarthritis Treatment, Rehabilitation <b>E. Aydoğ</b>	<b>Group B IL</b>	
<b>12.00- 12.50</b>	<b>Lecture</b> Pathophysiology of Musculoskeletal System Disorders I <b>M. Kaçar</b>	<b>Lecture</b> Epidemiology, Prevention and Control of Occupational Diseases and Injuries II <b>H.A. Taşyikan</b>	<b>Lecture</b> Soft Tissue Pain <b>E. Aydoğ</b>	<b>Group C IL</b>	
<b>12.50 – 14.00</b>	<b>LUNCH BREAK</b>				<b>NATIONAL HOLIDAY</b>
<b>14.00- 14.50</b>	<b>Lecture</b> Pathophysiology of Musculoskeletal System Disorders II <b>M. Kaçar</b>	<b>Lecture</b> Degenerative Joint Disease <b>F. Özkan</b>	<b>Lecture</b> The Ethics of Testing and Screening III <b>E. Vatanoğlu</b>	<b>Group D IL</b>	
<b>15.00- 15.50</b>	<b>Lecture</b> Congenital & Metabolic Diseases of Bone I <b>A.S. Çöloğlu</b>	<b>Lecture</b> Tumors of Soft Tissues I <b>F. Özkan</b>	<b>Lecture</b> The Ethics of Testing and Screening IV <b>E. Vatanoğlu</b>	<b>Independent learning</b>	
<b>16.00- 16.50</b>	<b>Lecture</b> Congenital & Metabolic Diseases of Bone II <b>A.S. Çöloğlu</b>	<b>Lecture</b> Tumors of Soft Tissues II <b>F. Özkan</b>	<b>Lecture</b> Fibromyalgia in Primary Care <b>H. Akan</b>		
<b>17.00-17.50</b>	<b>Independent learning</b>	<b>Independent Learning</b>	<b>Independent learning</b>	<b>Independent Learning</b>	

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

**COMMITTEE VIII - MUSCULOSKELETAL SYSTEM**  
**WEEK II / 22-26 May 2017**

WEEK 17 / 22-26 May 2017					
	Monday 22-May-2017	Tuesday 23-May-2017	Wednesday 24-May-2017	Thursday 25-May-2017	Friday 26-May-2017
09.00- 09.50	<b>Lecture</b> Osteomyelitis and Septic Arthritis B. Akman	<b>Lecture</b> Miscellaneous Rheumatological Disorders I M. Bıçakçığıl	<b>Lecture</b> Vasculitis I F. Özkan	Independent Learning	<b>Lecture</b> Connective Tissue Disorders I M. Bıçakçığıl
10.00- 10.50	<b>Lecture</b> Neuromuscular Disease B.Akman	<b>Lecture</b> Miscellaneous Rheumatological Disorders II M. Bıçakçığıl	<b>Lecture</b> Vasculitis II F. Özkan		<b>Lecture</b> Connective Tissue Disorders II M. Bıçakçığıl
11.00- 11.50	<b>Lecture</b> Neck, Shoulder and Wrist Pain E. Aydoğ	<b>Lecture</b> Bone tumors I A.S. Çöloğlu	<b>Lecture</b> Vasculitis I M. Bıçakçığıl		<b>Lecture</b> Trauma T. Özler
12.00- 12.50	<b>Lecture</b> Low Back, Hip and Ankle Pain E. Aydoğ	<b>Lecture</b> Bone tumors II A.S. Çöloğlu	<b>Lecture</b> Vasculitis II M. Bıçakçığıl		<b>Lecture</b> Upper Extremity Trauma T. Özler
12.50 – 14.00	LUNCH BREAK				
14.00- 14.50	<b>Lecture</b> Disease Modifying Antirheumatic Drugs F. Kaleağasioğlu	<b>Lecture</b> Medical Literature I Ç. Kaspar	<b>Lecture</b> Nonsteroidal Antiinflammatory Drugs I E. Genç	Independent Learning	<b>Lecture</b> Skeletal Muscle Relaxants E. Genç
15.00- 15.50	<b>Lecture</b> Pharmacology Case Studies F. Kaleağasioğlu	<b>Lecture</b> Medical Literature II Ç. Kaspar	<b>Lecture</b> Nonsteroidal Antiinflammatory Drugs II E. Genç	Independent Learning	<b>Lecture</b> Approach to the Patient with Backpain in Primary Care Ö. Tanrıöver
16.00- 16.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning
17.00-17.50				Independent Learning	Independent Learning

**COMMITTEE VIII - MUSCULOSKELETAL SYSTEM**  
**WEEK III / 29 May-02 June 2017**

	Monday 29-May-2017	Tuesday 30-May-2017	Wednesday 31-May-2017			Thursday 01.Jun-2017				Friday 02.Jun-2017				
09.00- 09.50	Lecture Foot Deformities U. Şaylı	Lecture Lower Extremity Trauma Ç. Uluçay	Pathology Laboratory (Musculoskeletal System) I. D. Ekici/F. Özkan	Group A	Group B IL	ICP-CSL (Physical examination of the musculoskeletal system) T. Özler/B.Akman				Lecture Benign Tumors of Bone M. Güven				
10.00- 10.50	Lecture Principles of Fracture Healing U. Şaylı	Lecture Traumatic Dislocations Ç. Uluçay		Group A IL	Group B	Group A IL	Group B	Group C IL	Group D IL	Lecture Malignant Tumors of Bone M. Güven				
11.00- 11.50	Lecture Sport Injuries I T. Özler	Lecture Spinal Deformities Ç. Uluçay		Lecture Upper Extremity Disorders Ç. Uluçay						Multidisciplinary Case Discussion Panel				
12.00- 12.50	Lecture Sport Injuries II T. Özler	Lecture Skeletal Dysplasias A. Ç. Kuşkucu		Lecture Lower Extremity Disorders Ç. Uluçay						Independent Learning				Multidisciplinary Case Discussion Panel
12.50 – 14.00	LUNCH BREAK													
14.00- 14.50	Lecture Clinical Trials II Ç. Kaspar	Lecture Muscular Dystrophies A. Ç.Kuşkucu	Lecture Fractures of Children M. Güven			ICP-CSL (Physical examination of the musculoskeletal system) T. Özler/B.Akman				ICP-CSL (Physical examination of the musculoskeletal system) T. Özler/B.Akman				
15.00- 15.50	Lecture Clinical Trials I Ç. Kaspar	Lecture Osteoporosis B.Akman	Lecture Developmental Disorders of the Skeleton M. Güven			Group A IL	Group B IL	Group C	Group D IL	Group A IL	Group B IL	Group C IL	Group D	
16.00- 16.50	Lecture Initial Approach to Trauma Patient S. Sarıkaya	Lecture Microsurgery and Replantation B.Akman	Lecture Congenital Dislocation of the Hip M. Güven											
17.00-17.50	Independent Learning	Independent Learning	Independent Learning			Independent Learning				Independent Learning				

**COMMITTEE VIII - MUSCULOSKELETAL SYSTEM**  
**WEEK IV / 05-09 June 2017**

	Monday 05-Jun-2017	Tuesday 06-Jun-2017	Wednesday 07-Jun-2017	Thursday 08-Jun -2017	Friday 09-Jun -2017
09.00- 09.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning
10.00- 10.50					COMMITTEE EXAM
11.00- 11.50					
12.00- 12.50					
12.50 – 14.00	LUNCH BREAK				
14.00- 14.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Program Evaluation Session Committee VIII Coordination Committee Members
15.00- 15.50					Independent Learning
16.00- 16.50					
17.00-17.50					

## STUDENT COUNSELING

Student counseling is a structured development process established between the student and the consultant that aims to maximize student success by focusing the student to her/his target. Although the major component of this relationship is the student, the faculties also take part by bringing the requirements of this interaction to their systems. The targeted outcomes of the consultant-student interaction are success in the exams, success in the program, and preparation for the professional life. The aim of counseling is to help students to solve their problems, to give professional guidance, to provide coaching, to contribute to adopting the habit of lifelong learning, to provide information about the University and Faculty, to follow their success and failure and to help them select courses. The consultants selected among Basic Medical Sciences instructors for the first three years transfer the students to Clinical Sciences instructors for the following three years.

### ***The topics that will be addressed by the consultants are as follows:***

- a. Inform students about the university, faculty and surrounding facilities
- b. Inform students about the courses and help them select courses
- c. Inform students about the education and assessment regulations
- d. Follow students attendance to lectures and success
- e. In case of failure, investigate the causes and cooperate with the students to overcome them
- f. Help students in career planning
- g. Contribute to students adapting the habit of lifelong learning
- h. Guide students to counseling services of the university
- i. Set a role model as long as the professional susceptibility, professional guidance, intellectual responsibility, interaction with peers, ethics, professional values are concerned
- j. Contribute to cultivation of professional and intellectual development in a rapidly changing world
- k. Inform the coordinator when there are unsolved problems of the students

Consultant-student relationship is a dynamic and mutual process carried out within the campus and the hospital. It is recommended that the consultant and the student meet at least twice during a semester.

### ***The expectations from the student are as follows:***

- a) Contribute to improvement of satisfaction level in the problem areas
  - b) Report the social and economic conditions that require consultant's help
  - c) Specify expectations from the education and the department from which this training is taken
  - d) Give feedback on the counseling services regarding their satisfaction level
- Student counsellors will be appointed after finalization of the class list and will be announced to the students.

After the announcement of the counsellors on the information board, each student is expected to contact his/her counsellor until the end of the current committee.

### LIST OF STUDENT COUNSELING - PHASE III

	NO	AD	SOYAD	EĞİTİM DANIŞMANI
1	20140800075	DİLARA UMUT	ALTUN	DOÇ. DR. ÜNAL USLU
2	20130800010	HİLMİ	ALPTEKİN	DOÇ. DR. ÜNAL USLU
3	20140800096	LADEN	ALTAY	DOÇ. DR. ÜNAL USLU
4	20150800107	MUHARREM BERKER	ALTINTAŞ	PROF. DR. GÜLDEN ÇELİK
5	20130800009	ALEV	ARSLAN	DOÇ. DR. ÜNAL USLU
6	20130800033	ÇAĞDAŞ	ATAOĞLU	YRD. DOÇ. DR. DENİZ KIRAÇ
7	20140800022	İLKE ESİN	AYDINER	YRD. DOÇ. DR. DENİZ KIRAÇ
8	20140800023	MUSTAFA CANER	AYDİN	YRD. DOÇ. DR. DENİZ KIRAÇ
9	20140800017	İPEK	AYRI	YRD. DOÇ. DR. ÇİĞDEM KASPAR
10	20140800083	BUENA	AZIRI	YRD. DOÇ. DR. ÇİĞDEM KASPAR
11	20140800015	BERİL	BALAK	YRD. DOÇ. DR. ÇİĞDEM KASPAR
12	20140800018	ECE	BATUR	YRD. DOÇ. DR. ÇİĞDEM KASPAR
13	20140800073	NIYAZI GÖRKEM	BEKTAŞ	DOÇ. DR. MEHTAP KAÇAR
14	20140800068	İREM	BOLLUK	YRD. DOÇ. DR. AYLIN YABA UÇAR
15	20130800074	YILDIRIM HAN	BOZAL	YRD. DOÇ. DR. AYLIN YABA UÇAR
16	20140800088	BASSEL	BSAT	YRD. DOÇ. DR. AYLIN YABA UÇAR
17	20140800014	HATİCE ZEYNEP	CEYLAN	PROF. DR. TURGAY İSBİR
18	20130800079	VOLKAN	CİVELEK	PROF. DR. TURGAY İSBİR
19	20130800059	YUNUS EMRE	ÇADIRCI	PROF. DR. TURGAY İSBİR
20	20130800084	BORA	ÇAĞAN	DOÇ. DR. MEHTAP KAÇAR
21	20140800020	EGEMEN KAAH	ÇAKAR	DOÇ. DR. ELİF VATANOĞLU
22	20130800045	SEÇKİN	ÇELİK	PROF. DR. TURGAY İSBİR
23	20140800070	ECE MELİS	ÇETİNKAYA	DOÇ. DR. ELİF VATANOĞLU
24	20140800009	GÖKTUĞ	ÇETİNYOL	DOÇ. DR. ELİF VATANOĞLU
25	20130800069	BÜŞRA NUR	ÇOŞAN	DOÇ. DR. ELİF VATANOĞLU
26	20130800001	SERKAN	DEKTAŞ	YRD. DOÇ. DR. HALE ARIK
27	20140800102	BATUHAN BERK	DEMİR	YRD. DOÇ. DR. AYLIN YABA UÇAR
28	20140800069	UMAY	DİLEK	PROF. DR. FERDA KALEAĞASIOĞLU
29	20130800006	HASAN	DÖNER	DOÇ. DR. ÇAĞATAY ACUNER
30	20140800081	EZGİ	DUMAN	DOÇ. DR. ÇAĞATAY ACUNER
31	20130800097	SENA	EKİZ	DOÇ. DR. ÇAĞATAY ACUNER
32	20130800020	MELİKE SABA	ERDİNÇ	DOÇ. DR. ELİF VATANOĞLU
33	20120800088	DAMLA	ERDOĞAN	DOÇ. DR. ELİF VATANOĞLU
34	20130800075	MURAT	ERDOĞAN	YRD. DOÇ. DR. ALEV CUMBUL
35	20140800077	MERYEM BEYZA	ERKAN	YRD. DOÇ. DR. ALEV CUMBUL
36	20140800027	MERCAN	EZELSOY	DOÇ. DR. ÖZLEM TANRIOVER
37	20140800053	GÖRKEM	FEYZULLAHOĞLU	DOÇ. DR. ÖZLEM TANRIOVER
38	20140800074	BAŞAK	GÜNAY	DOÇ. DR. HÜLYA AKAN
39	20140800084	LORINA	HAZIRI	DOÇ. DR. HÜLYA AKAN
40	20130800008	ZELİHA NUR	IRMAK	PROF. DR. İNCİ ÖZDEN
41	20140800019	AYLİN	İKİS	PROF. DR. İNCİ ÖZDEN
42	20140800041	ÖMER SERTAÇ	İLİSLAN	PROF. DR. İNCİ ÖZDEN
43	20140800039	AYSU	KAÇAR	DOÇ. DR. JALE ÇOBAN
44	20140800045	OSMAN KAMİL	KAMİLOĞLU	YRD. DOÇ. DR. ARZU AKALIN
45	20130800068	SİDAR	KARABULUT	DOÇ. DR. JALE ÇOBAN
46	20130800048	SILA	KARAKUŞ	DOÇ. DR. JALE ÇOBAN
47	20120800045	İREM BUSE	KARAKUM	DOÇ. DR. ÖZLEM TANRIOVER
48	20140800058	BURAKSU	KARSLI	YRD. DOÇ. DR. ARZU AKALIN
49	20140800034	MELİH KAĞAN	KAVCIOĞLU	YRD. DOÇ. DR. ARZU AKALIN
50	20130800076	EREN	KAVUKÇU	PROF. DR. ECE GENÇ
51	20120800023	KORAY	KAYA	PROF. DR. ECE GENÇ
52	20140800013	ALİ	KESER	PROF. DR. ECE GENÇ
53	20130800054	BENGİSU	KESKİN	YRD. DOÇ. DR. AYŞEGÜL KUŞKUCU
54	20130800004	KEVSER	KİŞİFLİ	YRD. DOÇ. DR. AYŞEGÜL KUŞKUCU
55	20130800028	DENİZ	KOCA	YRD. DOÇ. DR. AYŞEGÜL KUŞKUCU
56	20140800004	KIVANÇ	KORKMAZ	PROF. DR. FERDA ÖZKAN
57	20130800012	ATA	KÖKEN	PROF. DR. FERDA ÖZKAN
58	20140800076	ECE	KUDUBAN	PROF. DR. FERDA ÖZKAN
59	20130800043	GÖZDE	KURAN	PROF. DR. FERDA ÖZKAN
60	20130800007	DİLGE	KÜÇÜKCAN	DOÇ. DR. İŞİN DOĞAN EKİCİ
61	20130800088	JOSEPF FURKAN	KÜÇÜKTAŞ	DOÇ. DR. JALE ÇOBAN
62	20130800078	SENA	LOĞOĞLU	DOÇ. DR. İŞİN DOĞAN EKİCİ
63	20130800046	ÖNCEL	MEYSA	DOÇ. DR. İŞİN DOĞAN EKİCİ
64	20140800082	EDA	OLCAYTUĞ	DOÇ. DR. GÜLDEREN YANIKKAYA DEMİREL
65	20140800072	ECİM	OLTULU	YRD. DOÇ. DR. SONER DOĞAN
66	20130800035	DENİZ CAN	ÖNEN	PROF. DR. RECEP EROL SEZER
67	20140800071	YAĞIZ	ÖZDAĞ	PROF. DR. RECEP EROL SEZER

68	20140800038	FEHMİ GİRAY	ÖZGÜN	PROF. DR. RECEP EROL SEZER
69	20120800005	OĞUZ GÖKBERK	ÖZHAN	PROF. DR. ECE GENÇ
70	20130800005	SELMA NUR	ÖZKIRAZ	PROF. DR. RECEP EROL SEZER
71	20130800070	DUHA YAREN	ÖZTÜRK	YRD.DOÇ.DR. SERDAR ÖZDEMİR
72	20140800001	ALİ EMRE	ÖZTÜRK	YRD.DOÇ.DR. SERDAR ÖZDEMİR
73	20130800050	ATİLA BERKE	ÖZÜS	YRD.DOÇ.DR. SERDAR ÖZDEMİR
74	20140800046	NAZ	PAYTONCU	YRD.DOÇ.DR. SERDAR ÖZDEMİR
75	20140800063	HÜMA ARDA	PEDİRİK	DR. BİLGE GÜVENÇ TUNA
76	20120800002	KONURALP	SAĞLAM	YRD. DOÇ. DR. HALE ARIK
77	20130800072	PELİN	SARI	DR. BİLGE GÜVENÇ TUNA
78	20140800033	DILANUR SULTAN	SEÇİLMİŞ	DR. BİLGE GÜVENÇ TUNA
79	20130800065	SEMIH SERGEN	SEMERCI	DR. BİLGE GÜVENÇ TUNA
80	20120800009	OĞUZCAN	SERNİKLİ	YRD. DOÇ. DR. HALE ARIK
81	20140800064	AYŞE EZGİ	SEVER	PROF. DR. FERDA KALEAĞASIOĞLU
82	20140800035	ZELİHA İLKE	SUNGUR	PROF. DR. FERDA KALEAĞASIOĞLU
83	20140800086	NAİLE	ŞABAN	PROF. DR. FERDA KALEAĞASIOĞLU
84	20140800056	MUSTAFA EFE	ŞÜKÜROĞLU	PROF. DR. FERDA KALEAĞASIOĞLU
85	20130800066	ELİF NUR	TAKIR	PROF. DR. FERDA KALEAĞASIOĞLU
86	20130800060	AYŞE NAZ	TEKKÖK	DOÇ. DR. MEHTAP KAÇAR
87	20140800067	ESRA EZGİ	TEMÜR	DOÇ. DR. MEHTAP KAÇAR
88	20140800079	DENİZ	TURGUT	YRD. DOÇ. DR. ÇİĞDEM KASPAR
89	20130800004	ZEYNEP İLAY	YALÇIN	YRD. DOÇ. DR. DENİZ KIRAÇ
90	20130800071	OLCAY	YAVUZ	YRD. DOÇ. DR. ALEV CUMBUL
91	20130800042	YEKTA	YILDIRIM	DOÇ. DR. MEHTAP KAÇAR
92	20140800049	ÖYKÜ MERVE	YILMAZ	YRD. DOÇ. DR. AKİF MAHARRAMOV
93	20140800007	MERVE	ZENGİN	YRD. DOÇ. DR. AKİF MAHARRAMOV

## CONTACT

---

**Faculty Secretary :**

Tel: +90 216 578 00 00 (3005)

**Dean Secretary:**

Tel: +90 216 578 05 05 – 06

Fax: +90 216 578 05 75

**Student Affairs :**

Tel: +90 216 578 06 86

**Documents Affairs:**

Tel: +90 216 578 05 93

**Phase 3 Coordinator/ Co-coordinators:**

Ferda Kaleağasıoğlu, MD, Prof. (Coordinator), 0216 578 00 (1551) / [ferda.Kaleağasıoğlu@yeditepe.edu.tr](mailto:ferda.Kaleağasıoğlu@yeditepe.edu.tr)

Naz Berfu Akbaş, MD, Asst. Prof. (Co-coordinator), 0216 578 00 00 (4220) / [nbakbas@yeditepe.edu.tr](mailto:nbakbas@yeditepe.edu.tr)

Ayşegül Ç. Kuşkucu, MD, Asst. Prof. (Co-coordinator), 0216 578 00 00 (5777) / [aysegul.Kuskucu@yeditepe.edu.tr](mailto:aysegul.Kuskucu@yeditepe.edu.tr)

Hale Arık Taşyikan, MD, Asst. Prof. (Co-coordinator), 0216 578 00 00 (6300) / [hale.arik@yeditepe.edu.tr](mailto:hale.arik@yeditepe.edu.tr)

Serdar Özdemir, MD, Asst. Prof (Co-coordinator), 0216 578 00 00 (3066) / [serdar.ozdemir@yeditepe.edu.tr](mailto:serdar.ozdemir@yeditepe.edu.tr)

Özlem Tanrıöver, MD, Assoc. Prof. (ICP Coordinator), 216 578 00 00 (3742) / [otanrioever@yeditepe.edu.tr](mailto:otanrioever@yeditepe.edu.tr)

A. Arzu Akalın, MD, Asst. Prof. (ICP Co-coordinator), 216 578 00 00 (1525) / [arzu.akalin@yeditepe.edu.tr](mailto:arzu.akalin@yeditepe.edu.tr)

**Address:**

Yeditepe University Faculty of Medicine  
İnönü Mah. Kayışdağı Caddesi,  
26 Ağustos Yerleşimi,  
34755 Ataşehir, İstanbul

**Web :** [www.yeditepe.edu.tr](http://www.yeditepe.edu.tr)

<http://www.yeditepe.edu.tr/fakulteler/tip-fakultesi>

**e-mail:** [tipfakdek@yeditepe.edu.tr](mailto:tipfakdek@yeditepe.edu.tr)





YEDİTEPE UNIVERSITY  
FACULTY OF MEDICINE

İnönü Mah. Kayışdağı Caddesi,  
26 Ağustos Yerleşimi,  
34755 Ataşehir, İstanbul

+ 90 216 578 00 00

[www.yeditepe.edu.tr](http://www.yeditepe.edu.tr)  
<http://www.yeditepe.edu.tr/fakulteler/tip-fakultesi>  
[tipfakdek@yeditepe.edu.tr](mailto:tipfakdek@yeditepe.edu.tr)